

US EPA ARCHIVE DOCUMENT

----- X  
:  
FIFRA SCIENTIFIC ADVISORY :  
:  
PANEL (SAP) OPEN MEETING :  
:  
-----X

METHODS USED TO CONDUCT A PRELIMINARY CUMULATIVE  
RISK ASSESSMENT FOR ORGANOPHOSPHATE PESTICIDES

February 6, 2002

[8:30 a.m.]

SHERATON CRYSTAL CITY HOTEL  
1800 Jefferson Davis Highway  
Arlington, Virginia 22202

1

**PARTICIPANTS**

2

**FIFRA SAP Session Chair**

3

Ronald J. Kendall, Ph.D.

4

5

**Designated Federal Official**

6

Mr. Paul Lewis

7

8

**FIFRA Scientific Advisory Panel Members**

9

Herb Needleman, M.D.

10

Christopher J. Portier, Ph.D.

11

Stephen M. Roberts, Ph.D.

12

Mary Anna Thrall, D.V.M

13

14

**FQPA Science Review Board Members**

15

John Adgate, Ph.D.

16

William Brimijoin, Ph.D.

17

Richard Bull, Ph.D.

18

Rory Conolly, Sc.D.

19

Patrick Durkin, Ph.D.

20

Natalie Freeman, Ph.D.

21

Jean Harry, Ph.D.

3

1 Steven Herringa, Ph.D.

2

3 Ernest McConnell, D. V.M.

4 Peter MacDonald, D. Phil.

5 Nu-May Ruby Reed, Ph.D.

6 Lorenz Rhomberg, Ph.D.

7 Lauren Zeise, Ph.D.

1 DR. KENDALL: Good morning, this will convene the meeting  
2 of the FIFRA Scientific Advisory Panel to continue our discussions on  
3 methods used to conduct a preliminary cumulative risk assessment for  
4 organophosphate pesticides. My name is Ron Kendall. I'm the chair  
5 of the Science Advisory Panel and will be chairing this session.

6 I'd like to again thank EPA for being ready, and I thought we  
7 had an excellent and productive day yesterday. And I'm looking  
8 forward for the continuation of our discussion today.

9 We have several new panel members that are seated; therefore, I  
10 will, as a matter of protocol, ask the Panel to reintroduce itself in  
11 total. I'd like to begin on the far right and then move around. And,  
12 please, for the record, state your name, affiliation, and expertise if you  
13 would briefly.

14 DR. CAPEL: My name is Paul Capel. I'm with the US  
15 Geological Survey Water Resources Division. My expertise and water  
16 chemistry for the drinking water exposure part.

17 DR. ENGEL: Purdue University. My expertise would be in the  
18 hydrologic water quality modeling area.

19 DR. BULL: I'm Dick Bull with Washington State University.  
20 I'm a toxicologist.

21 DR. DURKIN: Pat Durkin with Syracuse Environmental

5

1 Research Associates. I am a risk assessor and I've worked with the  
2 Agency in development of methods for mixtures risk assessment.

3 DR. HARRY: Jean Harry, National Institute of Environmental  
4 Health Sciences in North Carolina. My research area is in  
5 neurotoxicology.

6 DR. CONOLLY: Rory Conolly, CIIT Centers for Health  
7 Research in Research Triangle Park, North Carolina. I'm interested in  
8 mechanisms of toxicity and risk assessment.

9 DR. RHOMBERG: Lorenz Rhomberg, Gradient Corporation,  
10 and also the Harvard School of Public Health. I'm interested in  
11 quantitative risk assessment methodology.

12 DR. MCCONNELL: Gene McConnell. I'm a veterinary  
13 pathologist-toxicologist. My area of expertise is in the design,  
14 conduct, and interpretation of animal bioassays.

15 DR. ROBERTS: Steve Roberts; toxicologist; University of  
16 Florida.

17 DR. PORTIER: Chris Portier, National Institute of  
18 Environment Health Sciences in Research Triangle Park, North  
19 Carolina. I direct the environmental toxicology program and manage  
20 the national toxicology program. My area of expertise biostatistics  
21 and risk assessment.

6

1 DR. ZEISE: Lauren Zeise, Kelly P. Office of Environmental  
2 Health Hazard Assessment. My expertise is in risk assessment.

3 DR. RICHARDS: Pete Richards, director Of the Water Quality  
4 Lab at Heidelberg College in Ohio with expertise in exposure patterns  
5 in agriculture systems in the upper Midwest and the statistics applied  
6 to those.

7 DR. ADGATE: John Adgate, University of Minnesota School of  
8 Public Health, exposure analysis and risk assessment.

9 DR. REED: Nu-May Ruby Reed, California Environmental  
10 Protection Agency, Department of Pesticide Regulation. I do  
11 pesticide risk assessment.

12 DR. FREEMAN: Natalie Freeman, Robert Wood Johnson  
13 Medical School and the Environmental and Occupational Health  
14 Sciences Institute in Piscataway, New Jersey. Residential and  
15 children's exposure.

16 DR. MACDONALD: Peter MacDonald from the Department of  
17 Math and Statistics at McMaster University in Canada. General  
18 expertise in applied statistics and model fitting.

19 DR. HEERINGA: Steve Heeringa, the Institute for Social  
20 Research at the University of Michigan. I am a biostatistician. My  
21 specialty is in population-based research.

1 DR. KENDALL: I'm Ron Kendall from Texas Tech University.  
2 I direct the university's Institute of Environmental and Human Health.  
3 My area of expertise is in environmental toxicology and risk  
4 assessment.

5 I'd like to now introduce our designated federal official from  
6 EPA, Mr. Paul Lewis, for any administrative procedures that he needs  
7 to inform us on to get going today. Paul.

8 MR. LEWIS: Thank you, Dr. Kendall. And again thank you  
9 again for agreeing to serve as our chair for this challenging and  
10 interesting meeting over the next four days with our Scientific  
11 Advisory Panel. I want to thank the members of the panel to agreeing  
12 to serve and we're looking forward to your upcoming deliberation and  
13 challenging discussions beginning with what we had yesterday and  
14 carrying on today and beyond and for new members that have joined us  
15 this morning for discussion on vary exposure considerations.

16 I want to remind everyone again that this meeting follows of the  
17 guidelines of the Federal Advisory Committee Act. This is an open  
18 meeting. There's an opportunity for public comment. All the materials  
19 for the meeting will be available in a public docket. In addition, the  
20 primary background materials and our subsequent report that serves as  
21 meeting minutes for discussion during this week will be available in

8

1 the docket edition on our SAP web site.

2 Thank you again. I'm looking forward to both a challenging and  
3 interesting over the next few days. Dr. Kendall.

4 DR. KENDALL: Thank you, Paul. Yesterday was a very  
5 aggressive and forward-looking day. We actually got much further  
6 than we thought we would. Therefore, today, we are at the point of  
7 assessment of food exposure in terms of Session 2 as we continue our  
8 review.

9 Dr. Perfetti, would you like to introduce your group or  
10 Margaret, either one of you?

11 DR. PERFETTI: Thank you, Dr. Kendall. First of all, I'd like  
12 to welcome the panel to today's session on food and drinking water.  
13 And again I would like to thank the panel for all your valuable past  
14 advice on the total assessment as well as yesterday's very interesting  
15 discussion on hazard and dose response.

16 For the food presentation, Dr. William Smith, sitting to my left;  
17 and Dave Miller will provide that presentation on food. Presentation  
18 on water will be performed by Kevin Costello and Nelson Thurman.

19 I have a few points that I'd like to make, Dr. Kendall, before we  
20 continue.

21 DR. KENDALL: Very well.

1 DR. PERFETTI: As mentioned yesterday, we intend to address  
2 all of the points brought up yesterday during the public comment  
3 period. We intended to address many of those points anyhow in our  
4 presentation; but we have modified them such that we think we will be  
5 able to speak to all of them.

6 To that end, we heard yesterday that OPP would be receiving an  
7 OP cumulative assessment using the CARES software. OPP has also  
8 contracted the Lifeline Group to perform a cumulative risk assessment  
9 for the organophosphate pesticides.

10 This project has three components. The first is to modify the  
11 Lifeline version 1.1 software as required to allow estimation of  
12 cumulative exposure and risk for the organophosphate pesticides. In  
13 addition to modifying the software, Lifeline Group will perform a  
14 cumulative risk assessment for the OP and revise the user and  
15 technical documentation to the Lifeline model so that it can be used by  
16 all of the risk assessment community. We have done this in order to --  
17 basically, we thought ahead. We did this in order to have yet another  
18 software package for cumulative risk assessment.

19 And, finally, I cannot stress strong enough that OPP has no  
20 intention of exclusively endorsing a particular model for estimating  
21 pesticide exposure and risk. We'll accept any and all risk assessments

10

1 conducted in accordance with EPA and OPP guidelines and performed  
2 with an appropriately peer-reviewed model. That can never be  
3 stressed more strongly or often enough.

4 Thank you, Dr. Kendall.

5 DR. KENDALL: Thank you. Well, at this point, we can begin.

6 Let's go ahead and begin the presentation. Dr. Smith.

7 DR. SMITH: Good morning. This is an outline of what I plan  
8 to discuss today. I want to cover three general areas in this  
9 discussion. First, I would like to summarize the exposure inputs to the  
10 cumulative food assessment. This includes the residue data, primarily  
11 from the PDP monitoring program for food consumption data from the  
12 USDA continuing survey of food intakes by individuals.

13 Secondly, I'll briefly review the residue adjustments involved in  
14 the cumulative assessment. These are fairly simple calculations  
15 compared to what we dealt with yesterday. This involves a conversion  
16 to index equivalent residues, that is, methamidophos equivalence, the  
17 relative potency factor method.

18 And then last, we'd like to review the preliminary assessment as  
19 published in December which is a probabilistic exposure risk  
20 assessment using the DEEM software.

21 Also, I will include some analysis of the important assumptions

11

1 that were incorporated in the exposure calculations and the beginnings  
2 of the analysis of important contributors to the exposure distribution.

3 Essentially, all the residue data that we used in this assessment  
4 are from the PDP Program. We, also, considered FDA monitoring  
5 data, but this was primarily as background. There were only very  
6 limited uses of it on a quantitative basis. All of these data are  
7 available on the internet at these Agency's internet sites.

8 The OP active ingredients that are included in this assessment  
9 are all included in the PDP monitoring program. What you see here  
10 are essentially the parent active ingredients. PDP also analyzes for  
11 important metabolites of these chemicals and degradates. And they  
12 are also included in the assessment. I think between the span of 1994  
13 to 2000, PDP has done significant analysis on maybe 70, or  
14 approximately 70, OPs, either parent active ingredients or metabolites.  
15 The extent of how we use these data are the extent of the availability  
16 as well as how we use is available in our preliminary document in the  
17 appendices.

18 We do not include cancelled uses in the assessment nor do we  
19 include violative residues. Now these are tolerance-exceeding  
20 residues or residues from nonregistered uses. Violative residues are  
21 generally infrequent and for the most part at low concentrations. And

12

1 both PDP, our primary source, and for that matter, an FDA data,  
2 which is designed to enforce tolerances.

3 I do not have an exact accounting of our the effect of our  
4 omission of these violative residues. But it will be available with the  
5 final assessment. But I can offer some general statistics.

6 In the most recent PDP data, tolerance-exceeding residues are  
7 on the order of .2 percent of the analyses. And residues from  
8 nonregistered uses account for a little bit over 1 percent. The FDA  
9 monitoring, which one would expect to have more violative residues  
10 since it is designed to analyze raw commodities close to their source,  
11 has a little bit more. It has with domestic, approximately 1 to percent  
12 violative residues; and import, closer to 4 press.

13 So for just as a general background response to public comment  
14 about this, that is what we generally see in all the monitoring data.  
15 Also, the data bases that are available on the internet from these  
16 agencies as well as our data -- let me retract that. Our data do not  
17 flag the violative residues, but the data bases as available from USDA  
18 and FDA do. So one can easily pick out of the residues. There is a  
19 field in the data base that identifies these.

20 There has been approximately 50 different foods that have been  
21 analyzed in the PDP Program since 1994. And this is, of course,

13

1 counting some processed forms such as canned, frozen, this sort of  
2 thing. All of these foods are included in the assessment. But some  
3 specific chemical commodity combinations have been excluded to  
4 account for cancellations or tolerance revocations and phase outs of  
5 uses.

6 The residue data for these foods as supplied by PDP have been  
7 adjusted by processing factors where suitable to include all the related  
8 food forms found in the CSFII survey. Again, for example, using a  
9 raw commodity with a processing factor to estimate residues on a  
10 cooked, canned, frozen form, possibly a juice or dried form.

11 These data were extended to the extent possible by translation.  
12 And in this case, it was done to food crops that had similar use  
13 patterns. I will come back to these crops a little later in the discussion  
14 of the preliminary assessment.

15 These are based on SOPs that we have developed for single  
16 chemical assessments, and they are limited to crops for which use  
17 patterns are similar. So we done translate a chemical that would not  
18 be appropriate to the other commodity.

19 Although, we primarily use FDA's background, there are some  
20 exceptions. Eggs and seafood were included in the assessment. And  
21 in both cases based on a long history of analysis by FDA with

14

1 negligible appearance of OPs. It was our judgment that we could  
2 include these in our assessment as negligible residues.

3         Also, we included, based on the FDA total diet study, which is a  
4 study -- the available data now on the internet goes through 1991 to  
5 1997. These are market basket analysis -- actually, at-the-plate  
6 analyses of prepared foods. Based on these assessments, it was our  
7 professional judgement that we could include an estimate in our  
8 assessment for the meats: Beef, pork, sheep, and goats. This is an  
9 conservative estimate of residues based on the maximum values  
10 determined from the total diet study. It's the only exception in the  
11 assessment in which we use what one may consider a default  
12 assessment. As it turns out, we have seen no real impact of this on the  
13 total assessment. These values are still very low.

14         There are some other foods that were assumed negligible,  
15 although we did not have extensive monitoring data. These are sugars  
16 and syrups that are highly processed and refined. Based on that fact  
17 alone with information we have on related commodities, led us to  
18 conclude that we would not expect OPs to be present in these. So they  
19 were included as negligible in the assessment, also.

20         Now, as a means of getting one perspective of assessing what  
21 portion of the diet we're covering by these data that I've just

15

1 summarized, we ranked the foods as consumed by children from the  
2 CSFII survey on a per capita basis in a descending order. And then for  
3 each food we assigned it a percent value based on the total  
4 consumption.

5 And what I have here in the table is an indication of what  
6 proportion of the per capita consumption is covered by the things I  
7 just summarized.

8 In this case, the PDP data, both of the raw commodities and any  
9 processed commodities that we translated these data to, account for  
10 approximately 86 percent of the diet. The translation that indicated, I  
11 showed you, about 20 different crop names up there, account for only  
12 1.3 of the per capita consumption. The data, the FDA-supported data  
13 on eggs and fish and meat, account for approximately 6 percent of per  
14 capita consumption.

15 Our assumption of negligible for sugars and syrups is another 3  
16 percent. And this leaves approximately 4 percent of the food per  
17 capita consumption that we have not included in the assessment.

18 Again, with this ranking of foods for children three to five in  
19 this case, the top 30 foods in this ranking are included in the  
20 assessment. And the top cumulative 95 percent of this diet that is  
21 comprised of 556 foods, of 52 those are included. The ones I excluded

16

1 are dried beans, some corn-processed commodities and onions.

2 Other foods. Those and the other foods that are not included,  
3 we do not expect to impact significantly on the assessment; although  
4 we do have means to still test this and it is ongoing. Many of these are  
5 highly processed or blended foods; therefore, you wouldn't expect to  
6 have very high levels of these chemicals. And based on FDA data and  
7 chemical registration data, we believe that all these would have  
8 infrequently detected residues or low levels.

9 Moving on now to the residue adjustments. We're all familiar  
10 with our way of dealing with exposure and risk here. We talk in terms  
11 of margins of exposure, which would be a point of depart divided by  
12 an exposure. The point of departure is in this case is a benchmark  
13 dose 10. The exposure, of course, is composed of residue and  
14 consumption.

15 The residues for this assessment are the cumulative residues.  
16 We can converted chemical-specific residues on food samples to a  
17 common residue. And this is an index-equivalent residue. This was  
18 done on a sample-by-sample basis.

19 So an index-equivalent residue on a given PDP sample would be  
20 estimated by multiplying that residue value by any applicable  
21 processing factor and by its relative potency factor -- its potency

17

1 relative to methamidophos. And these residues would be summed for  
2 each sample to become the cumulative residue in terms of  
3 methamidophos.

4 Then these cumulative residues become inputs for the  
5 assessment. Either as distributions of cumulative residues with each  
6 number in the distribution representing a PDP sample or average  
7 cumulative residues for some highly blend foods.

8 For our consumption modeling we used the CSFII, years '94  
9 through '96 as supplemented in 1998. There are over 20 thousands  
10 participants in this version of the CSFII. The surveys were conducted.  
11 It was 2 days that were approximately 3 to 10 days apart. And this  
12 does contain a 1999 supplemental children's survey where an  
13 additional 5,500 children from birth to nine years old were included.

14 This survey is a significant increase for the number of children  
15 as compared to the '89-'91 survey which we have been using at OPP  
16 for you all of our single chemical assessments to date. This is  
17 illustrated in this table which compares the number of children of  
18 various age groups between the '89 to '91 data and the more recent.  
19 You can see, for example, for children one to two, the number of  
20 individuals is increased from 574 to 2,179.

21 The assessment, as currently published, includes four population

18

1 groups. Other age groups can be assessed easily, but none has  
2 exposure estimates that exceed these groups we have. And the  
3 children one to two are the highest exposed.

4 The exposure assessment models that we're using in this  
5 assessment are DEEM and Calendex. My comments are going to be  
6 restricted to the assessments as conducted with DEEM. David Miller  
7 will be discussing some issue after I'm finished that incorporating the  
8 Calendex. And he will highlight differences at that time.

9 DEEM combines residue and consumption distributions in a  
10 Monte Carlo-like procedure to produce a distribution of one-day  
11 exposure and associated margins of exposure.

12 We're using the FCID version of DEEM, which has recently  
13 been released. This uses EPA's food commodity and intake data base  
14 and commodity definitions. This may lead to some confusion on the  
15 part of one who is reading through our assessment as published  
16 because this came at a fairly late date in our assessment. And you will  
17 find that we are referring to food forms as defined in the earlier CSFII.  
18 But when we get to the actual assessment, we translate these to the  
19 FCID form.

20 And, of course, among the differences in these, that is, one  
21 difference in this FCID version of DEEM is that foods do have

19

1 different codes and many of them have different names. There are  
2 some separate breakouts, for example, commercial baby foods are  
3 broken out for each appropriate commodity.

4 Another significant difference is that this version of DEEM uses  
5 publicly available recipes for relating the foods consumed to the raw  
6 commodities or the values that would be plugged into the for  
7 estimating exposure.

8 So this is the preliminary assessment as published in December  
9 the 3rd. And this plot is a representation of the entire distribution  
10 from zero to 100 percent of the exposure distribution. The top line of  
11 the graph represents the BMD10 of .08 milligrams per kilogram per  
12 day. The bottom line represents a value that is one million times lower  
13 than that.

14 And there are four populations on this graph. If we can move to  
15 the next one. This focuses in on the top 10 percentile of the exposure  
16 range. And from this, I think you can begin to see that children one to  
17 two are the most highly exposed population group. And then with the  
18 specific numbers broken out for these four populations between the  
19 90th and 99.9th percentile.

20 By June of this year we expect to have completed all the  
21 refinements of the preliminary assessment and this includes, of course,

20

1 consideration of all the public comments as well as some QA on our  
2 own part, changes we know need to be made. So this is very -- we're  
3 very actively pursuing this.

4 We, also, have been conducting sensitivity analysis to gauge the  
5 relative importance of the assumptions that have gone into the inputs.  
6 We first revealed some of these in the case study that we presented to  
7 the panel in December of 2000. And in principle, our results have not  
8 changed from that in terms of the validity of those assumptions as we  
9 tested them. And we're, also, beginning the process of the  
10 interpretation of the results.

11 So next. Could you go back one. So, first, I would like to  
12 show you a few results looking at the potential effects of input  
13 assumptions and refinements on the assessment. Look at the effects of  
14 translation of PDP data to other foods using processing factors to  
15 estimate residue.

16 These data on this slide if you recall I showed you about 20  
17 foods for which PDP data were translated because we feel they have  
18 similar use patterns. And, of course, this is subject to question  
19 always. This is a test of just what effect -- if we were making wrong  
20 assumptions, what effect this would have on our assessment. And this  
21 somewhat confirms our rankings that we had from the per capita

21

1 consumption, too, the foods to which we translated make up a relative  
2 small proportion of the consumption and the total exposure. At the  
3 higher percentiles, there is very little difference in the assessment if  
4 one removes the assumption of OPs from all the translated foods. And  
5 that's what this represents.

6 We have a particular case here of a translation of data to a  
7 process commodity. In this case, we do not have processing factors or  
8 other information input into the model for conversion of OPs from the  
9 raw commodity to the baby foods. And, of course, we wanted to test  
10 and see how this assumption could effect our end result.

11 And with the new version of DEEM, one can selectively remove  
12 the contribution from all the baby foods. We did this for children one  
13 to two. And it confirms that there is essentially no effect on the  
14 assessment. This is probably not totally unexpected.

15 We, also, have done the same thing for children less than one.  
16 And there is no effect because they eat more baby food. However,  
17 children less than one as a group have a lower exposure than children  
18 one to two.

19 This is somewhat of a boundary on all of our processing and  
20 other extrapolations that we made. In this case, the top line, the top  
21 row, is the full assessment. And the other row of information

22

1 indicates that a similar assessment in which we removed all translated  
2 commodities and all extrapolated data so the only information, the  
3 only OPs incorporated into the assessment, are directly related to PDP  
4 analyses.

5 So there are no assumptions of processing factors; there are no  
6 processed commodities unless PDP analyzed that processed  
7 commodity. And there were no translated crops. And we felt this was  
8 interesting to just sort of set a boundary on what we could expect to  
9 accomplish with a number of refinements that we want to make to  
10 these assumptions.

11 This is the previous slides in a graphical form the top 15  
12 percentile of exposure. The top line represents the full assessment  
13 and, also, coinciding on it in this scale is using only not translating to  
14 other crops. And the lower lines represents removing all  
15 extrapolations.

16 Now, we gave you a revised question, one for food. This is  
17 partially the result of the limitations in time we have in doing some of  
18 these analyses. And we were working on this part of the assessment at  
19 the time we submitted the question. Based on the complexity of what  
20 we were getting and the fact we did not have time to finish some of the  
21 analyses, we choose to focus on some later things we're going to show

23

1 you. But I wanted to show you this anyway because it has come up  
2 and it has been put on the internet.

3 In this case, we have questioned all along what the impact might  
4 be of the fact that our PDP data ranges in the time frame of 1994 to  
5 the year 2000 now. That's approximately seven years of data. Some  
6 of the information comes from only the earlier portion of that time;  
7 some from the later; some is spread across the seven years. We have  
8 as little as one year of data for a food and as much as five years. We  
9 wanted to evaluate the later data to see if they better represent the  
10 current use practices.

11 This is incomplete; but at least in terms of an assessment, I can  
12 show you how removal of older data, to the extent that only the most  
13 recent two years maximum was included for any given food, has some  
14 effect on the upper portion of the distribution. Maybe not a dramatic  
15 effect, but it is shown in this slide.

16 So this analysis is not complete. We need to carefully look at  
17 use pattern changes that have accompanied this. And we can, also,  
18 look at specific chemicals that were removed by removing the older  
19 data. So these are complex factors. We know, we did know, we were  
20 working with multiple distributions representing different segments of  
21 time.

1           Now for the final portion of this, I'd like to briefly summarize  
2           our progress so far. I want to first qualify this by saying that we are  
3           beginning to analyze critical exposure contributors; however, we're  
4           doing this on the preliminary data. So for this reason, although the  
5           process is of interest to us and we want as much input that we can get  
6           on this process and how we can interpret it, the actual results that  
7           we're getting at this point we're sure may be subject to some change;  
8           therefore, we're going to speak in terms of pseudonyms again. I  
9           apologize for that.

10           This case we were looking at -- could you back up one? I  
11           should point out that the DEEM software has a critical exposure  
12           commodity analysis incorporated in it. This is a means of looking at  
13           the top much as 5 percentile of exposure to get an idea of which food  
14           commodities are food are contributing, which food consumptions are  
15           actually contributing to that part of the distribution. And we're  
16           looking at this to get some idea of which foods and, also, which  
17           chemicals are important. And we also, by keeping track of our sample  
18           analysis on a sample-by-sample basis, we also have a history on all  
19           these numbers. So we can go back and actually get sample details,  
20           such as the origin, whether it's domestic or import data and whether  
21           sample was taken in 1994 or the year 2000.

1           So working with the preliminary results and looking at, in this  
2 case, we're looking at the area of the distribution between the 99.8th  
3 percentile and the 100th percentile of exposure. And the critical  
4 commodity exposure element does give you a listing of sort of a  
5 descending ranking of foods that are contributing to that portion.

6           And over in this range, under the conditions of our run, which,  
7 again, are preliminary, we had over 60 percent of the contribution to  
8 this area was coming from three foods in all their forms. This could  
9 include the raw commodity; it could include juices, dried forms,  
10 sauces. It's three food crops that are contribution to this. And we  
11 examined the impact of removing these residues from the assessments  
12 to see how this may impact the upper part of this distribution.

13           Again working with children one to two, we looked, we  
14 compared the full assessment. Two runs in which we removed singly  
15 each one of the foods. Food A was the most abundant in this part of  
16 the distribution. And if you remove only Food A, that second row  
17 illustrates what effect that has on the distribution at the higher end.  
18 Removing only Food B, there's less of Food B; the effect is less. And  
19 same sort of thing with Food C.

20           Taking both A and B out, again, depending on one's perspective,  
21 probably not a lot of change. It required removing all three foods in

26

1 all their forms to affect the change at the very top end of the  
2 distribution of a two-fold change.

3 And this is just illustrating graphically what we have here that  
4 as you go toward the lower parts of the distribution, effects can be  
5 observed. But at the very top end of the distribution, it's difficult at  
6 times to tell the significance of the differences.

7 And, again, just another way of looking at this. Also, I've  
8 included the 50th percentile here which may not be in your background  
9 materials. Just comparing the ratio of the MOEs at these different  
10 points in the upper part of the distribution, you can see that the upper  
11 portion of the exposure distribution is not affected very dramatically  
12 by removing of these major contributors singly. And, again, to get a  
13 two-fold change, required all three.

14 So our interpretations of the risk results are a little premature  
15 to do that. But we do conclude at this point, that the PDP residue  
16 data do cover the major food consumption items. We, also, based on  
17 what we have so far, further refinements of the PDP data are not likely  
18 to drastically alter the results at the higher end of exposure  
19 distribution. And a rather nebulous conclusion here: Complex factors  
20 are contributing to the exposure distribution.

21 There was, also -- if you back up, there's also a calendar-based

27

1 exposure which we used for food as well as the other pathways of  
2 exposure. And David Miller will discuss that next.

3 So now I think probably that ends my part of the presentation.

4 DR. KENDALL: Any points of clarification? Thank you, Dr.  
5 Smith. Very good. Any points of clarification from the Panel before  
6 we move to the next section? Dr. Bull.

7 DR. BULL: This last piece is a little counter-intuitive to me;  
8 maybe not to others. I think you were saying is the higher the  
9 exposure, the less able you're able to account for causing that  
10 exposure. That's my interpretation of what you're saying. I would  
11 have thought -- and just to give you a minute to think -- that  
12 something would be driving that very high exposure and that's not  
13 what you seem to be ferreting out of that data.

14 DR. SMITH: In a sense, that's what we're asking you is how do  
15 we interpret these results to help us however you can. As you go to  
16 lower parts of the distribution, of course, the total exposure is  
17 decreasing to very low values. So for that reasons, there's not much  
18 difference.

19 DR. KENDALL: Go ahead. Dr. Portier.

20 DR. PORTIER: Following up on that same question, it seemed  
21 to me that there's two possibilities for what could drive these margins

28

1 of exposures and reducing them for single commodities. One is the  
2 commodity which very seldom has an OP level in it, but that OP level  
3 is rather high when it's in there. That would contribute to the high end  
4 of the tail of the distribution.

5 The other possibility is a commodity that has a fairly common  
6 OP contamination in it but at a lower level. And it seems to me the  
7 analyses you focused on for the commodity here is to find the rare  
8 events. Did you know that when you went into that, or have you  
9 thought about looking at reducing the entire distribution by finding  
10 potential commodities that have low levels by consistently there?

11 DR. SMITH: Yes, we have thought about that. And there is a  
12 companion part of this output from the DEEM in that you actually see  
13 those highest exposure events. What I was talking to you about was a  
14 summary of these highest events. And but we can also pick out the  
15 actual food consumptions that contain the highest residue or the  
16 highest consumption value. And we are trying to compare those. And  
17 it is a little less straight forward.

18 At this point, we can't say much beyond what we've done -- it is  
19 easy to pick out the top foods, you know, the ones that are coming to  
20 the top of the assessment. And they of course, you're right. There is a  
21 combination of having and some of them have a high percentage of

29

1 residues and/or high residues. Both factors are there. In addition, of  
2 course, to whether it's a high consumption or not.

3 DR. KENDALL: Dr. McConnell,

4 DR. MCCONNELL: Two questions. First, are we are allowed  
5 to ask what A, B, and C are? Oh, we have to go to the top.

6 MS. MULKEY: We made a judgment that we could obtain the  
7 science thinking about this without identifying at this stage.

8 DR. MCCONNELL: Well, sure.

9 MS. MULKEY: Because there is a real market place, we  
10 thought it was prudent we get the benefit of an enhance understanding  
11 of the science before we did that.

12 DR. MCCONNELL: I guess the PC cops are out today.

13 What has been your experience over the past seven years? Have  
14 the percentages of exceedence been going up or down, or finding that  
15 in the particular commodity has it been increasing or decreasing with  
16 time for the, if you will, for the problematic commodities?

17 DR. SMITH: Exceedence, well, there's exceedence of  
18 tolerance.

19 DR. MCCONNELL: Maybe I didn't use the right term. I think  
20 you know what I mean.

21 DR. SMITH: Yeah, you mean just the occurrence of these.

30

1 DR. MCCONNELL: Yes.

2 DR. SMITH: In general, the terms are hard to pick out based  
3 on the information we have, but there is a decrease. So from 1994  
4 through the year 2000, one can see the appearance of a decrease of  
5 occurrence. This is -- I hesitate to say that that's a fact because this is  
6 being observed without extensive statistical analysis. And of course,  
7 we are interested in that and part of our goals are to decrease the  
8 levels on foods.

9 DR. DURKIN: You have identified the top three foods. You  
10 have, but we can't know it. What about the top three chemicals? Is  
11 there a parallel analysis where you look at it by chemical over the total  
12 diet so you can identify the chemicals that are there?

13 DR. SMITH: We are also looking at the chemicals in these top  
14 foods, and we can track that because of the way we did the  
15 distributions. We kept it tied to a PDP sample ID. And we do know  
16 the processing factors and the origins of the samples. And in these  
17 three chemicals -- I can say there are more than three chemicals  
18 involved in those three foods; yes.

19 DR. DURKIN: I just want to be rear clear here. There could be  
20 a parallel analysis where essentially you could spit out a vector of the  
21 chemicals combined over the total diet. So if we wanted to identify, as

31

1 I'm sure you do at some point, what are the specific chemicals that  
2 contribute most to risk and how is that laid out? Is that possible with  
3 the software you have now?

4 DR. SMITH: Yes, it is. That is also underway. I choose not to  
5 discuss it. We can selectively remove a given chemical's contribution  
6 from the cumulative assessment. We can do it for a given food  
7 chemical combination or just across the board. And that's also  
8 actively in progress. But I just don't have -- I don't have any anything  
9 really to relate to you on that at this point.

10 DR. KENDALL: Dr. Rhomberg. Dr. Durkin, any further  
11 clarification? Dr. Rhomberg.

12 DR. RHOMBERG: I'm stepping a little bit out of my realm of  
13 expertise here. It seems to me that one could say that it could be that  
14 all sort of common diets are the same and every eccentric diet is  
15 eccentric in its own way. So that might say that it would be a mistake  
16 to focus on the single chemical or single food that causes the biggest  
17 contribution to risk if that's something that's ubiquitous and  
18 unavoidable.

19 It's sort of raising the baseline for everybody. And then the  
20 people that have various odd combinations of things, which would be  
21 very different for each of the different people, are the things that are

32

1 causing peaks and throwing a certain individual into the tail of  
2 distribution one way or the other. That would be very important to  
3 know for risk assessment purposes.

4 Is there a single thing that you can do? Is the way to avoid  
5 problems that are caused by single unusual events in people because of  
6 an exceedence or very eccentric diet is the way to handle that,  
7 lowering the level of everybody, sort of lowering the average level so  
8 that the peaks don't go higher or to attack the peaks particularly?

9 As I say, this is out of my realm both from the point of view of  
10 assessing diets and from risk assessment. But I think it would be  
11 important to pull out those kinds of observations from these things.  
12 So that in a way, when you're looking at the peaks, maybe the thing  
13 isn't the biggest contributors; it's the ones that are most different from  
14 the main stream of people farther down in the distribution and are  
15 there consistencies there that can be got at.

16 DR. PERFETTI: Dr. Rhomberg, if I understand correctly, I  
17 think what you're asking is do the peaks represent unusual  
18 consumptions.

19 DR. RHOMBERG: Unusual consumptions or unusual residues,  
20 whatever. Just things that are -- it's got to be unusual something  
21 because there has to be some reason why they go up into the peak.

1 DR. BULL: Otherwise you wouldn't get that distribution that  
2 we just talked about. I was right.

3 MR. MILLER: The CEC does print out essentially those  
4 individuals in the upper tails of the distribution. It lists out the  
5 consumption and lists out the residues associated with that. And what  
6 we do is look through that and get an idea of what's doing it. Is it  
7 unusual consumptions entirely by one commodity or unusual residues  
8 or such. So that is something we do look into in evaluating these  
9 things and judging their reasonableness.

10 DR. SMITH: You know, to not be totally precise in describing  
11 this, it is a very complex and even some of our single chemical  
12 assessments maybe were not that different in their complexity. But in  
13 this case, we are -- we do have the overlapping situation of  
14 distribution of consumption, a distribution of a variety of possible  
15 chemical uses. So more than one chemical is involved. And there's  
16 not necessarily a direct correlation between the frequency of  
17 occurrence and the relative potency of that chemical because these are  
18 all adjusted relative to methamidophos and we have a wide range of  
19 potencies in the chemicals over a few orders of magnitude.

20 We have, to our way of thinking, a fairly complex overlay and  
21 the possible time frame consideration, a possible, fairly complex

34

1       overlying of potential distributions. And we are look thing for what  
2       are the single things we can do to interpret what this means. And to  
3       this point, it's not necessarily a single thing; it's a combination.

4             DR. KENDALL: Dr. Portier.

5             DR. PORTIER: I was going to try to clarify Lorenz's comment.  
6       But I think it's more appropriate for a discussion later on.

7             DR. KENDALL: I agree. Dr. Heeringa.

8             DR. HEERINGA: I have a very quick question about the  
9       mechanism of the simulation where you remove foods A, B, and C.  
10      When you do that in the simulation, do you literally strike those foods  
11      out of the sample child's diet; or do you sample children who consume  
12      those foods on that day? In other words, is there a replacement of  
13      other diets that's taking place in the simulation?

14            DR. SMITH: We're removing the OP contribution to that diet.

15            DR. HEERINGA: You actually sample the child. And if it  
16      happens to be a contribution A, B, and C, so you're essentially  
17      lowering an expectation the overall residue consumption.

18            DR. SMITH: Correct.

19            DR. KENDALL: Dr. Freeman.

20            DR. FREEMAN: Two things. When you did this, are you only  
21      looking at commercially used pesticides as opposed to residential

35

1 fruits and vegetables that are treated? And the second thing is, a  
2 number of these commodities, based on the data that we were provided  
3 with, are produced in very specific regions. You know, they're either  
4 warm weather crops or they're cold weather crops. And so you may  
5 have three areas of the country that are generators of, say, one of  
6 these crop items.

7 Have you looked at the differences in pesticides according to  
8 the regions from which the samples were obtained? And have you  
9 tried to do some sort of weighting based on some sort of distribution  
10 across the regions as to how it's going to impact on the pesticides in  
11 these foods?

12 MR. MILLER: The assumptions in this assessment is that PDP  
13 does sample proportionate to a national basis proportionate to  
14 production. So if 20 percent of crop A is grown in California, or  
15 consumed in California, 20 percent of the samples would be from  
16 there. So overall, on a national basis, yes, it is proportionate to that.

17 In terms of looking at regional residues, for example, we assume  
18 essentially it's a national distribution of the commodity. So we don't  
19 look at specific regions and don't look at specific residues in specific  
20 regions.

21 DR. FREEMAN: Yeah. I'm a little concerned about that

36

1 because you see a constellation of pesticides in one region for say  
2 apples that you may not find in another region that grows apples.  
3 They have one or two that are the same, but there may be differences.  
4 And that might impact your results.

5 DR. KENDALL: Dr. Adgate.

6 DR. ADGATE: I'm curious. What's the rationale for removing  
7 the violative residues?

8 DR. SMITH: Should I pass that to the end of line or try it  
9 myself?

10 MS. MULKEY: In pesticide regulation, there's always the  
11 challenge of whether you regulate to violations or regulate on the  
12 basis of the assumption that people comply with the law. It's not  
13 unique to this situation. We face that issue a lot. And if we believe  
14 that violations are endemic, that there's sort of an inherent aspect of  
15 the lawful use, we will consider violative scenarios. I'm talking now  
16 generally, not in this one. I think we do not have a basis in these  
17 examples in believing that the violations predictable, sustainable, sort  
18 of unavoidable by product of lawful use.

19 But if we did or had some basis to, then that would be the  
20 situation in which would typically take into account violations. This is  
21 not a policy we developed just for this approach. That's been our

37

1 longstanding approach to the way we thought about pesticide  
2 regulations. And it involves not just foods but other exposure  
3 situations, too.

4 DR. KENDALL: Dr. Portier. This is the last question.

5 DR. PORTIER: No, this is four or five. I was waiting to see if  
6 anyone else would ask them. Again, hopefully, these are just  
7 clarification questions. In what you just presented, those are single  
8 day resamples for single-day diet; is that correct?

9 DR. SMITH: Yes. But it's using both days of the diet.

10 DR. PORTIER: Okay. I don't understand that. Run that by me  
11 again.

12 DR. SMITH: They are single-day exposures, but they are  
13 obtained by using a survey that is composed of two separate days.

14 DR. PORTIER: And in the two-day survey that you're using,  
15 you're just using the one of the days as the resampling for food  
16 consumption.

17 DR. SMITH: No, in DEEM, both days are used.

18 MR. MILLER: The count is separate. I'll get into it a little bit  
19 in my presentation. The account is essentially separate people. In the  
20 diet food Person No. 1, Diet No. 1, counts as essentially a separate  
21 person than Diet No. 2 for that same individual.

1 DR. PORTIER: But you're sampling the day's diet.

2 MR. MILLER: Yes.

3 DR. PORTIER: For one of the two days by random draw.

4 MR. MILLER: Yes, yes.

5 DR. PORTIER: So that was the second part of my question.

6 There is a random draw for diet as well as a random draw for pesticide  
7 residue.

8 MR. MILLER: Random draw. But the random draw for diet is  
9 connected to that individual. Well, actually, I'll talk about it a little  
10 bit more in my presentation.

11 DR. PORTIER: We talked about the violations issue. I wanted  
12 to raise that again. I think you want to look that the policy, at least  
13 try to collect some data on what percentage of violations are actually  
14 caught.

15 The PDP data is market basket from food stores. Does it  
16 include market places? Road-side buys? Anything like that?

17 DR. SMITH: PDP is primarily from food distribution centers.  
18 It's not at the grocery store in general. In some commodities, for  
19 example, some of the grains and I think maybe grains were taken from  
20 a earlier point in the distribution, the idea was to get it as close to the  
21 distribution as practical to be able to reproducibly over time go back

39

1 and resample.

2 DR. PORTIER: To follow up on that question we had a minute  
3 ago, I didn't understand the resampling scheme. If I resample a diet  
4 and the child gets two apples in one day, assuming apples may or may  
5 not be exposed to OPs. But I'm going to choose apple for the fun of  
6 it. Do the apples get two separate random draw residues independent  
7 of each other, or do the two apples get the same residue?

8 MR. MILLER: In the DEEM, what it does is it totals it over the  
9 day. So if your child has, the person you're drawing, has two apples in  
10 one day, they will, essentially, be combined in consumption of grams  
11 per kilogram. And then it will draw one random residue value for that.

12 DR. PORTIER: That basically assumes, I guess, the two apples  
13 have the same residue which is fine for me.

14 And there was a another statement you made, and this is my last  
15 question. When you looked at the population groups assesses and  
16 noted that the children one to two years old have the highest  
17 exposures of all these groups, I gather, because you did not show us,  
18 you did not do less than one year and you did not do the other groups.  
19 You are assuming that those other groups are not as high of an  
20 exposure; is that correct? Or did you actually do the less than one  
21 year olds?

1 DR. SMITH: We have done less than one and the exposure is  
2 less. Some -- I mean the possibilities are, you know, you can go in  
3 and adjust the years that you want to take. So there are a number of  
4 possibilities. And at different stages in the assessment, we've looked  
5 at other combinations. At this point, I cannot give you an assessment,  
6 say, for children one to six all inclusive. We have three to five broken  
7 out from one to two, and we have looked at less than on. We just  
8 haven't included it.

9 DR. PORTIER: And do you intend to include that in the final?  
10 We got several questions about that yesterday. And I'm trying to  
11 understand why it's not in here then.

12 DR. PERFETTI: I mean, basically, not just this analysis, but  
13 with a lot of them. One to two are the most highly exposed right down  
14 across the line. We could put zero to one in or all the other age  
15 groups, but it would always, be to our knowledge, and, Dave, I think  
16 you can agree with me, it's always the one to two because they have  
17 the largest consumption with respect to body weight. So they always  
18 are going to get quote the "highest exposure". So if you know that  
19 one to two are going to be the worse case, everything else, the  
20 exposure is going to be less.

21 DR. PORTIER: I guess you can assume I'm from Missouri. I

41

1 like to be shown. "Show me" is the basic tenet here.

2 DR. KENDALL: Thank you. Any further points of  
3 clarification? Dr. Zeise. Remember, Dr. Miller, we'll go forward and  
4 probably clear up a lot of these questions. The presentation is quite  
5 long so I didn't want to break in the middle, at least let people to have  
6 a chance. So points of clarification.

7 DR. ZEISE: Yes. I was, also, wondering what the teenager,  
8 the upper end might look like for teens. Just curious, looking through,  
9 they're conspicuously missing. And I also wondered in terms of  
10 thinking through what might be happening with the tail if you looked  
11 at the issue of using composite sampling. What that would do is  
12 you're smearing out and probably have more zeros, more cases of zero  
13 and then higher values and that the composite sampling is actually also  
14 doing some smoothing at that upper end.

15 DR. SMITH: Actually, we do have limited -- we do have  
16 information from single serving versus composite samples. PDP has  
17 looked at three different commodities: peach, pear and apples. And  
18 there is also an industry market basket study that was done on  
19 single-serving basis; although, they do not have a composite direct  
20 comparison to a composite.

21 At this point we do not see a lot -- maybe surprisingly -- a lot of

42

1 difference between the distribution in the PDP between the single  
2 serving and the composite.

3 DR. ZEISE: At that upper tail.

4 DR. KENDALL: Dr. Bull.

5 DR. BULL: Just a real quick clarification of Chris's. When you  
6 looked at the less than one year old, is that distribution more or less  
7 the same; or is the high end exposure still even more exaggerated?  
8 When you say "across the board," I was trying to figure out what  
9 across the board meant. Am I making myself clear?

10 DR. SMITH: I'm not sure I can give you correct answer on  
11 that.

12 DR. BULL: Well, you have a curve that describes the  
13 distribution of exposures in terms of MOEs, the fraction of the MOE.  
14 Is that slope of that curve similar in the less than ones as it is to the  
15 one and twos. I could see the extremes being more marked in that  
16 group.

17 DR. SMITH: That's a good point. And I haven't carefully  
18 looked at that. We do know that they are less exposed in terms of  
19 comparing the curve shapes, we haven't gotten to that. But that is a  
20 good point.

21 DR. KENDALL: Dr. Reed.

1 DR. REED: This is a quick clarification question. Because you  
2 didn't see a great difference in residue distribution between  
3 single-serving-size surveys and the composite samples, and that's the  
4 reason you didn't use single-serving-size data; is that correct?

5 DR. SMITH: Yes. Possibly another reason. That's part of it.  
6 And just the feeling that if we have this huge data base of composite  
7 samples, and to use the single serving, we're limiting ourself to one  
8 small segment of data. If it did not make a difference, the composite  
9 samples, it would be consistent kind of analysis. We feel that  
10 composite samples may be better suited for catch catching co-  
11 occurrence. Can't prove that; but that's our general sense of it. That  
12 would be another reason.

13 DR. REED: Thank you. The other short question is: There's  
14 mention about choice years of PDP data. The analysis seemed to  
15 indicate that maybe you don't need that many years of data. There's a  
16 mention in the document about correlating that or the concern for pest  
17 pressure. Have you gotten any chance to go back and sort of looking  
18 backwards to see if there's any past pressure situation in that the PDP  
19 data actually picked that up in terms of residue?

20 DR. SMITH: That's part of the analysis that led us to change  
21 the question somewhat because we have not completed that. We are

1 interested in whether we can pull that out. We don't know.

2 DR. KENDALL: Any further comments related to this stage of  
3 the presentation? Before we move to Mr. Miller, I'd like to welcome  
4 Ms. Marsh Mulkey, the Director of Office of Pesticide Programs. We  
5 appreciate you joining us again. Would you like to address the Panel?

6 DR. ADGATE: No thank you.

7 DR. KENDALL: Mr. Miller, are you ready to proceed?

8 MR. MILLER: Just to kind of go through quickly the outline of  
9 the presentation. I'll provide an introduction, background  
10 information. It will be a brief overview and recap of probabilistic  
11 techniques used in preliminary cumulative risk assessment, or PCRA.  
12 I'll then talk a little DEEM(FCID) versus DEEM(FCID)/Calendex. As  
13 Bill had mentioned, his talk was on DEEM(FCID). And all the FCID  
14 means is the new recipes, the new publicly available recipes and the  
15 new '94, '96, '98 data. Do a little talk about the difference between  
16 those two and how the one includes a time component.

17 I'll talk a little bit then about the time frame considerations.  
18 Why it's important. There will be more details relating to this  
19 tomorrow. Specifically, how to compare these with a tox endpoint.

20 Then talk about modes in which Calendex can be used for a  
21 cumulative risk assessment which goes directly to the time frame

45

1 consideration issue. Consecutive daily estimates is one potential  
2 mode. That was the mode that was used in the preliminary cumulative  
3 risk assessment, PCRA, that provides separate estimates for January 1,  
4 January 2, January 3, et cetera. And alternative, methodology, which  
5 is available in DEEM which was not used for the December 3  
6 document was rowing or sliding assume time frame approach. Again,  
7 there will be a little bit of discussion of this in terms of interpretation  
8 on this on Thursday.

9       And then going to strengths and limitation of these modes and  
10 the associated issues. This will include a comparison of some runs  
11 we've done comparing the 1-day assessment with the 7-, 14- and  
12 21-day rolling averages. And you'll see those numbers here.

13       And then, finally, the questions for the SAP.

14       Just some points to remember, the presentation will not  
15 extensively review the step-by-step mechanics of DEEM(FDIC)  
16 Calendex algorithms. DEEM Calendex was reviewed in previous  
17 SAPs. However, I will try to give you a flavor of what's happening.  
18 And where it's important, I'll go into the details and differences  
19 between the modes.

20       The main presentation, here, concentrates on exposures through  
21 food. However, the principles apply to all routes. And, finally, I'll

46

1 remind you that no decision has been made on an appropriate MOE or  
2 threshold percentile for regulation.

3 When I talk about X-percentile graphs, they are meant to be  
4 illustrative only, intended to illustrate the concept. It's not that we've  
5 made a decision or are leaning toward any specific percentile or MOE.

6 Just some background, DEEM(FCID)/Calendex provides  
7 probabilistic assessment of exposures through food, water, and  
8 residential pathways. DEEM(FCID)/Calendex incorporates the  
9 concept of a calendar to aggregate or accumulate exposures -- it's a  
10 time-based approach -- which allows us to look at individual days of  
11 the year. Importantly, the approach allows appropriate temporal  
12 matching of exposures through food, drinking water, and residential  
13 pathways.

14 These temporal aspects are important for OPs to the expected  
15 seasonal use patterns. For example, it would be important to match  
16 springtime exposures from one applications through exposures through  
17 drinking water associated with spring runoff. Likewise, it would also  
18 be important to preclude or appropriately discount nonsensical or low  
19 probability events, perhaps treatment of house for fleas during the  
20 wintertime in the northeast.

21 So this is what Calendex allows us to do. Thus Calendex uses

1 probabalistic techniques to appropriately combine exposures from the  
2 food, water, and residential pathways in a manner which incorporates  
3 probabilities of exposure, use and application practices, human  
4 activities patterns, et cetera. Importantly, it considers their  
5 associated seasonality and timing.

6         So we expect, for example, probabilities of exposure, one can  
7 input as a data for Calendex at maybe perhaps 6 percent of the  
8 individuals users of a pesticide, or the 15 percent of apricots contain  
9 residues. So the probabilities of exposures can be counted in that  
10 way.

11         Use and application practices can also be accounted for. If the  
12 label directions say apply in spring, then it will be applied in the spring  
13 as per Calendex. If the label directions say, for example, or if we  
14 know that 80 percent of the users apply it one time and 20 percent  
15 apply a second application 2 to 4 weeks after the first, that  
16 information can be incorporated as well.

17         It also incorporates human activity patters, time spent on lawn,  
18 for example, time spent inside, et cetera.

19         The result of the result of the Calendex analysis is a collection  
20 or distribution of aggregate exposures, that's food, residential and  
21 drinking water combined, for each day of the year for the relevant

48

1 region. These exposures can be plotted as a time line or profile of  
2 population daily exposures for any given percentile in this  
3 distribution. This is illustrated on the next slide.

4 This is just a quick 3D graphic which kind of summarizes DEEM  
5 Calendex output in a compact form. You can see the vertical access is  
6 the exposure. That's plotted against a time line in the bottom of  
7 horizontal axis from zero or 1 to 365 days. And the depth is the  
8 percentile for any given percentile. In other words, what we can do is  
9 plot exposures as a time line against any given percentile.

10 The graph emphasizes an important point that a time line,  
11 time-based profile exists for any selected percentile. We've shown  
12 some specific ones here, 10, 30, 50, et cetera. For example, there's  
13 one at 99 here which goes on. It goes along there from January 1 to  
14 December 31. And what that does is it shows or plots out the 99th  
15 percentile exposures for each of the 365 days of the year. 99th  
16 percentile for January 1, 99th for January 2, et cetera.

17 The three 3D graph essentially summarizes output that's  
18 specifics to DEEM(FCID)/Calendex as opposed to DEEM(FCID)  
19 which Bill talked about. Again, you get the three-dimensional part  
20 because of the time component is added here.

21 DEEM(FCID) analysis assess exposure from food alone, as Bill

49

1 said, without respect to timing or seasonality issues. What it does is it  
2 randomly matches report food consumption by individual with residue  
3 data. There's no time component to this. The result, as Bill described,  
4 is a single distribution of exposures and a single value estimate of risk  
5 at any percentile of exposure.

6 How does DEEM(FCID)/Calendex, which incorporates the time  
7 component differ DEEM(FCID) when we do an aggregate or  
8 cumulative assessment in which pathways are combined, time and  
9 considerations become important? DEEM Calendex performs this  
10 analysis in a manner in which time considerations are incorporated. It  
11 does this by performing separate analyses for each day of the year.  
12 The result is 365 separate distributions of exposures for each day of  
13 the year. And exposures can be at any given percentile, 99th, 95th, et  
14 cetera, can be plotted as a time-based exposure profile.

15 These differences are summarized on the next slide.  
16 DEEM(FCID) considers food alone; whereas the  
17 DEEM(FCID)/Calendex considers all pathways, food, water,  
18 residential. Timing is not considered in DEEM(FCID). There's no  
19 day-to-day variation, whereas timing is considered in  
20 DEEM(FCID)/Calendex. There's some day-to-day variations in the  
21 diet. That will be explained a bit later in this presentation.

50

1           And another difference is single-exposure estimate is provided  
2           DEEM(FCID) at any given percentile; whereas,  
3           DEEM(FCID)/Calendex provides 365 sequential daily exposure  
4           estimates for any given percentile.

5           With that as background and the knowledge that  
6           DEEM(FCID)/Calendex can consider time, there are several issues to  
7           the SAP regarding time-frame considerations. Remember that  
8           exposure's only half the risk equation. It's important to consider how  
9           the estimated exposure is compared with the toxicity endpoint.

10           In the preliminary cumulative risk assessment, PCRA, toxicity  
11           endpoint is based on the BMD10 which reflects a multi-day dosing  
12           study or a series of multi-day dosing studies. And you heard about  
13           this yesterday from Anna and Woody. You, also, heard about it last  
14           September at the 2001 Scientific Advisory Panel meeting.

15           In the report you provided, there were two statements that  
16           cumulative risk assessment should ideally compare toxicity endpoint  
17           and exposure durations of the same time frame. And, also, to the  
18           extent possible, comparison should take into account the pattern of  
19           human exposure.

20           Again, you're scheduled to hear more about this comparison  
21           tomorrow under the risk characterization session. But in my talk here,

51

1 what we'll focus on is the time-frame issue and how it's handled by  
2 DEEM and Calendex.

3 DEEM Calendex program can perform analyses using a variety  
4 of time frames. You heard from Bill the single day. This presentation  
5 considers two specific modes of analysis which are available in  
6 Calendex. One is the single consecutive daily estimates, January 1,  
7 January 2, et cetera. That was the analysis that was used in the PCRA.

8 The second is a rolling or time-frame approach where it takes a  
9 rolling average, considering, for example, January 1 through 7, then  
10 January 2 through 8, then 3 through 9, et cetera. It provides an  
11 average exposure over that time period.

12 I'll emphasize that the examples I'll give you here are  
13 illustrative only, intended to illustrate the concept. The numbers are  
14 not real. And PCRA used, again, the first option; the  
15 single-consecutive day rolling estimate not the rolling time frame.  
16 Although at the end of this presentation, you'll see those results for  
17 the rolling time frame and be able to compare the two.

18 Just first option, the single-consecutive-day analysis, the  
19 analysis we used in the December 3 assessment, provides separate  
20 independent exposure and risk estimates made for each day of the  
21 year. And I'll show this in the next few slides, summarize how that is

52

1 done.

2 The estimates, then, are arrayed chronologically into an  
3 exposure time line for any selected percentile and graphed. These  
4 represent independent daily estimates of risk on each day of the year.  
5 Importantly, they're not necessarily -- as you'll see in the following  
6 slides, they're not necessarily the same individual on consecutive days.  
7 What I mean by that is the next several slides show how this is done by  
8 DEEM Calendex.

9 So for a single-consecutive-day analysis, the analysis that was  
10 done in the assessment, and, again, the numbers here are not  
11 necessarily -- they're not necessarily the numbers. It's illustrative  
12 only. What DEEM would do would begin with January 1.  
13 DEEM(FCID)/Calendex begin with January 1, CSFII, Individual No. 1.

14

15 What DEEM Calendex would do would then estimate the  
16 exposure and plot that exposure to the individual on the histogram.  
17 So that could come across as -- essentially think of it as a first block  
18 of a histogram would be located someplace along there.

19 How is that exposures estimated? It's done for that Individual  
20 No. 1 on January 1. It's done by randomly choosing one of Individual  
21 No. 1's self-reported diets and then randomly selecting a residue for

53

1 each component of that diet. And that is essentially summing them up  
2 and estimating an exposure based on that.

3 And the same thing would be done with Individual No. 2. And  
4 that would work out -- actually, if you could back up for a second.  
5 That would be the same thing would be done for Individual No. 2.  
6 And the result is a slowly build up essentially a distribution which  
7 might look something this, a histogram with a shape that looks  
8 something like that.

9 In this case then what we do is, if we were choosing to plot out  
10 the 99.9th percentile, what we would do is estimate what that is. In  
11 this case, it might be individual No. 10,456 that would plot out at the  
12 99.9th percentile and essentially estimate the exposure from that  
13 individual at that percentile. That might, for example, translate to a  
14 MOE of 84.

15 We than move on to January 2 and do the same thing. Starting  
16 with Individual No. 1, estimating the exposure and plotting. And,  
17 again, we do it for all the individuals. Individual No. 1, 2, 3, et  
18 cetera.

19 In this case, these would be plotted out for all the individuals.  
20 In this case, the 99.9th percentile individual exposure might be  
21 Individual No. 1,492. We estimate exposure. And that might work

54

1 out to be, for example, an MOE, margin of exposure, of 92.

2 We would proceed through each day of the year in this through  
3 December 31, which is here. In which case of the 99.9th percentile  
4 individual or exposure, might be Individual No. 18,912. again, we'd  
5 estimate an MOE with that exposure.

6 The net result of this is we end up with 356 different 99.9th  
7 percentile values. Again, what we've done is for each day of the year  
8 we've run through each individual and we can pick out the 365th -- the  
9 99.9th percentile values.

10 What we do is take each of these 365 99.9th percentile values  
11 and then plot them out for each day of the year, January 1 through  
12 December 31, that population percentile. The resulting time-based  
13 exposure profile represents, in this case 99.9th percentile exposure for  
14 each day of the year.

15 It's important to remember that each day of the year is  
16 considered independently. It is not the same individual. If you  
17 remember on January 1, it was Individual No. 10,456 that was at the  
18 99.9th percentile. On January 2, it was a different individual.

19 One can see this plot on the next slide here. The vertical axis.  
20 These plots are central to the understanding and interpreting the  
21 cumulative risk assessment. I'll go through it in some detail.

55

1 Remember, this is the single day assessment as we used in the  
2 preliminary assessment.

3 This is the vertical axis here. It's the exposure. Here is the  
4 time line. The horizontal axis is the day of year from January 1  
5 through December 31.

6 Continuing with the example, if you remember, January 1, the  
7 99.9th percentile exposure value was associated with Individual No.  
8 10,456. He had an MOE of 84. So that would be plotted here for  
9 January 1.

10 For January 2, the 99.9th percentile individual, the value  
11 associated with the 99.9th percentile exposure would also be plotted.  
12 In this case it might be an MOE of 92. It continues through the year  
13 through December 31.

14 Just some key points. These are all, again, each different  
15 individuals. These are also one-day exposures.

16 How is this interpreted, for example? Day, for example, if you  
17 wanted to interpret the MOE associated with Day 31, this would  
18 essentially look up here, and this would be perhaps an MOE of 58.

19 How is that interpreted? On Day 31, the day we were looking  
20 at, on the next slide, the MOE for food, the interpretation would be  
21 the MOE for food at the 99.9th percentile would be 58. The

56

1 translation of that would be the exposure to the 99.9th percentile  
2 individual on Day 31 is 58 times lower than the BMD10.

3 Day 32, it may be that the MOE was estimated as 66. The  
4 translation of that would be that the exposure to the 99.9th percentile  
5 individual on that day is 66 times lower than the POD. Remember, it's  
6 very likely that that is a different individual than the 99.9th percentile  
7 individual on January 31. Just as on January, the 99.9th percentile  
8 individual was different from the individual on January 2.

9 The next slide shows some pros and cons of this method. This  
10 was the method that was used in the PCRA. It's easier to identify risk  
11 contributors and sort them out using the CEC function of DEEM.  
12 That's the function that Bill had talked about some.

13 It's also health protective from a multi-day standpoint. When  
14 one looks at a sustained or extended period of time of elevated  
15 exposures, it's unlikely to be the same individual that's being exposed.

16 However, there are a number of disadvantages to this. One is  
17 that the point of departure, the BMD10, is based on multi-day  
18 exposures. The animals, if you remember from yesterday, are dosed  
19 daily for an extended period of time to estimate the BMD10. It might  
20 of be of concern would be the relevance of comparing a series of  
21 elevated single-day exposures to a multi-day endpoint.

1 Another disadvantage is the second consecutive daily estimates  
2 are likely to over estimate multi-day exposures to an individual at the  
3 higher percentiles. For example, it's not possible to interpret an  
4 extended series of elevated exposures on consecutive days as  
5 representing extended period of exposure to the same individual. In  
6 other words, we haven't strung together consecutive days for the same  
7 individual. So the individuals are different.

8 If we were to string together consecutive days for the same  
9 individual, what we'd get from DEEM we'll be able to have essentially  
10 a rolling time frame approach. And this is what this next series of  
11 slides considers. And I'll talk about stringing the days together and go  
12 through a detailed example of how this is done.

13 It can, also, be looked at as essentially a multiple sequential day  
14 option. In this rolling-time-frame option, a rolling average exposure  
15 is calculated over multiple days for each individual. For example,  
16 January 1 through 7, then January 2 through 8, and January 3 through  
17 9, et cetera.

18 It's this series of multi-day average exposures that then serves  
19 at a basis of comparison with the BMD10 -- with the POD. More,  
20 specifically, this distribution of individual-based multi-day average  
21 exposures is compared with a multi-day BMD10.

1           The next slide show an example of this. And, again, the  
2 numbers are not real but are meant to be illustrative only.

3           Specifically, this specific example will deal with a 7-day rolling  
4 average. It begins with individual No. 1 on January 1. And you can  
5 see this is going to be this January 1 through 7 rolling average. This  
6 exposure to this individual on January 1 is estimated from this DEEM  
7 Calendex software as .012 milligrams per kilogram per day. That's  
8 estimated, as always, by randomly choosing CSFII Individual No. 1,  
9 Day No. 1 or Day No. 2 diet; randomly choosing residues associated  
10 with each component of that diet; combining those; and summing them  
11 over all foods reported consumed by that individual on that day. So  
12 that point .012 is estimated in that way.

13           The same thing is done for that individual for January 2, again,  
14 choosing one of his two randomly reported diets. And January 3, et  
15 cetera, all the way through through January 7. You can see on January  
16 2, the estimated exposure using that is about a little bit over .006.

17           The next step after that, after we've calculated exposure from  
18 each of those days is to calculate an average exposure over the entire  
19 full 7 days. Here the average exposure, you can see, is about .006  
20 milligrams per kilogram.

21           We've done this then for Individual No. 1 for January 1 through

1 7. We now move on to Individual No. 2 for this same time frame.  
2 Again, starting with January 1, estimating the exposure as before for  
3 each day, January 1 through January 7. After that's done, we calculate  
4 a 7-day average over this time period. Here you can see it works out  
5 to be about .007 milligrams per kilogram.

6 We continue this through all individuals in the survey,  
7 calculating it for January 1 through 7. If there were 15,243  
8 individuals in the survey, for example for the last individual, the 7-day  
9 average exposure works out to be .005 milligrams per kilogram.

10 If there were 15,243 individuals in the survey, we'd end up with  
11 15,243 7-day average exposures for January 1 through 7. Then what  
12 we would do is sort them from high to low and pick out this 99.9th  
13 percentile exposure and plot this value for January 7.

14 So what we've done is for January 1 through 7, calculated for  
15 each individual a rolling average and picked out the 99.9th percentile  
16 values in this case just as an example.

17 For the next rolling time frame is January 2 through 8, we go  
18 back to Individual No. 1 and calculate exposures for each of the days,  
19 January 2 through 8, again randomly choosing each day one of his two  
20 reported diets and combining it with a randomly selected residue. We  
21 do the same with Individual No. 2, Individual No. 3, et cetera, for

60

1 January 2 through 8. Continue all the way through and then slide  
2 along and do 3 through 9, January 4 through 10, et cetera, until we get  
3 to this last individual which would be January 1 through 6. It rolls  
4 around. We'd end up with 365 different 99.9th percentile 7-day rolling  
5 average exposures and plot them over time as we did before.

6 There are a number of advantages and disadvantages to this  
7 approach. One advantage is that it incorporates the variability in  
8 exposure for an individual across multiple days. This multi-day  
9 average exposure may be the actual exposure of interest to compare  
10 with a multi-day endpoint.

11 It's also likely to provide a more realistic estimate of exposures  
12 across multiple days. And, again, if it's not a series of single-day  
13 exposures we're interested in, this allows us to calculate high end  
14 multi-day average.

15 It's also flexible with respect to matching time frames  
16 associated with the POD. One can chose, for example, this example  
17 was 7 days. But one could chose 7-, 14-, 21-, or 28-day rolling  
18 averages.

19 There are a number of disadvantages, too, to this approach.  
20 Break down into two basic areas, one associated with food  
21 consumption and the other associated with residue. UDSA, CSFII

61

1 does not provide consumption data across the multiple consecutive  
2 days which would be of interest. It's limited to two days of records of  
3 reported intake. Also, those two days are not consecutive. They are 3  
4 to 10 days apart.

5 As a result, the multi-day average exposure for any individual  
6 uses only two days of reported consumption data for that individual.  
7 With the rolling average approach, what we're using is those two days  
8 of reported intakes to simulate 7 or more days of eating. It repeats  
9 these randomly throughout the time frame of interest.

10 The other aspect concerns food residues. There are no  
11 longitude and residue data available. For example, if I ate a star fruit  
12 yesterday and star fruit today, if they came from the same Safeway,  
13 they're likely to have the same residues than if the one I ate yesterday  
14 was from Safeway and the one I ate today was in the company  
15 cafeteria. So there's no longitudinal basis on residues for that.

16 Just more specifically on those two points regarding, first, on  
17 food consumption aspect. Any consecutive day period of interest for  
18 an individual will contain a series of repeated diets which would tend  
19 to underestimate the variability. This will tend to over state potential  
20 exposure at the upper tails of this distribution to the extent that  
21 reported food choices or diets are associated with higher exposure.

1           On the aspect of the residues, the second aspect I talked about  
2 more specifically. Since residue values are anew at random, for each  
3 day during the time frame of two occurring on subsequent days, may  
4 not be accurately reflected understate potential at the upper times. If  
5 an individual exposure is associated with pesticide residue, two  
6 examples, one might be juice you drink from this morning, may very  
7 well be the very same one you drink from tomorrow morning. And it  
8 will have the exact same residue concentration. In  
9 DEEM(FCID)/Calendex, a brand new residue was selected for that  
10 second day.

11           Similar situation is bags of produce. The produce I eat today  
12 may very well be from the same bag I eat tomorrow. They likely share  
13 the same treatment history.

14           If the rolling time frame average in DEEM is selected, it allows  
15 -- the example I gave was 7 days. But it allows the user to choose  
16 various time frames. We've redone the analysis using a 7-, a 14-, and  
17 21-day time frames. And you'll see these in the next graphs.

18           Increases, two things you'll note as you go through these. And,  
19 again, you'll note when the next graphs are shown. But increases in  
20 time frame, going from 1 to 7 to 14 to 21 over which the averaging is  
21 performed, results in two main things. One is the attenuation of

63

1 variability; and this other is an increase in the MOE, essentially, a  
2 decrease in the exposure.

3 You'll see that in the next two slides. Keep in mind that it's a  
4 reverse log scale. And, also, the degree to which these changes occur  
5 are dependent upon the selected percentile. The effect seems to be  
6 greater at higher and more pronounced at higher percentiles than at  
7 lower percentile.

8 These are shown in this slide here. The very top one, the sky  
9 blue one, is the one day. What we did in the assessment using the one  
10 day time period. The next three underneath that are 7-, 14-, and  
11 21-day time periods.

12 So, again. These are averaging exposures. You note the  
13 attenuation goes down as you go from the one day here, the sky blue  
14 down here, less variability. And the there's a decrease in the MOE.  
15 You're averaging additional days into it, so there's an increase in the  
16 MOE, a decrease in the exposures.

17 This is actually -- this is an example of this higher percentile  
18 example where the effects were more pronounced. At the lower  
19 percentile example, you can see the same thing except the effects are  
20 less pronounced. Again, the sky blue is the one day; and it looks like  
21 the 7, 14, and 21 are almost coinciding, but they're very close.

1 I guess a series of questions would be the next set.

2 DR. KENDALL: Think I'd like you to have you stop there  
3 because we'd like to have some clarification from the Panel. Then we  
4 will take a break and come back with the public comment period.  
5 After that, I'll have you read the questions. And then we'll begin the  
6 deliberations.

7 At this point, any clarification questions from the panel? Dr.  
8 Durkin.

9 DR. DURKIN: I have three quick things and it may be a lack of  
10 understanding here. You indicated that Calendex makes assumptions  
11 about when the chemical is applied. So if the label said it's applied in  
12 the spring, that enters into it in some way.

13 MR. MILLER: That is entered into it in the residential side of  
14 the assessment.

15 DR. DURKIN: Only the residential. Okay. That's fine. We'll  
16 move on.

17 You showed some 3D graphs. If we asked for a 3D graph of the  
18 day of the year, the percentile, and then on Z axis the chemical, would  
19 that be possible? Can you spit those out?

20 MR. MILLER: If you were looking at a specific chemical.

21 DR. DURKIN: No. An array of different chemicals. It gets

65

1 back to my previous question about can we track these by chemical. I  
2 guess that's what I'm trying to nail down real clearly here. It seems  
3 like you could do it from the food, the Calendex.

4 DR. SMITH: We think we can do that. It would be a lot  
5 manual.

6 DR. DURKIN: So it's not easily done.

7 DR. SMITH: It would require kind of a multi-step process.

8 DR. DURKIN: It wouldn't just spit it out. Okay.

9 And then the last item is really just a follow-up on a question  
10 that Natalie had. In any of these residues is home grown vegetation  
11 considered?

12 DR. SMITH: No.

13 DR. DURKIN: Okay. Thank you.

14 DR. KENDALL: Any further questions?

15 DR. RHOMBERG: On the residential exposure component, I  
16 assume, does that take into account some kind of attenuation of  
17 exposures over time in ways that are modeled according to residential?

18 MR. MILLER: Yes. Jeff Evans will be talking about that later  
19 today. But it does. If you applied that three days ago, it would  
20 attenuate that over the three day up to today.

21 DR. RHOMBERG: You made a big point of saying they were

66

1 not real numbers for the rolling average. Was any of this real at any  
2 place? In that when these last graphs that you showed with the rolling  
3 averages, were those based actually on doing the exercise that you had  
4 described earlier?

5 MR. MILLER: Yes, yes. The point I wanted to make on the  
6 real numbers is that, when I was showing the average, the rolling time  
7 average, the Excel graphs from 0 to .014. Those real numbers there.  
8 We didn't go back and look at Individual -- that's good. We didn't go  
9 back. We didn't go back and look at Individual No. 1,492 plot out his  
10 exposures for example. There was some confusion about that at the  
11 technical briefing.

12 DR. RHOMBERG: Okay.

13 DR. MILLER: So I wanted to make it clear.

14 DR. RHOMBERG: And since you only have two days of diet for  
15 each person, you are sort of flipping back --

16 MR. MILLER: Flipping back and forth, yes, over those seven  
17 days.

18 DR. RHOMBERG: Randomly, you could pick the same diet  
19 twice in row if it happened.

20 MR. MILLER: Yes.

21 DR. RHOMBERG: And when you come up with different

67

1 values, that's because --

2 MR. MILLER: Different residues.

3 DR. RHOMBERG: -- of different residues.

4 MR. MILLER: Yes.

5 DR. RHOMBERG: Okay. Thank you.

6 DR. KENDALL: Further questions? Dr. Portier.

7 DR. PORTIER: In essence on the flipping diet issue, you  
8 actually flipped the diets for 365 days for an individual, don't you,  
9 because the 1 to 7 is the same individual for 2 to 6.

10 MR. MILLER: Yes.

11 DR. PORTIER: And then you and 2 to 7 and then you add the  
12 8. So the diet is flipped completely.

13 MR. MILLER: Yeah. But it's always connected to the same  
14 individual.

15 DR. PORTIER: Just so I'm really comfortable, I want you to  
16 reassure me again that the graphs that you show with the rolling time  
17 frames approach, the examples are clearly not OPs since those numbers  
18 are only 10 away from the BMD. Not the later graphs, but the early  
19 single rolling time frame graphs.

20 MR. MILLER: Yes, yes.

21 DR. PORTIER: I want to be certain.

68

1 MR. MILLER: Yes. Those are not.

2 DR. PORTIER: The couple of questions I had about some of  
3 the statements you made in -- 1, 2, 3 further graphs down from that  
4 one -- you have pros and cons for rolling-average-based estimates.  
5 There.

6 The second point. Why? I'm not sure I understand this.  
7 Clearly, the assumptions that go into the analysis are violated; there's  
8 absolutely no doubt about that. The double diet back and forth is  
9 clearly not a realistic diet. The residues selected independently from  
10 day-to-day without any correlation structure is clearly going to be  
11 violated especially into details of the distribution. Why do you believe  
12 this is more likely?

13 MR. MILLER: Which specific slide and which specific point?

14 DR. PORTIER: It's this slide, Point No. 2.

15 MR. MILLER: Okay. Why do we believe it's likely to provide a  
16 more realistic estimate of exposures across multiple days?

17 DR. PORTIER: Yes.

18 MR. MILLER: If you're interested in a multiple-day time frame,  
19 we believe that it provides -- the alternative, the one-day time frame --  
20 let me take a look.

21 DR. PERFETTI: Dr. Portier, in my own simple way. The way I

69

1 look at it is, if you do this day by day, you're picking an individual,  
2 say, at the 99.9th percentile one day and you're picking that individual  
3 at that percentile is unlikely to be at that percentile on a following  
4 day. Whereas for this day by day, you got a different individual each  
5 time.

6 I mean if you get exceptionally bad day on one day, the chances  
7 that you're going to have an exceptionally bad day for the next seven  
8 days are rather low.

9 DR. PORTIER: But the question here, I guess, I'm interpreting  
10 maybe differently than what you're saying. I'm thinking about  
11 distributions. So I got a distribution for single-day exposures. And  
12 then there's a distribution for multiple-day exposure. And the way I  
13 read this is that you're arguing that the distribution seen here for this  
14 procedure is more likely to be correct if you're interested in truly  
15 multiple days --

16 MR. MILLER: It's multiple days, yes.

17 DR. PORTIER: -- than is the distribution for single exposures.  
18 And I'm not convinced of that. I was trying to give you an opportunity  
19 to convince me that the two assumptions that are violated don't simply  
20 drive us regression to the mean, which is why we might see reduced  
21 variability, why we'd see lower tail behavior, and to get some question

70

1 -- have you done alternatives? There are some obvious alternatives.  
2 Don't use the two days back and forth. Choose random days and bring  
3 them together, find some correlation structure from day-to-day  
4 sampling, and use that.

5 Have you done any of that, some of the things we discussed  
6 when Calendex came up?

7 MR. MILLER: Yeah. We've talked about that one. One  
8 possibility is to hold the day constant -- hold the diet constant  
9 throughout the seven days, don't randomly bounce back and forth.  
10 Another possibility would be to choose different residues -- keep the  
11 same residues, for example, and find out how much of an effect that  
12 has.

13 We haven't gone ahead and done any of those analyses at this  
14 point. We're looking for recommendations and thoughts from you on  
15 how that might be applied.

16 DR. PORTIER: And let's see if I had any other questions.  
17 Yeah. Two more slides down I'm trying to understand this conclusion  
18 as well. Could you repeat the explanation for me.

19 MR. MILLER: Any I'll just read the slide first and then go  
20 through it. Any consecutive day period of interest for an individual  
21 will contain a series of repeated diets which tend to underestimate

71

1 variability. So, for example, if we're repeating, if an individual has  
2 reported --

3 DR. PORTIER: That I got. It's the next one.

4 MR. MILLER: Okay. This will tend to overstate potential  
5 exposure at the upper tails of the distribution to the extent that  
6 reported diets are associated with higher exposure. So for example, if  
7 I consumed, for example, two ginkgo fruits over these two days -- and  
8 that's an unusual event -- I'm going to repeat consuming those ginkgo  
9 fruits through all seven days.

10 So it's kind of -- in reality over seven days, I wouldn't be eating  
11 those on all seven days. But it's artificially repeating that  
12 consumption pattern over the seven days.

13 So if to the extent that the diet is responsible for high residues,  
14 the choice of the diet, the food choices, that would have a tendency to  
15 overstate the potential exposures.

16 DR. PORTIER: Okay. I guess I understand that point now.  
17 And by overstate, you mean overstate to some true distribution that  
18 we really don't know.

19 MR. MILLER: Yes, yes. And that's just at the higher  
20 percentiles. It would be kind of a regression to the means. As you  
21 add more variety to the diets -- instead of repeating the two diets over

72

1 and over again, if you're high, you would tend to move lower.

2 DR. PORTIER: And in the food consumption survey, were all  
3 diets two days?

4 MR. MILLER: All the diets -- okay. There were -- they asked  
5 everybody for two days and the data that we use in DEEM is only  
6 those individuals that reported the full two-days worth of  
7 consumption.

8 DR. PORTIER: So the individual-day diets are derived from the  
9 two-day diets absolutely guaranteed.

10 MR. MILLER: Yes.

11 DR. PORTIER: Thanks.

12 DR. KENDALL: Any further points of clarification? Mr.  
13 Miller, I thank you for an excellent presentation. We'll break at this  
14 point for 15 minutes. We will reconvene for the public comments.  
15 And then we will move into the panel discussion. Thank you.

16 [Break.]

17 DR. KENDALL: If everyone with take their seats, we'll  
18 reconvene. Okay, this are reconvene. We're in the public comment  
19 period now. We have had two individuals registered to speak. The  
20 first I would like invite to the table Ms. Ingrid Kelly of Bayer  
21 Corporation. If you would approach the public commentor position

73

1 over there. The microphone is available. Please state your name and  
2 affiliation for the record.

3 DR. KELLEY: I'm Ingrid Kelley, Bayer Corporation.

4 I'm here today on behalf of the Implementation Working Group  
5 to talk a little bit about their comments on the OP cumulative risk  
6 assessment, especially the food exposure part of it.

7 First of all, IWG commends the Agency for doing such a  
8 wonderful job in their move forward toward producing a cumulative  
9 risk assessment, which is, as you all know, a tremendous job. The  
10 IWG recognizes the difficulties involved and we want to be sure to  
11 acknowledge that we believe that the Agency is on the right track.  
12 There are many, many improvements that can be made that we can see,  
13 and we would like to advance some of them here.

14 We feel that, as I said, we are on the right track. But the  
15 OP-CRA process and methodology is precedent-setting technology and  
16 methodology all of the other chemicals will be evaluated with a similar  
17 technology. That's why we feel, as Marsha Mulkey put it, it we need  
18 to put in the best and sound science. Science must be the basis for this  
19 risk assessment.

20 Transparency and understanding are equally important. Because  
21 if we don't have that, we don't really understand the science.

1           Stakeholder input is equally important because each of us have  
2           our own little niche and we must be sure to listen to all the opinions  
3           and stakeholders, including the growers who have a particular interest  
4           in this risk assessment.

5           So we hope and, therefore, that the Agency will continue to  
6           improve this assessment; and, finally, will give us another opportunity  
7           to comment. In other words, we are hoping the Agency will produce  
8           an interim cumulative risk assessment where we will have the  
9           opportunity to see what the improvements might have done and how  
10          further we can improve this assessment.

11          I have to put my glasses on. IWG believes that the accuracy and  
12          realistic assumptions for the dietary data inputs are extremely  
13          important in the cumulative risk assessment, as well as single risk  
14          assessments. The assessment is, if it is peppered with overly  
15          conservative assumptions, often is taken as protective would then  
16          would mask the real risk drivers. Therefore, we have to be sure and  
17          not be overly conservative in our assessments then we want to find  
18          real risk drivers.

19          I have, myself, found this to be the case with individual  
20          assessments. I have some proof of this that conservatism can, in fact,  
21          lead you to the wrong direction.

1           And with this in mind, we hope that the Agency, as they have  
2 indicated, will further refine the risk assessment. We hope that they  
3 will consider the following considerations. Perhaps they might  
4 reevaluate the blended and nonblended issues.

5           Part of the reason for that is because the new DEEM(FCID)  
6 does include new recipes, new food groups, that have never been there  
7 before. They should be evaluated whether or not an item is blended or  
8 nonblended. This makes a big difference in the risk assessment.

9           Processing information is plentiful. The Agency has at its  
10 disposal the processing information from industry; it has, also, at least  
11 40 years literature around the world that has been produced by  
12 scientists in universities that show that OPs, especially, degrade when  
13 they are processed in homes by cooking and baking and other  
14 processing.

15           We are applauding the Agency for using registered and  
16 supported users only in the risk assessment. These are, after all, the  
17 only thing that the Agency or industry can do anything about. All of  
18 rest of it that might be illegal use should fall into a separate category.

19           We believe that the Agency should adjust the PDP data to  
20 reflect only current use patterns. In the lease 10 years, many  
21 companies, including my own, have come up with different and

76

1 competitive chemicals to OPs. These have already replaced many OPs.  
2 And the 1994-1995 PDP data does not reflect this. I, again, have from  
3 my own company several instances where this is the case. I will  
4 forward those to the Agency, and they may share them with you as  
5 they wish.

6 Also, there is the OP market basket survey which was conducted  
7 on I believe 10 or 13 -- I'm not entirely sure -- commodities on single  
8 servings. This data is in the hands of the Agency. They have  
9 evaluated it, and we believe that it could be used appropriately.

10 We believe that the incremental changes taken collectively will  
11 improve the overall credibility of the OP-CRA. We also believe that in  
12 refining the assessment, the Agency will have a better tool for more  
13 reliable decision-making.

14 The stakeholders need to have opportunity and access to the  
15 EPA's CRA tools and data. As I have mentioned, the Agency has used  
16 the new DEEM-Calendex. None of our colleagues in our industry have  
17 access to this data base or this model. We have not had a chance to  
18 evaluate it. The versions that are out now have not been peer  
19 reviewed, even though older versions have been.

20 The new translations of recipes incorporate new food forms that  
21 include baby food. We are not familiar with those food forms. We

1 have not really had a chance to get an input on that.

2 Also, these new translations -- and I don't understand how --  
3 and this is where, perhaps, transparency gets lots. The new  
4 translations in some way incorporate into the new recipes processing  
5 factors, I was informed; and this is something where we need some  
6 clarification. Because whatever processing factors we might give the  
7 agency, they may not be able to use but we won't know why. So we need  
8 to have some review state to find out what went on there.

9 Also, new PDP data have been used. We congratulate the  
10 Agency for working with USDA so closely to obtain this newest data.  
11 We are very glad for that. But the registrants and the stakeholders  
12 have not had a chance to see the data as yet. It just came out, I  
13 believe, last week publicly.

14 We, also, believe that it is useful, and the Agency did indicate,  
15 which we're glad for, that they will do analyses using the CARES and  
16 other software. We believe that is essential. Sometimes the different  
17 model will point out different problems in data sets or things that are  
18 important that have not shown up in one particular model because they  
19 have not been anticipated.

20 Finally, the IWG supports the rolling time frame average for the  
21 dietary CRA and the whole risk assessment. Partially, if the Agency is

78

1 going to use the BMD10 based on a 21-day toxicology value, it kind of  
2 would match the hazard, the acetacholinesterase inhibition at steady  
3 state with the duration of exposure. We believe that this makes sense.

4 Also, Jeff Driver will later on, for the nondietary portion,  
5 inform you why there is also good reason why this makes sense for  
6 nondietary considerations.

7 UDSA Food Survey Research Group should be consulted on  
8 related food consumption issues as you have discussed when David  
9 gave his talk. There is, for the food consumption, only one- and  
10 two-day period for each individual that information was gathered.  
11 And it was not in consecutive days.

12 However, the UDSA, have older data bases that do is  
13 consecutive information. And this could be used to correlate  
14 consumption patterns. And in addition to that, ENHANES (ph) might  
15 be able to relate some of these food consumption patterns and see  
16 what is the best way to handle this particular data.

17 Our final recommendations from the IWG is that EPA should  
18 reissue or issue a revised or interim OP-CRA that has inaccuracies and  
19 improvements included in it. Hopefully, by then, there might be a  
20 comparison also and an analysis of the outcomes of alternative models,  
21 the Calendex and CARES and the Lifeline. I think we can learn from

79

1 all of them.

2 We have to, also, evaluate the alternatives in methodologies as  
3 David has pointed out. I think the Agency is doing a good job in doing  
4 that. And I think they're going to go further on that. We appreciate  
5 it.

6 And, finally, we do hope and we do encourage the Agency to  
7 allow sufficient time for additional peer review and public comment  
8 before finalizing the OP-CRA. It is an important tool for now and for  
9 the future. Thank you.

10 DR. KENDALL: Thank you. Any questions from the Panel for  
11 Ms. Kelly. Thank you very much. The next public presenter that's  
12 registered is Dr. Judith Schreiber, New York State Office of the  
13 Attorney General.

14 DR. SCHREIBER: Good morning. My name is Judith  
15 Schreiber. I'm a research toxicologist in the Office of the Attorney  
16 General of New York State and a Senior Public Health Official there.

17 I have a number of comments, mostly clarifications, of what was  
18 discussed this morning. I didn't bring any prepared comments with me  
19 today. These are all really just questions of clarification. But my  
20 office will be submitted comments, written comments, to the docket.

21 We certainly thank the EPA and SAP for undertaking such a

80

1 broad and comprehensive and very needed assessment on OPs.

2 That said, the hotel actually provided me with this apple as prop  
3 which was very nice. Just one comment regarding the ginkgo fruits  
4 and how many times you might eat them in a row. I would just point  
5 out it's much more likely that a family is going to buy a bag of apples  
6 and eat those apples over the course of a week, perhaps one time a  
7 day.

8 That's not an unreasonable assumption. I just wanted to point  
9 that out. My family eats a lot of apples. And I think children in  
10 general eat a lot of apples and apple products.

11 I was very concerned about the decision by the EPA of not  
12 including violative and nonregistered use residues in the exposure  
13 assessment. Of course, what goes into that model is very key about  
14 what kind of numbers you generate coming out.

15 I was interested in whether the EPA has conducted or whether  
16 the SAP had requested the EPA to conduct a sensitivity analysis of,  
17 for example, using those violative residue data and looking at how the  
18 assessment would differ. I think that's really very critical.

19 I don't know. Maybe someone on the SAP can inform me  
20 whether that was something that was requested or has EPA ever  
21 looked at that? Anybody?

81

1 MS. MULKEY: Why don't we hear all the questions, and we'll  
2 try to address them just as we have tried with other public  
3 commentators.

4 DR. KENDALL: Very well. We'll try to summarize a response  
5 at the conclusion of your presentation.

6 DR. SCHREIBER: All right. I'd just like to emphasize that it  
7 seems to me would be just like having a high school student grade  
8 point average that we decide not to include his flunking grades, his  
9 failing scores, because he wasn't supposed to fail and so we're only  
10 going to include the passing scores to figure out these averages.

11 It just doesn't seem to make sense to me to exclude what we  
12 know as, we do have a lot of data, that indicate that there are residues  
13 on foods for which there is no tolerance for various OPs. Why not  
14 include those if in fact they turn up time and time again.

15 I had asked this question once before at one of the KARAT  
16 meetings, and I was told that the data is so robust, that it wouldn't  
17 make any difference. Well, if that's true, I'd like to see that analysis.  
18 I think it would be very important for both U.S. and imported products  
19 for those.

20 One thing that I'm not sure this is the appropriate time for it.  
21 But the MOEs have come up quite a bit through this morning's

1 discussion. Has the EPA or the SAP considered what is the  
2 appropriate margin of exposure for the cumulative risk assessment?  
3 And I understand, at least in part from this morning's discussion, that  
4 that is something that EPA is not ready to decide at this point.

5 If that's true, I think the risk assessment is missing the punch  
6 line, is missing the risk management part. And I think it would be very  
7 hard for public commentors to make any final determination on this  
8 risk assessment without that component. So I think that really is very  
9 necessary and perhaps either the EPA or the SAP can elaborate on  
10 what is the margin of exposure that is going to be considered to be  
11 sufficient under the FQPA for cumulative risks for OPs.

12 In following the previous commentor, I, also, do agree that if  
13 there is going to be substantial changes or elaborations of these kinds  
14 of points in the final risk assessment, that you public be allowed to  
15 comment once move before the document is finalized.

16 And one other point. I believe it was mentioned that the  
17 children age one to two are the most highly exposed population. And I  
18 was wondering, also, whether for the younger children from zero to  
19 one year olds is exposure through breast milk and contaminated  
20 formula included in the assessment in the OPs? Perhaps somebody  
21 could address that.

83

1           That concludes my informal comments. And as I mentioned, we  
2 will be providing written comments to the EPA on this document.  
3 Thank you very much.

4           DR. KENDALL: Thank you. Ms. Mulkey.

5           MS. MULKEY: This might be as good a time as any to say a  
6 little bit more about the violative and also talk about the canceled and  
7 phased-out products. And then I'll ask our scientists. We have had  
8 this question about breast milk and the water in formula and so forth.  
9 So I'll ask them to go ahead and do that, and that will wrap this piece  
10 up if that makes sense to you guys.

11          DR. KENDALL: Yes.

12          MS. MULKEY: Since it is the same topic that we're in the  
13 middle of anyway.

14          DR. KENDALL: Absolutely.

15          MS. MULKEY: I explained a little bit of the policy thinking  
16 behind the way we have addressed violations in other context. But  
17 with regard to this particular data set where you have in the PDP data  
18 residue levels that are above the tolerance, I understand that Dr.  
19 Miller did give some data this morning about the frequency and the  
20 extent of those data in the data set.

21               And I think that is a situation which we've been very mindful of

1 trying to understand the science implications of that policy choice.  
2 And I don't want to leave the impression that we are uninterested in  
3 that. That is why we developed the information about the extent to  
4 which we're seeing it and so forth. So I don't think I have anything  
5 more to say about that other than that's what led to our having the  
6 information we offered earlier about the extent of that situation.

7 The other is something that also came up in public comment  
8 yesterday and the Dr. Portier asked us to speak to which is the  
9 chemical crop combinations. In some cases, it's whole chemicals; in  
10 some cases it's chemicals and some uses as to which we have taken  
11 regulatory action as part of the individual chemical risk assessment  
12 process and/or where the companies have voluntarily changed their  
13 registrations materially whether for risk-regarded reasons or  
14 otherwise.

15 And we do have -- we have done that with regard to a number of  
16 OPs and their uses. And in most cases, as is typical for a practical way  
17 of ending a use, there is some kind of time line. Even when there is a  
18 immediate cessation of the sale of the product, there is a period of  
19 clearing the channels of commerce. Even after there is a period  
20 beyond which there is now allowed use, there is a period for treated  
21 foods, for example, to clear the channels of commerce.

1           So we are in the glide path for a fair amount of risk reduction.  
2           I've looked at the dates, and it would take a while to read all the dates.  
3           But sort of the last dates in the list are not, at this point, five more  
4           years from now. Most of them end the at the end of '02 or '03. There  
5           are some residential uses that go into -- there's one that goes to the  
6           end of '05. But even that, of course, is less than four years from now.

7           Our thinking on this was simply that the risk management  
8           choices had been made and that they were on a path of either such  
9           expedition as that you couldn't practically make a lot of difference in  
10          that or reasonable expedition; and that since risk assessments are  
11          conducted among other reasons for the purpose of risk management,  
12          that including these in the risk assessment would not materially  
13          improve our risk management decision-making. So that's the thinking  
14          behind that.

15          Almost all of the direct food uses have end sale dates or end use  
16          dates by the end of this year, especially those on fruits and vegetable.  
17          A few go into '03. That gives you a general answer. That information  
18          is all available on our web site, but I won't read through each one. If  
19          there is interest in a particular one, of course, we could speak to it.

20          And now maybe Dr. Smith can address the formula and breast  
21          milk issues.

1 DR. SMITH: With respect to children less than a year old, or  
2 for that matter any of them, the potential for contamination of formula  
3 is covered to the extent that the survey would adequately reflect what  
4 they ate.

5 What is not in the survey is beast milk, the mother's breast milk.  
6 It is our best judgment that that is not a significant oversight on our  
7 part. The evidence that we see indicates that there's not much  
8 potential of OPs in mammalian milk. We are including cow's milk, of  
9 course. And there are no OP residues accumulating in those.

10 So, basically, that's all I would say on that. It's not included,  
11 but it's our opinion that that is not a major oversight.

12 DR. KENDALL: Any points the Panel wishes to make or ask  
13 EPA? Dr. Bull.

14 DR. BULL: I have a little bit of concern, and I'm going to ask  
15 this question kind of publicly. The issues related to the cumulative  
16 risk assessment and there's issues that go to OP's regulatory mandate.  
17 I'm trying to figure out, if we're really, truly interested in cumulative  
18 risk assessment, where you would have to bring in some of these other  
19 less frequent contributors to OPP exposure but recognize at the same  
20 time if you do bring those in you have to realize that you can't address  
21 many of those extreme exposure through your regulatory mandate. It

87

1 probably goes to other places within the Agency or perhaps, or  
2 probably in a lot of cases, to other agencies.

3 So I'm trying to figure out when we're talking about a  
4 cumulative risk assessment, are we really talking about a cumulative  
5 risk assessment or are we just talking about a cumulative risk  
6 assessment that deals with what's in OPP purview?

7 MS. MULKEY: We are not limited to what is within our  
8 purview. I didn't mean to leave that impression. We do not, in the OP  
9 risk assessment, other than some drinking-water-related  
10 considerations, most of the exposure sources do happen to be within  
11 our program. But I didn't mean to leave the impression that that was  
12 an inherent element of our approach.

13 DR. KENDALL: Any other points from the Panel? Are there  
14 any other persons who would like approach the Panel for public  
15 comment? With none, we will close the public comment period.

16 I would like now to have Dr. Smith and Miller to go ahead and  
17 present the questions to the SAP, and we'll move forward.

18 DR. SMITH: Question one for food. In the preliminary OP  
19 cumulative risk assessment OPP used all available PDP monitoring  
20 data generated since 1994 as the basis for the residue distributions of  
21 pesticides in treated foods. As a result, some foods multiple years of

1 data (as many as five), while others have only a single year of data.  
2 All years of data were included to provide the most robust data set  
3 possible. These data were extended to cover foods and processed  
4 forms of foods for which data are not directly available. Additionally,  
5 some other foods were included in the analysis based on other less  
6 robust data from FDA.

7       OPP is conducting a sensitivity analysis in which the residue  
8 contributions from specific foods, either one at a time or in  
9 combination with other foods, are removed from the analysis. This  
10 analysis is being conducted as part of the effort to determine the  
11 contributions of specific commodities and chemicals to the upper tail  
12 of the exposure distribution. And some of the preliminary results are  
13 shown in Table 1 of the addendum which was supplied to the Panel.

14       Partly as a result of this exercise, OPP has observed -- can I just  
15 toss in, too -- that, also, it was shown on the slides in my presentation  
16 in a slightly different forms for the sake of other people here.

17       Partly as a result of this exercise, OPP has observed that the  
18 more variables, that is, commodities, chemicals, years of data, that are  
19 included in the exposure distribution, the more difficult it becomes to  
20 effect the tail of the distribution by removing commodity pesticide  
21 combinations from the calculations. While removal most exposure

1 contributors results in a demonstrated change in the lower portion of  
2 the distribution, the exposures at the upper end of the tail, for  
3 example, the 99.9th percentile, are relatively unaffected by removal of  
4 a single commodity even if it is identified by DEEM as a frequent  
5 contributor to the high end of the exposure distribution.

6 And so we would like the Panel to please discuss the  
7 significance of this observation and its potential impact on the  
8 interpretation of the output distributions and the results from highly  
9 complex distributional analyses such as the Preliminary OP Cumulative  
10 Risk Assessment.

11 DR. KENDALL: Okay. At this point, Dr. Heeringa, would you  
12 lead off please?

13 DR. HEERINGA: I'll take a first crack at this one and my  
14 colleagues can join. First of all, I want to say that simulation tests of  
15 the types reported in addendum Table 1 and also shown in summary  
16 form in the presentation this morning, they're very important to  
17 confirm that the model is performing as we expect. And I think that as  
18 we get down to the development of these models and comparison, that  
19 these types of simulations play a very, very important role in the work  
20 that we're doing.

21 The simulation tests that produce illogical or unstable results or

90

1 seemingly illogical results. I believe that DEEM-Calendex should  
2 provide the ability to tag and replay the inputs for these simulations.  
3 So, in fact, you do have data, as I understanding Calendex, to go back  
4 and analyze the contributors to these upper percentiles.

5 So in some ways, I think there's a general problem here of  
6 distributional theory and a more specific problem of what happened in  
7 your particular simulation; and, hopefully, we can make those two  
8 consistent with one another.

9 Just a little bit on the distributional piece here. I don't want to  
10 bore individuals. But in a sense when we create these composite  
11 residues in a daily diet, we're compounding multiple distributions.  
12 And this yields a very complex composite distribution for daily  
13 residues intake. And this is a function of a number of factors. I'll just  
14 list those here because they may be explanatory in what's happening to  
15 you in this particular simulation.

16 We have to factor in the child's weight in kilograms, and this  
17 could be highly variable for children ages one through two because  
18 you're actually sampling people, children from the infants from the  
19 CSFII, and taking their weight in kilograms. So that divisor itself  
20 could have a factor of twofold.

21 And I'm not sure, given how diets are reported for these

1 children, I mean you put an apple on a high chair tray and about half of  
2 it goes to the wall and half of it goes someplace else and a quarter of it  
3 may go down the stomach. So those issues I think are there. I don't  
4 think that's going to be the answer, though.

5 The diet for the day, obviously, is very important in determining  
6 these distributions of total residue intakes. First of all, does the food  
7 appear in the diet? And there are any number of foods that could be  
8 considered. It's a narrower set for one to two year olds.

9 Secondly, if the food appears, is there a positive residue amount  
10 assigned to that food in the stochastic draw. If I recall correctly from  
11 previous reviews of these DEEM models and others, that in many of  
12 these foods, there's a high proportion that come from untreated or  
13 presumably zero or no detect residues. So even if the food appears,  
14 when we that the stochastic draw for the day of the residue amount,  
15 we may get a zero value for it. So there's a tremendous amount of  
16 variability.

17 And then for non-zero amounts, it's actually the value of the  
18 stochastic draw that does take place. If we think about the  
19 distribution, the means of the these distributions, essentially, because  
20 we're treating these foods independently, the means are essentially the  
21 sum of the individual expected values for all the contributing

1 distributions.

2 In other words, you have a distribution for every food  
3 component that could appear in that diet for the day. Obviously, the  
4 only ones that come into play in any significant way are the ones that  
5 are consumed during the day.

6 The mean of that composite for the day is going to be the sum of  
7 the means for the individual components that go into it. Likewise,  
8 since we assume independence in our draws of these residue amounts  
9 for the foods, the variance of that composite distribution is also going  
10 to be the sum of the variances of the individual, non-zero food  
11 contributions from each source.

12 Removing food groups A, B, and C, as you've done in the  
13 simulation, changes the mean and the variance of this composite  
14 distribution. And, in fact, as I looked at this, my first response to  
15 your question is I don't see the problem here because it looked to me  
16 that the results from your simulation appear to be very consistent with  
17 what we expect, not just the removal of groups A, B, and C, A but  
18 even the sequential removal of A and then B and then C appear to  
19 produce a logical shift in the distribution of this residue distribution.

20 So the changes that you observed, and you actually  
21 acknowledge in terms of the form of the distribution rate, are exactly

1 what we would expect. So I didn't see anything unusual there.

2 The importance of foods groups A, B, and C to the composite  
3 distribution is quite obvious. You get a three-and-a-half fold decrease  
4 of mean MOE; a fourfold decrease in the 95th percentile. So, clearly,  
5 removing these groups is dragging the body of the distribution back  
6 toward the origin here.

7 Now, a 2.5 decrease in the 95th percentile, which I think is  
8 significant in many ways. And even a two-fold decrease in the 99.5th.  
9 But focusing on this 99 and 99.5th, which is your problem, the  
10 distribution of these quantities in this composite distribution is really  
11 somewhat unrelated to the distribution of the composite itself.

12 In other words, we can do a lot of things to the body of the  
13 distribution without being able to influence this extreme tail and really  
14 a function of the extreme values generated under of -- and not so much  
15 the function of the mean and particular variance of the composite  
16 distribution.

17 If you think about it, if I were to analyze the DEEM inputs to  
18 the particular simulation, if you think about how foods A, B, and C  
19 can contribute to extreme values, there's really two ways. One of  
20 them, is A, B, and C can form a stepladder. They are big. They are  
21 prevalent in the diet. They may have large residues. So they serve as

1 a stepladder.

2           And then we come along and we get another extreme value on a  
3 less commonly consumed food and added to that A, B, C value, it puts  
4 us into the extremes. So essentially, A, B, and C are boosting some  
5 other not so extreme values from other into the extreme.

6           The other way you can get it is that A, B, and C could actually  
7 be generating the extreme values themselves. And i think the basis of  
8 your question, you're sort of assuming, well, I removed A, B, and C,  
9 so A, B, and Cs extreme values aren't there. So why aren't the extreme  
10 values changing in the distribution.

11           Well, the only thing that you really removed is you removed the  
12 ability for A, B, and C to boost something else up or for A, B, and C  
13 to generate its own. Now the probability that A, B, and C in a mixture  
14 of diets is going to generate those extreme values all on their own is  
15 relatively small because there are only three groups. And if you think  
16 about it, even if the entire residue distribution were based on A to get  
17 to the 99.5th percentile, you essentially have to something with odds  
18 of almost 99.9th percentile, you have to have something that has odds  
19 of one in a thousand of being drawn from a distribution.

20           So the probability of getting an extreme event from A, B, and  
21 Cs residue distributions extremely small; and even in combination, it's

1 pretty small. So what happens here is that you've got 69 other food  
2 groups which might occur someplace in some child's diet during your  
3 simulation run and each of those 69 food groups also has extremes,  
4 and so as I sum across all of these children in the particular profile for  
5 a given day, someone is going to eat these odd foods.

6 And although they aren't as prevalent in the diets as A, B, and  
7 C, the sheer numbers of them that could be there and the fact that they  
8 could each contribute with some low probability an extreme value,  
9 essentially the strength in numbers means that you're still generating  
10 extreme values from all of these low prevalence food groups; and so  
11 these maximums are not being affected as much as you might think.

12 That's my statistical explanation. In other words, you have  
13 several different routes. And that what's happening is because you are  
14 still generating potentially with low probabilities but add small  
15 probabilities across large numbers of food groups, you generate higher  
16 probabilities for generating extreme values from these sort of  
17 nonprevelant foods.

18 I suspect that that's what's happening. This is a guess. And  
19 you'll be able to affirm that with DEEM. We can't rule out what I  
20 think are more pathological explanations in a statistical sense. That  
21 there may be some -- and this is what I think you're hunting for --

1 extreme residue commodity potency factor relationships in DEEM that  
2 don't make sense and are producing these outliers. Clearly, you want  
3 to hunt those down and try to rectify the data there to make sure that  
4 it is consistent with empirical data that you have on these  
5 distributions.

6 Also, another factor that occurred to me is that potentially,  
7 even though -- and this is really a stretch but I think it's worth looking  
8 at in your analysis. If you remove food groups A, B, and C, we're only  
9 looking in the simulation at a short one year interval. But most of us  
10 know that children's diets change considerably over that one year  
11 interval.

12 So it could well be that what you're doing when you remove A,  
13 B, and C is that you're actually removing foods that are eaten later in  
14 the interval, like whole fruits and vegetables, as opposed to sort of  
15 mashed fruits and vegetables or other types of cereals at the  
16 beginning. There may be some time-related dependency between food  
17 groups A, B, and C in the year one to year two.

18 And why would that be important? It would be important  
19 because the it affects the weights of the these children. The weights  
20 of these children could be actually the kilogram divisor in the exposure  
21 could be changed.

1           So those are, again, the last is a bit of a stretch. But I think if I  
2           had to analyze how to decompose the problem, theoretically, I think  
3           what's happening is that, as you draw out A, B, and C, you are in fact  
4           contracting this distribution significantly, pulling the body of the  
5           distribution back toward the origin, but you're not able to impact the  
6           very extremes because you still have this underlying, very thin extreme  
7           value distribution for all these other components.

8           DR. KENDALL: Thank you, Dr. Heeringa. As you can hear,  
9           there is music next door. We did not know this. We were only  
10          informed this morning that apparently there is to be a concert in ten  
11          minutes. So I'm going to -- which started even earlier. And, quite  
12          frankly, apologize for this happening. We were just notified a couple  
13          of hours ago. So we're going to take our lunch break beginning at  
14          approximately 11:30.

15          I ask everyone to bear with us for the next ten minutes or so. I  
16          hope that will work. And they'll be concluded by 1230, and we'll  
17          reconvene. So let's grin and bear it. And, Dr. Reed, can you follow  
18          Dr. Heeringa, please.

19          DR. REED: Yes. I just want to commend the Agency for the  
20          enormous task and a lot of work put into it. It's impressive.

21          What Steve was saying, I totally agree. It's a very complex

1 analysis. I'm sure if there is an easy way to go back and see what  
2 happened to it or in terms of what is the major contributing factor  
3 except to do what you're doing. And that's something we do very  
4 often in our program, too.

5 I think even down to look at the CC to identify the high  
6 contributing commodities takes some looking around. You've looked  
7 at three of them. I want to follow what Steve was saying in that,  
8 actually, after you get rid of three of them or even one at a time, look  
9 at the CC again and see if you're right on track.

10 Also, when you look at the CC, as Steve pointed out, see that  
11 the H vector would come in to play within that 3-to-5, 1-to-2 bracket.  
12 The eating pattern, the distribution of contribution from different  
13 commodities, that sort of thing. A lot of times we have to go back and  
14 forth and find that high contributing commodities that way.

15 I'm sure there are many more sets of sensitivity analysis that  
16 could be done. Something was mentioned -- and I thought it was  
17 worth sort of mentioning again -- was the curiosity of whether  
18 chemicals will make a difference. You're looking at commodity;  
19 contribution, look at the chemical contribution.

20 Other things are -- I mean, in that case, you sort of trap the high  
21 contributing chemical and then do as you did, removing one at a time

1 and to see what happened.

2 In terms of things to consider, I think there's so many things to  
3 consider. But the Agency is under the time constraint to complete  
4 something at this time. What I was thinking was as the most important  
5 thing is this: From the presentation and the document, it reflects a lot  
6 of experience from the Agency in doing what you do and giving the  
7 assumption that we assume, for example, dietary exposure does not  
8 fluctuate significantly over the year, that type of thing, or even though  
9 it's calendar-based in terms of the whole assessment but dietary is not.  
10 You know, these assumptions, PDP data, single unit analysis data, will  
11 not impact a whole lot as compared to using composite.

12 I think the Agency has lots of experience with this. It would be  
13 good to present it in a way. I think people would like maybe to see  
14 some support instead of just a single sentence statement. I think that  
15 would help.

16 DR. KENDALL: Thank you, Dr. Reed. Dr. Zeise, would you  
17 like to follow, please.

18 DR. ZEISE: I agree with the comments earlier, and I think the  
19 explanation provided for the finding is very reasonable. And,  
20 obviously, we need to explore to see really what is happening in the  
21 tail and whether or not there is a problem with the model or whether

100

1 or not that explanation that was given holds up.

2 In addition to exploring that, I think it's very important to focus  
3 on the tails. It represents many individuals in the population. And it's  
4 important, I think, to explore other factors that might change the tail  
5 significantly. It's not clear the extent to which violated exposure  
6 would change that. The extent to which consideration of degradates  
7 might change the assessment.

8 And then the issue -- and I didn't see it explored in the  
9 document -- of binge eating and seasonality of fruits coming in in the  
10 summer months, and so forth, if CSFII appropriately captured some of  
11 the cases where you might expect larger exposure. I think that would  
12 be useful to explore.

13 And the nondetect, I'm assuming that that has been adequately  
14 addressed. There was a discussion in the document. It wasn't clear to  
15 me the extent to which, if you assumed at the high end of the  
16 distribution, if you threw in some nondetects as half the detection  
17 level, whether or not it would significantly change the evaluation at  
18 the tail.

19 And the reason why it is so important to look at the tail is that  
20 the MOE is rather small there. In fact, if there are even larger  
21 exposures than that, that really indicates that there is a problem. So

101

1 really understanding that region is important. And I'll leave it at that.

2 DR. KENDALL: Thank you very much. Any comments from  
3 the Panel in addition to the comments already made on this particular  
4 question?

5 DR. MCCONNELL: Yes. I was struck by the fact that you  
6 depend a great deal on the UDSA for a lot of your input in your  
7 calculations. I was wondering, and it was suggested by one of the  
8 people from the audience, that you have relationships with UDSA. I  
9 don't know what they are. Do you have periodic meetings with them  
10 to update yourself with what they're doing? Their science must be  
11 evolving as is your science, and do you have a way to keep up with  
12 that?

13 DR. SMITH: Yes, we do. In one area, of course, one of the  
14 major areas we're discussing today, are the residue data that we're  
15 using. That's the PDP program. And we work very closely with them.  
16 We advise them as to what our interests are and then things we'd like  
17 to see done from year to year. So it's a very close relationship. Also,  
18 there has been considerable interaction in the area of the CSFII. I  
19 don't know that I can say much more about that; other than I don't  
20 know if, David, is there anything you'd like to add to that?

21 MR. MILLER: Yeah, we do communicate with USDA on the

1 CSFII and the food research group that is responsible for it.

2 DR. DURKIN: Thank you.

3 DR. KENDALL: Any further comments? Dr. Durkin.

4 DR. DURKIN: Very briefly, we will be discussing residential  
5 exposure at a later time. But this does relate to food and, again, it is  
6 the issue of homegrown vegetation. I did not see that in the  
7 residential exposure. And we may clarify it then. But it's clearly not  
8 in your food exposure. And I'm rather concerned that that could be  
9 the 800-pound gorilla.

10 The concern is with people in a rural area, especially rural  
11 south, who may live in a region of agricultural usage that could be  
12 very high. And I am a little concerned about what I've heard up to this  
13 point that we could have, again, a bimodal distribution of risk that  
14 we're simply not addressing.

15 DR. KENDALL: Okay. Any further comments? Mr. Lewis, our  
16 DFO, has informed me that they're running late over there. Therefore,  
17 we may have time to go to the next question. I'd like to take an hour  
18 break. So could we procedure into the next question as recommended  
19 by the best intelligence information I've got. And it's the military next  
20 door.

21 MR. MILLER: The Calendex model can be used in a number of

1 modes to develop a profile of exposure estimates. In the current  
2 assessment, OPP conducted a series of single-day assessments arrayed  
3 chronologically to develop a response surface of exposures. A  
4 constant percentile of exposure was selected to represent the potential  
5 exposure to a given percentile of the population. For example, the  
6 99th percentile for each day would be arrayed for 365 days to reflect  
7 the population estimate across the calendar year.

8 Calendex can also be used in a multi-day sequential series  
9 analysis, as referred to as a "rolling time frame mode." A rolling time  
10 frame provides an estimate of the average of daily exposures for an  
11 individual calculated over multiple (7, 14, 21, or 28) days for each  
12 multiple day period over the course of a year, (e.g., days 1-7, then  
13 days 2-8, then days 3-8, etc.).

14 In this model, an individual's food exposure is tracked across  
15 the calendar year by randomly selecting day one or day two of that  
16 individual's reported consumption from the CSFII and combining each  
17 commodity which comprises that consumption with randomly selected  
18 residue values for each day of the calendar year. These rolling  
19 averages for each individual are assembled to develop a distribution of  
20 rolling average exposures.

21 During previous SAP meetings, the Panel has expressed concern

104

1 about the use of CSFII records to represent longitudinal consumption  
2 patterns for individuals. Concern arose as a result of the design of the  
3 CSFII study, in which two nonconsecutive days of data (separated by 3  
4 to 10 days) were collected for each individual.

5 Please comment on the use of CSFII data to support each of  
6 these two modes of Calendex as they pertain to the cumulative risk  
7 assessment of pesticides in foods.

8 DR. KENDALL: Dr. MacDonald, can you lead off, please.

9 DR. MACDONALD: Well, I guess to begin with, I'm under the  
10 impression that CSFII is about all we have that's relevant. So we don't  
11 have a lot of choice here. I guess there would scope for doing some  
12 kind of sensitivity analysis to see what the impact would be of having,  
13 say, you could make up some data on longer term records and just see  
14 what impact it would have on the estimates.

15 As far as the different modes of running the Calendex model  
16 goes, I think Dr. Portier's remarks earlier were very relevant. And I  
17 hope they'll get into the response for this question.

18 But, basically, I think the effect of using the rolling average is it  
19 will mitigate effects of sampling nonconsecutive days to some extent;  
20 but, mostly, it will just reduce the extremes in the simulation.

21 Is this relevant? I don't really know. I think we have to know

105

1 more about the metabolism of the OPs in humans at different life  
2 stages. I think the limitation here is the margin of exposure computed  
3 as the point of departure divided by exposure, so we have to make sure  
4 that the exposure measure and the point of departure are both  
5 relevant.

6 For example, what we saw yesterday in the adult rats, the dose  
7 response curve, we saw there was a shoulder and in many cases in that  
8 suggest in some situations a moderate short-term exposure is totally  
9 innocuous. But that's for adult rats. As the NRDC has pointed out, it  
10 might be totally different in humans; it might be totally different in  
11 human infants and fetuses. So it's really hard to say what the effect of  
12 changing your exposure measure is going to be if we don't really know  
13 what type of exposure is most relevant in the population we're  
14 considering.

15 I think to conclude, the rolling average is probably a good idea  
16 if the main concern is chronic low to moderate levels of exposure. But  
17 if the real concern is acute levels, than reducing the extremes is  
18 perhaps going to be missing some of the more dangerous episodes.

19 DR. KENDALL: Thank you, Dr. MacDonald. Dr. Freeman.

20 DR. FREEMAN: The two methods used with Calendex, you can  
21 almost think of them as bounding examples. The use of a single-day

1 constant percentile of exposure for every day provides an exceedingly  
2 conservative estimate of exposure. It is clearly not representative of  
3 individual exposures over time. And I find it difficult to understand  
4 what it actually means in terms of population exposures. And, also,  
5 I'm not quite sure how you're going to use that.

6 In contrast, the second method which uses the rolling averages,  
7 is not only less conservative, but for very young children when you  
8 only have two samples of food, may actually reflect what young  
9 children over a limited time period, as Dr. Heeringa was suggesting, is  
10 fairly realistic. Young children tend to have very narrow food habits.  
11 So that while you only have two samples to draw from, they probably  
12 aren't that different from each other because the children aren't eating  
13 a wide range of foods. So that may actually be useful in representing  
14 sort of the average young child with fairly limited ranges of foods in  
15 their diets.

16 On the other hand, that same rolling average, because you only  
17 have two food samples to work with, may underestimate or suppress  
18 the high-end exposures from diets in the same children. And I'm not  
19 sure what you can do about that.

20 A concern of mine is in the application of all this stuff. In the  
21 examples that you give, you suggest that diet is treated as uniform

107

1 throughout the country. And unless you have already done so, I think  
2 this is a hypothesis that needs to be tested, particularly in areas such  
3 as Region 3, the Texas Fruitful Rim, which are predominately  
4 Hispanic. I wonder whether the diet for based on the CSFII for the  
5 total United States is really appropriate. And one thing that you could  
6 do is to compare the diets associated with that region from one such as  
7 the Easter Upperlands or the Northern Great Plains where the  
8 demographics are very different.

9 Another alternative -- that also assumes that the CSFII has not  
10 under represented minorities in their sampling, which may also be the  
11 case. And if that's the case, you may have to go back and look at  
12 census data for those areas and do some sort of proportional weighting  
13 based on census characteristics.

14 So that adds more complexity to your model.

15 DR. KENDALL: Thank you very much. Dr. Reed.

16 DR. REED: I want to follow up on what Natalie was saying. I  
17 think, basically, if we take a sort of a common sense way of thinking,  
18 we would think that the diet has seasonality and has regional  
19 differences. Again, I think it's partly I think because of the Agency's  
20 experience in this area, knowing the impact of parting them out into  
21 region and season, and maybe it doesn't come out to be a whole lot in

108

1 terms of impact. And it's time consuming and it's not readily available  
2 in terms of tools right now with DEEM and Calendex. I'm not sure  
3 about that part.

4 But what I'm trying to say is that I think it would be good to  
5 give some support to that assumption or, as Natalie was saying, run  
6 some data sets. Remember, we've in the past looked into things that  
7 are important to children. For example, apples, they do have  
8 seasonality and also regional differences. It could be up to about  
9 20-percent differences. So it's something that probably is worth  
10 looking into.

11 In terms of using that data for medical day sequential analysis,  
12 you have already presented the pros and cons. But I remember -- I  
13 just have one simple comment. I remember in September 2000, when  
14 we look at Calendex, there was the recommendation to look into this  
15 method. And I'm still very interested in following up on that.

16 That is instead -- I think maybe the overriding desirable idea  
17 right now for you is to trace an individual. And, therefore, you think  
18 that perhaps you need to stick with these two data points. But I think  
19 there's somewhere in the document that emphasizes that you're not  
20 actually tracing individual exposure pattern. So in that case, it is still  
21 possible, as what we recommended before, to base on demographic

109

1 characteristics, to pull the data together so that you would have a  
2 larger sampling size of population to draw from instead of just two  
3 points.

4 And I don't know how difficult that is. But I think that's  
5 something that's still worth looking into. I don't know if I'm clear on  
6 that point.

7 DR. KENDALL: Is that clear?

8 MR. MILLER: Yeah. I think what you're saying is when you  
9 say "pool the data," the way it's done now is each individual's diet is  
10 connected to that individual.

11 DR. REED: Right.

12 MR. MILLER: Each of those two days worth of diet.

13 DR. REED: Right.

14 MR. MILLER. What you're saying is maybe draw from,  
15 essentially a pool that has demographic similarity to that individual.

16 DR. REED: Right. Three to five pool with different seasons,  
17 four seasons.

18 MR. MILLER: Okay.

19 DR. KENDALL: Very well. Dr. Heeringa, anything to add?

20 DR. HEERINGA: Just briefly to Dr. Reed's comments. I think  
21 the idea -- right now, the way that you're using the CSFII data, is

110

1 essentially you're locking a child's body weight and gender and age  
2 into a particular diet or maybe at most three diets if in the CSFII and  
3 two diets for the infant and child observations in the '98 CSF.

4 And what we're doing there -- I don't think of us believe that  
5 this child is going to eat macaroni and cheese 365 days a year. But in  
6 your sample someplace else, there's a child eating green beans and a  
7 hamburger or there's a child eating oatmeal. So what you do is even  
8 though you're focused on an individual child, what you're assuming is  
9 exchangeability among children of the same age and same gender. And  
10 the thing you're doing is you're locking a particular body weight to a  
11 particular diet.

12 I think that's a constraint you don't need to use. Dr. Reed's  
13 suggestion is essentially sample the child. You need to get a  
14 representative samples of children with their body weights and their  
15 genders and their ages. But then, among children in your national  
16 sample, which you're assuming to be exchangeable anyway, sample  
17 their diets to link to those on a daily basis.

18 So I think that breaks one sort of false correlation in your  
19 current input structure that is unnecessary and doesn't contradict in  
20 any way.

21 Now, on the other response to this question, you are

111

1 constrained by the fact that you have two or at most three days of diet  
2 for any individual. By putting things in this pool, you've sort of  
3 unconstrained people's diets a little bit. But you haven't actually built  
4 in realistic patterns. You still have to assume, if you go Dr. Reed's  
5 route, that you have random eating and that there are no consistent  
6 correlations over time in consumption patterns. Which we know for a  
7 bag of oranges or a bag of apples or a bunch of bananas or even things  
8 like green beans, you might be eating them two or three times during  
9 the week in which they're bought. I think that's another level of  
10 sophistication that you might think about bring in at least in terms of  
11 simulation.

12           And this is what Dr. Portier brought out, yesterday or earlier  
13 this morning, that you might look at some testing in the model where  
14 you do two things. And that is you have a lag factor in the  
15 consumption in the dietary intake for some of these commodities that  
16 we know are going to be in the household for a protracted period of  
17 time. And I don't think macaroni and cheese is going to be one of  
18 them. But apples and various fruits that are bought in larger  
19 quantities than vegetables, and see what that does.

20           And if you do that, then I think you, in addition to sort of  
21 introducing a lag in people's dietary consumption during the period of

112

1 a three- or four-day average, also preserve the draws on the residue  
2 amounts because it's only realistic if you do that that these  
3 commodities that came from the same source would be expected to  
4 have nearly similarly residues amounts. We know there will be  
5 variability, but much less variability than a completely random draw.

6 So I think with the data that you have available and some  
7 assumptions -- and, again, I would only put this in simulation context  
8 right now, to look at what happens when you introduce not only  
9 lagged consumption from one day or time-correlated consumption of  
10 some of these commodities for short periods. And I would say three  
11 to four days would be fine on most of these or a week. And then, also,  
12 to preserve the residue amounts associated with those.

13 Now, that's complex, I know. But I think that would add a little  
14 bit more reality. Now if you do that, then I think this whole issue of  
15 whether you use these rolling averages or individual days, the rolling  
16 averages make sense as a measure of sort of short-term chronic or  
17 maybe steady state impacts of the residue consumptions; but I think  
18 they only make sense if you do these other steps. And that is allow  
19 foods to have time correlation over short periods of time and that the  
20 residue amounts on those fruits are also preserved as draws from your  
21 residue distribution. Then I think these rolling averages do approach a

113

1 better reflection of what the sort of chronic exposure over a 28-day  
2 period is more likely to be.

3 I think if you're doing fixed diets for kids, random draws of  
4 residues everyday for each child. I'm not sure that you're getting from  
5 these rolling averages what you would really like. It's not a good  
6 reflection, I think, of chronic exposure. And the one-day stuff gives  
7 you the acute exposure in a better sense, I think.

8 DR. KENDALL: Any further comments from the Panel? Dr.  
9 Portier.

10 DR. PORTIER: I agree with all the comments that have come  
11 forward, starting with the one that said you guys did a great job on  
12 this. But presuming something we can look at and comment on is  
13 really pushing the edge of what's been done previously.

14 I was sitting here trying to think about my question earlier  
15 concerning the conservativeness of this particular method. Especially,  
16 the two-day flipping back and forth. And your observation that you  
17 think this is going to be somewhat conservative. And we had several  
18 questions about that from lots of the public yesterday, both the  
19 grower's side and the environmental side asked a question to what  
20 degree can we assume this is conservative.

21 So I'm sitting here trying to ask myself how do we assess that

1 without doing a full independent resampling scheme where everything  
2 is independent. As Ruby pointed out, you sort of have two extremes  
3 that you could do. The first extreme is the individual day data, run it  
4 for 21 days. But that's exactly the same as the distribution for the  
5 individual day. Taking the average of that over the 21 days is going to  
6 give you exactly the same distribution. So you've got that one. That's  
7 one extreme.

8         The other extreme is everything is random. Every day a new  
9 draw, a new diet. Everything is completely random. That's the other  
10 extreme in the sense that we know there are probably some  
11 correlations in there.

12         But we know something about the other extreme. If your  
13 distributions are normal, which they're not. Then I'm going to choose  
14 the simplest case here. If your distributions were normal, you know  
15 that by averaging over 21 days, independent normal random variables  
16 drawn on a day-by-day basis, the 99.9 percentile, in fact, any  
17 percentile except the 50th percentile, is going to change by a factor of  
18 4.6; the square root of 221.

19         If it's log normal, you can actually calculate the same things.  
20 The 99.9th percentile. But it's not a constant. The 99.9th percentile  
21 change is about a factor of 12. The 95th percentile change is about a

115

1 factor of 6.

2 But the point there is you can look at your two-day consecutive  
3 draws, compare it to your extreme single-day case, and ask yourself,  
4 have I dropped the 99 percentile and the variances by some number  
5 that appears to be in this range or less. So is it on the conservative  
6 side or on the independent side?

7 Judging from your quick graphs there, David, it looks like it's  
8 on the independent side not on the conservative side in terms of a very  
9 consistent redraw. But I'm not sure because I don't see the full  
10 distribution for that.

11 But I think you could address it that way. You might see some  
12 mean shifts as well which could tell you something about theoretically  
13 how conservative that approach might or might not be.

14 But I agree with everyone that you need to try some other  
15 things, potentially theoretical or to resampling technique.

16 DR. KENDALL: Thank you. Any further comments from the  
17 Panel? Dr. Rhomberg.

18 DR. RHOMBERG: Just briefly. And I hope this is the right  
19 place to raise it. On the single-day analysis, you know, in the end  
20 what that is able to show is seasonality. Otherwise it's just doing the  
21 same thing over and over and over again and they're just replicates.

116

1 The only thing that's really different between one day in January and  
2 another day in May is seasonal differences.

3 And I guess I was struck by the fact that there didn't seem to be  
4 many, that if you looked at those graphs, including the one that's right  
5 on the front of the report there. Yes, there's some variation up and  
6 down; but there's no big sway, no big seasonal sway of going up and  
7 down.

8 And my question is why is that? I would really have expected at  
9 least some such effect. And the only reason that there wouldn't be any  
10 is if seasonal effects are at all important, that they are somehow  
11 excluded here. Would that mean that seasonal effects are driven  
12 maybe more by seasonal effects on food choices than they are by  
13 seasonal effects on residues or what? I guess I'd just like some  
14 discussion of why there isn't more seasonal effect there when one  
15 would expect some.

16 MR. MILLER: I'll say we're not -- when we use the PDP data,  
17 we're not taking into account -- and it's just clarify it. We're not  
18 considering the seasonal effects of when the food is sampled. So there  
19 is no seasonal component.

20 When I said we start with January 1, it's not necessarily a diet  
21 that a person reported eating on January 1. So for example, when the

117

1 CSFII went out, they didn't -- the January 1 diet is not specifically a  
2 January is 1 diet. It was essentially the seasonality component is  
3 added to the assessment by means of the drinking water which is  
4 seasonal. We take into account the season there and the residential  
5 uses.

6 DR. KENDALL: Any further comments? Yes, Dr. Zeise.

7 DR. ZEISE: I just want to reinforce the idea that when you  
8 consider the averaging period, you carefully look at the  
9 pharmacokinetics in humans and determine what makes sense to do. It  
10 might make sense to actually build in a pharmacokinetic parameter to  
11 address the issue of persistence across time.

12 DR. KENDALL: Very well. We understand now the program  
13 next door may go as late as 1, so I'd like to try to move into 2B. We  
14 are tracking their program. I think somebody is speaking at this time,  
15 to be followed by a concert. The concert is going to blow us out of  
16 this room. So let us push forward.

17 Today's one of those challenges. We will take a break for one  
18 hour. And I will see you for 1 o'clock. Thank you very much.

19 [Lunch recess.]

20 DR. KENDALL: We'll go ahead and get started. This will  
21 reconvening the SAP. The point at which we are currently is

118

1 addressing Question 2B. Please read that question, Mr. Miller; and  
2 we'll go on from there.

3 MR. MILLER: The random PDP residue values assumes that the  
4 residues in foods consumed across a series of days are independent of  
5 each other. In other words, foods consumed are from unrelated  
6 sources and there is no carryover from one day to another. This  
7 assumption may be inappropriate given that many consumers obtain  
8 food in bulk (i.e., multi-day) quantities that may have similar  
9 treatment history and would typically consume this food over a short  
10 multi-day period (e.g., leftovers). In such a case the residues  
11 contained in the foods would violate the assumption of independence.

12 Please comment on the use of PDP data to support each of these  
13 two modes of Calendex as they pertain to the cumulative risk  
14 assessment of pesticides in foods. What issues are likely to accrue  
15 from the assumption of independence in residue data?

16 DR. KENDALL: Dr. Reed, can you lead off, please.

17 DR. REED: In terms of single-day exposure mode, I don't have  
18 a lot of problem with it. As long as it was clearly stated, you know,  
19 what the announce is about. I think the only issue that we're been  
20 throwing about is the composite nature of the data.

21 We knew that from single-eating-size analysis that you would

119

1 have essentially higher, possibility to a higher, residue in a  
2 single-eating-size sample. But that's for a single chemical. And I  
3 don't have any feel about what is it going to look like for index  
4 equivalence-type of residue data base.

5 So I would really appreciate that, again, I think that assumption  
6 was that there's not a substantial difference in it. And I think it would  
7 be good to present something like that in the documents so a reader  
8 could understand and follow.

9 In terms of multiple day rolling average, I think PDP data is  
10 suitable for that, especially when the composite is not a problem. I'm  
11 not sure -- or I am sure that this does not really address the carryover,  
12 leftover, or same batch exposure scenario. I would go about and find  
13 the heightened contributing commodities and see if linking days would  
14 make a difference. I would not offhand go in and link everything from  
15 day-to-day yet.

16 The reason I say that is because I think linking days would be  
17 really specific to certain foods. You know in the past we talk about  
18 Thanksgiving meal and that kind of thing, also the buying-eating  
19 pattern; people buy a bag of apples and eat for how many days;  
20 shopping pattern and all of that.

21 That being so, I think what I'm thinking is it's important to find

120

1 places where it might make a substantial difference and not just  
2 shotgun and go in and do all of that. And I'm thinking of that mostly  
3 in terms of resources. And I'm thinking of now of approach and risk  
4 assessment is about. You decide when and why you want to go in and  
5 refine something so that you're more focused and you're not spending a  
6 lot of time and effort.

7 That goes back to the comment that I made earlier that it is  
8 important to make a clear presentation in terms of what are the  
9 assumptions and why you think so; and so when it comes to the steps  
10 whether we link days or not, it would be much clearer as a choice or  
11 not.

12 DR. KENDALL: Thank you. Dr. Heeringa.

13 DR. HEERINGA: I very much agree with what Ruby has just  
14 presented. Just a few added comments.

15 In response to the earlier question, I mentioned exploring the  
16 issue sort of continued consumption of a single food item over several  
17 consecutive days. Again as Ruby has just pointed out, it requires  
18 modeling, buying, and retention patterns within the household. My  
19 sense is that even has something sort of three to five days retention of  
20 a fruit or vegetable batch would be an appropriate bound to set on  
21 testing that.

121

1           Clearly there if you do that, then I think you want to preserve  
2           the sampled residue amount over those three to five days, also, to  
3           preserve that correlation which you would naturally assume in the  
4           purchased food product.

5           With regard to the independence on a single-day analysis, I  
6           think the independence assumptions, since you're doing it on a daily  
7           basis, it really doesn't come into play. It's more when you look at sort  
8           of chronic or accumulating over multiple day analyses that I think you  
9           need to take into account the correlation, not only in foods eaten, but  
10          also the residues on those particular foods over the days.

11          One additional comment to, I guess, related to the question,  
12          that is, the use of OPP residue data base. I believe that most of these  
13          are composite amounts. We're not only compositing the servings over  
14          the day, but we're also compositing the residues over multiple articles.  
15          If anything, I think that would tend to attenuate the extremes that we  
16          would observe on a daily analysis.

17          So if anything, it's probably a little bit anti-conservative to use  
18          the composited, samples as opposed to some strategy which I know  
19          we've investigated in the past to try to derive a single serving or a  
20          single-serving residue amounts for use in these analysis.

21          DR. KENDALL: Dr. MacDonald. Thank you, Dr. Heeringa.

1 DR. MACDONALD: I don't have a lot to add to Dr. Reed and  
2 Heeringa. But I will express my sympathy for what I see what must be  
3 a very frustrating situation because there are just limitless ways to  
4 start making these models more complicated and you'd really like to  
5 know ahead of time which of these ways are going to be worthwhile.

6 I guess all I could suggest here is if you -- I don't think you  
7 even have to do a pilot study. If you could make up some the data  
8 with the consecutive days or with the correlations built into it and just  
9 try some small simulations and see what kinds of differences it makes.

10 Certainly, that in the other context, the study you did with the  
11 A, B, C gave some -- it seemed to be a very simple thing to do, but it  
12 gave a very useful results fr what would happen if you change some of  
13 the data. And maybe you could devise something like that with the  
14 correlations.

15 DR. KENDALL: Dr. Zeise.

16 DR. ZEISE: I don't have a lot of add to the comments that  
17 already been made. We've talked about this this morning as well.

18 The one thing I would add is that there are likely to be  
19 differences across the different age groups in terms of the extent to  
20 into which this comes into play. And particularly for the younger age  
21 groups, one would expect a lot more similar behavior from day to day.

123

1 As an upper bound kind of analysis, one might assume that every day  
2 they consume the same value or sample between the two days.

3 Another possibility comes to mind along the lines of -- I like the  
4 idea of the correlation analyses that have been proposed. And another  
5 possibility would also be to do some scenario plane to kind of test and  
6 speculate what could be happening at the extreme by looking at  
7 different scenarios for some high consumption of foods, say, during --  
8 I don't know -- watermelon season or when you might expect very  
9 large consumption of fruits more so than other part of the year among  
10 certain subgroups.

11 DR. KENDALL: Good point. Any further comments from the  
12 Panel on this issue in food exposure? Dr. Portier.

13 DR. PORTIER: Not specifically on this. Well, let me ask a  
14 question on this one first.

15 Steve was just asking me, and I guess we're both a little  
16 confused about the issue. If the PDP data set has a residue that  
17 exceeds the limit, you still include that in the analysis? Yes or no, you  
18 take those out?

19 DR. SMITH: We take out residues that exceed tolerances, yes.

20 DR. PORTIER: Then I think from my perspective, I would  
21 recommend you not do that. I think it's going to be there's two

1 reasons. One is it's going to happen no matter what the tolerances are  
2 set; there will be samples that exceed the tolerance. That's the first.

3 The discussion we had of where PDP data comes from and the  
4 question of what happens when people buy things in the market or  
5 from not necessarily the large commercial sources, there may or may  
6 not be higher residue levels depending upon when and where, et  
7 cetera, where they buy it. And those things are just unknown. My  
8 recommendation would be that you include them in your over all  
9 analysis. And I don't know how the rest of the Panel feels about that.

10 The other point I wanted to make, which is more general, is  
11 yesterday we had a discussion about point of departure for margin of  
12 exposure from the point of view of hazard. And much of our  
13 discussion pertains yesterday pertains, also, here especially to some of  
14 the public comments which had to deal with the quality of an estimate  
15 of the 99.9th percentile.

16 I think one could argue that choosing a distributional point from  
17 which to compare margin of exposure could be driven by the science,  
18 find some optimal rule for deciding what seems supportable by the  
19 science that you're working with, and the margin of exposure process  
20 is adjusted based upon where that percentile is and the quality of the  
21 science that went into that exposure percentile.

125

1 I think that would potentially be a better solution than the  
2 continued debate about the quality of the 99.9th percentile. And I  
3 think I'll add that to my comments to you.

4 DR. KENDALL: Would EPA like to respond to that? Dr.  
5 Roberts.

6 DR. ROBERTS: Yeah, Chris asked how the rest of the Panel  
7 feels about the issue of including the violative residues from the PDP  
8 in the assessment. And I guess I would weigh in in favor of including  
9 them.

10 I think that as a follow up to some of our earlier conversation, I  
11 think that this probably is an unavoidable consequence even of the  
12 lawful use of pesticides despite everyone's best efforts. It's a human  
13 exercise, and there's going to be a small percentages of times when  
14 those levels are exceeded. And I think if we're going to make the  
15 argument that our cumulative risk assessment reflects reality, I think  
16 it's probably important to go ahead and include those small  
17 percentages in our assessment.

18 DR. KENDALL: Any further comment or agreement? Dr.  
19 Durkin.

20 DR. DURKIN: Yeah, I would like to simply endorse the idea of  
21 putting the residues in. I understand why they're not there in terms of

126

1 not being able to address them perhaps from a regulatory perspective  
2 and that does make a great deal of sense.

3 But we seem to have two tracks here, and we discussed this.  
4 Are we dealing with a regulatory tool, or are we dealing with some  
5 sort of a public health risk assessment? Do we have a problem here?  
6 And if that second part is important, and I believe it is from what I've  
7 heard, then I don't see a reason to exclude those residues. In fact, I  
8 see every reason to keep them in whether or not they make a great deal  
9 of difference. We're trying to reflect reality.

10 DR. KENDALL: Dr. Bull.

11 DR. BULL: He said it much better than I, but I agree with that.

12 DR. KENDALL: Okay. Dr. Rhomberg.

13 DR. RHOMBERG: I guess I'd like to take an agnostic position  
14 on this, but with a little discussion.

15 It seems to me that the purpose of doing the risk assessment is  
16 to serve risk management ends. So the real question is what risk  
17 management options that are available and what kinds of analysis  
18 would most inform them?

19 Now, you could imagine violative exposures, that being an  
20 argument for including or for excluding violative exposures. And in a  
21 way it sort of depends on some things about how inherent they are in

127

1 any kind of use of the agent as Dr. Portier was suggesting. Obviously,  
2 to some degree that's true.

3 But if you put them in, you have to be very sure that you then  
4 interpret the analysis accordingly. And if it happens that those  
5 violations are driving the upper percentiles, it has to, then, be  
6 acceptable to do a risk management solution that sort of takes that  
7 into account and takes into account what perceived responsibility  
8 there are for different parties to deal with the fact that that kind of  
9 things occurs.

10 So if we put it in, we have to be very clear that the analysis  
11 means sort of something different from a risk management point of  
12 view. We can't play it this way one time; and then when the Agency is  
13 going and making the risk management decisions, playing it the other  
14 way and to try to say, Oh, it's incumbent on the Agency to make  
15 regulations such that those things don't occur as well.

16 Whether they are not, is a complicated question that isn't really  
17 about exposure analysis anymore. I think that if we put them in, the  
18 analysis means something else; and it should be clear that we are  
19 expecting a different use and interpretation of it by the EPA in the  
20 regulatory arena as a result of that.

21 DR. KENDALL: Dr. Adgate.

1 DR. ADGATE: I mean not to beat the dead horse too hard. I  
2 think it would be useful to point out the fact that tolerances are in fact  
3 not health-based and that should provide you with some cover. And I  
4 think that fact you are all quite aware of often gets lost in these sorts  
5 of analyses. At least in theory what we're doing here is health-based.

6 DR. KENDALL: Dr. Portier.

7 DR. PORTIER: Following up on what Lorenz said, I guess the  
8 only regulatory control that would convince me you should throw out  
9 the violators would be one in which you were continually monitoring  
10 these products, and if it exceeded the tolerance, you threw away the  
11 product. If you didn't throw away the product but in fact mixed it  
12 with product with lower bounds, lower levels, then that could, of  
13 course, be incorporated into the sampling strategy for the PDP to look  
14 at the question of what impact could would that have. But I think the  
15 reality is those are the data and I would really encourage you to use  
16 them.

17 DR. KENDALL: Would EPA care to respond to any of the  
18 points made, or were they clear enough?

19 MS. MULKEY: I think we would like to encourage a little more  
20 elaboration if there is going to be a discussion of some sort -- and I'm  
21 over simplifying this -- trade off between choices about what part of

129

1 the distribution to consider regulating at and what kind of acceptable  
2 or target MOEs we might work with. And we are mindful that that is  
3 that's a mixed science and policy decision as you seem to be mindful.  
4 But if you're going to discuss the idea of the intersection between  
5 those two, do so in more than identifying it as an intersection, I guess  
6 is what we're trying to say.

7 DR. KENDALL: Okay. Anybody like to comment on that?  
8 Chris, do you want to comment? Lorenz? Go ahead and start, Chris.

9 DR. PORTIER: You know we've discussed this from the other  
10 direction before with the SAP in terms of using the benchmark dose  
11 and what happens with 1 percent, 5 percent, et cetera. On the side of  
12 exposure, I think it's got to be the same thing. And I don't have any  
13 fixed factors for you. I think it's a debate you have to have both  
14 publicly and internally as to how you do the margin of exposure and  
15 what constitutes a reasonably acceptable margin of exposure.

16 It's driven by a lot of things. In this case, instead of looking at  
17 a directly toxic endpoint, you're looking at potentially a biomarker of  
18 a toxic endpoint. And that weighs into your decision about how big or  
19 small you want the margin of exposure.

20 I think the same thing is true on the exposure side of that  
21 distance. In terms of, if you only have 10 or 20 or 13 samples from

130

1 which you're making your distributional assumption, you would want a  
2 larger margin of exposure against a fixed point. And that pertains -- it  
3 pertains to the variance of the estimate of the point.

4 If I choose a 99.9th percentile, I know the variance is going to  
5 be large; and I know, to some degree, that my choice of that percentile  
6 is driven a lot by tail behavior of my data set. So the bigger the data  
7 set, the less of a margin of exposure I would want if I believe 99.9  
8 percent is really safe.

9 If I believe 99.9 percent is safe and I'm going to set it at 90  
10 because that's the best thing I can do with the data set that I have,  
11 then I'm going to want some sort of factor in my head for this margin  
12 of exposure that makes it a bigger margin of exposure. Because I  
13 know chances are 10 percent of the population is somewhere above is,  
14 but I'm not sure what, how far above that actually goes.

15 There are no easy answers in that question. But I think we have  
16 to be as a Science Advisory Panel, we have to be clear where the  
17 science can take you and where it can't. And by deciding on a margin,  
18 deciding on a point of departure that's based science per se with  
19 reasonable objective rules and recognizing that sometimes the science  
20 pushes us closer to the tail of that exposure distribution and  
21 sometimes it doesn't, I think that needs to be factored into the margin

131

1 of exposure rather than always choosing a fixed point, 99.9, regardless  
2 of the quality of the information and a fixed margin of exposure  
3 against that.

4 DR. KENDALL: Okay. That's pretty clear. Dr. Durkin.

5 DR. DURKIN: I was going to weigh in with something a lot  
6 more simplistic. I think basically philosophically agreeing with what  
7 Chris has said here.

8 We are talking about margins of exposure and talking about  
9 these as things that can be basically set as a matter of policy. But I  
10 think it's good to keep in mind that for a very, very long time, the EPA  
11 and others involved in human health risk assessment have sort of  
12 looked at the reciprocal, the hazard index of chemicals, that was in  
13 turn based on a ratio of the exposure to the RFD, where the RFD was  
14 something that was pounded out as a matter of science to the extent  
15 possible.

16 And I think that this is -- you can still handle it as a margin of  
17 exposure if you're comfortable with that; although I think the hazard  
18 index approach is much more elegant. That's just my bias.

19 But I think the point is that we know a great deal about the  
20 organophosphates. You have picked yourself an index chemical, and  
21 we have, I think all, agreed that this is a reasonable approach and that

132

1 the relative potency method is reasonable. I don't think it is beyond  
2 the scope of OPP to look at whatever choices that they would like to  
3 make in terms of do we regulate at the, you know, 99.9 or the 99 or  
4 whatever, and then to look at both animal and the human data that we  
5 have, not simply methamidophos, but on the whole class of chemicals,  
6 and come up with what is functionally an RFD or, if you're old an ADI.  
7 That would indeed lead you directly to a margin of exposure that is  
8 more science-based than policy based. And I think that would  
9 probably be a reasonable way to go about this.

10 DR. KENDALL: Dr. Reed.

11 DR. REED: Maybe this is a good time for me to get something  
12 clear. I really appreciate in this, whether it's uncertainty or a  
13 sensitivity analysis or the material that we received, that you actually  
14 present not just one slice of the distribution, 99.9th or whatever, but  
15 that you actually present modal points.

16 I don't know. Are you thinking of doing that in the final  
17 document, or are you thinking of just presenting it one point?

18 MS. MULKEY: In almost all our risk assessments, we present  
19 these multiple points.

20 DR. REED: That's my understanding. Because to me, that's  
21 important. I think a lot of problems or lack of understanding about

133

1 when you read a document is that it's really bothersome if somebody  
2 just presents one point to me. It depends on how you slice it. The  
3 high end gets sliced off or high end gets included and that kind of  
4 problem.

5 Thank you for that clarification. I would like to see multiple  
6 points being presented.

7 DR. KENDALL: Dr. MacDonald. Okay. Dr. Bull.

8 DR. BULL: Just a quick point. I think it's building on what  
9 Chris started off here with. But one of the reasons I asked my  
10 question related to this earlier was I think you pick your point on the  
11 distribution, you may find that regulating at the 90th percentile will  
12 have absolutely -- taking your margin of exposure at 90th percentile,  
13 no matter what it is, the way I see the data there is some possibility  
14 you'll never affect the upper end of that distribution because those are  
15 going to get every more rare events as you get out. And when we  
16 come to the drinking water thing, that's what concerns me. If there's a  
17 hazard in drinking water, it's a very extremely rare event. And might  
18 be an important event.

19 But you're probably not going to change that by either  
20 adjusting, you know, within some reason between the 90th and 50th  
21 percentile on the way you deal with residues on these different fruit

134

1 crops. It's probably not going to effect those extreme values.

2 DR. KENDALL: Okay. This will conclude our food exposure  
3 assessment, unless there are any further questions from EPA for the  
4 Panel.

5 Okay. At this point I'd like to move us to drinking water  
6 exposure. And, Dr. Perfetti, would you like to introduce your  
7 scientist.

8 DR. PERFETTI: To do the water presentation, we have Nelson  
9 Thurman and Kevin Costello.

10 DR. KENDALL: Welcome.

11 MR. COSTELLO: Thank you give everybody a chance to get a  
12 hand out.

13 Good afternoon. I'm Kevin Costello and today with Nelson  
14 Thurman here we'll present a summary of the work we did designing  
15 and performing the drinking water exposure assessment OP cumulative  
16 risk assessment.

17 First, a road map of today's presentation. First of all describe  
18 the preliminary results of our assessment so that everybody can  
19 consider the rest of the presentation in that context. I'll describe the  
20 background which led up to our assessment, first reminding you of the  
21 data requirements we had for the exposure assessment. And then I'll

135

1 describe the knowledge we already had about the organophosphates in  
2 drinking water, what data we had available, and just briefly review the  
3 guidance we had received from the SAP in the past on the building  
4 blocks we used for this assessment.

5 Finally, Nelson and I will discuss the drinking water assessment  
6 as it appears in the December 2001 Draft. As we do, keep in mind the  
7 two questions that we posed which deal with the two issues basically  
8 presented here. First, the watershed modeling approach that we took  
9 for the drinking water exposure assessment; and, second, the regional  
10 assessment approach that we took which differs from the nationwide  
11 assessments we've done for individual chemicals.

12 We'll try to do our presentation in a way that clarifies, builds on  
13 those questions so that everybody understands better what it is we're  
14 looking for.

15 Although Nelson and I are the ones giving the presentation  
16 today, we're actually part of a much larger team that worked on this  
17 basically from March until the December legal deadline and completed  
18 it in time.

19 You can see that on the team from EFED beside us that we had  
20 ad hoc teams that worked to come up with new modeling scenarios.

21 And Ian Kennedy worked to get the model development together. We

136

1 have some folks working on a separate track for an SAP on water  
2 treatment effects. There are people from other divisions such as HED  
3 and BEAD helped us with all the usage data and with building regional  
4 assessments.

5 Now, the preliminary results of our exposure assessment  
6 indicate that drinking water is not a major contributor to the total  
7 cumulative risk from organophosphate insecticides. In fact, the  
8 assessment showed that the exposure from drinking water was up to an  
9 order of magnitude or more below of the food exposure.

10 Because of this result, it's very important to us that the Panel  
11 think in terms of whether, as we give the presentation and from what  
12 you've read, are there any systematic flaws in our approach that would  
13 lead to over estimations or underestimations of possible drinking  
14 water exposure. This is really important not only for the OPs, but this  
15 is the tool, this is the first shot at the tool, that we intend to use for  
16 future cumulative risk assessments for other pesticides families.

17 DR. BELL: Can I ask a question? I can't read this either there  
18 or there. And I'm trying to figure where we're at. Is this dealing with  
19 some level of residue?

20 MR. THURMAN: Actually, I think the whole part of that was  
21 just to illustrate. Basically, when you get above the 95th percentile,

137

1 you see the similar trend.

2 DR. BULL: So it's above the 95th percentile.

3 MR. THURMAN: It's a higher percentile. And the whole intent  
4 of it was just to illustrate that.

5 MR. COSTELLO: So as Dave Miller presented before, and as  
6 SAP has seen before in the case study, the cumulative risk assessment  
7 was done using a calendar-based approach. And daily exposures in  
8 water are one of the building blocks of this approach.

9 Now, for the OP assessment we used the daily time step as  
10 described before. But in future assessments, it could be -- that an  
11 error there. Calendex will allow the 7-, 14-, 21- or 28-day rolling  
12 averages we've gone through. And, also, as described earlier,  
13 Calendex is the tool used to combine these exposures from the  
14 different routes.

15 This is important especially for the drinking water and the  
16 residential exposures because they have seasonal differences, they  
17 have pulses of exposure that we consider in the assessment as opposed  
18 to the food.

19 So we knew that in order to work with Calendex our water  
20 assessment had to provide a distribution of daily concentrations for  
21 the probabilistic exposure assessment. We had to account for

138

1 variations in time, daily, seasonally, yearly. We had to account for  
2 variations in place because drinking water is much more of a local  
3 phenomenon than food because of how food can be distributed the  
4 around the country. And we needed to reflect the possibility of  
5 co-occurrence of multiple OPs for cumulative assessment as they  
6 occur together in place and time.

7       When we started this, we were not starting from scratch. We  
8 already had, from the previous five years, more than 24 individual OP  
9 assessments in the interim routes that had been done. From those, we  
10 were able to derive the pesticides properties, the physical chemical  
11 properties of the chemicals that we used to figure out environmental  
12 fate.

13       And on top of that, because of those, we had regulatory actions  
14 that had been taken voluntary cancellations, use rate changes for many  
15 of these pesticides. And as was described before, as uses were taken  
16 out, they were no longer considered in the assessment.

17       On top of that, we had a great volume of monitoring from  
18 surface water and ground water; and to a lesser extent -- I'm sorry.  
19 Can you go back one.

20       And we had the individual drinking water assessments that were  
21 done in the aggregate human health risk assessments done for each of

139

1 these routes.

2 And finally, very importantly, we had SAP guidance along the  
3 way as we refined our process for doing drinking water assessments.

4 Now, as we look through the available monitoring which had in  
5 fact grown in volume since we did the individual assessments, we  
6 found that in fact the OPs are found in drinking water sources.

7 Although this is not frequent, and they're usually not at high levels.

8 When considering all kinds of water monitoring, not just drinking  
9 water, surface water sources, generally, seemed to be more vulnerable  
10 to contamination by the OPs in a pattern that was seen not only in  
11 nationwide programs like the NAQUA Program, but also in the state  
12 programs because we actually contact all 50 states to see what kind of  
13 monitoring they've done over the last 10 years or so.

14 Chlorpyrifos, diazinon, malathion were the most frequently  
15 included; but they were also the most frequently found in surface  
16 water studies, ground water studies and drinking water studies. We  
17 found especially from the NAQUA Program that co-occurrence of the  
18 OPs in water is likely. Multiple OPs were detected together in  
19 individual samples. And this is not surprisingly related to usage in a  
20 particular watershed.

21 In looking another the monitoring, however, we did find that

140

1 there some limitations to what was available for our purposes. Most  
2 importantly, there is no single definitive study that can answer the  
3 question what OP exposure is in drinking water. So we knew we  
4 would need to look in monitoring in a weight-of-evidence approach  
5 from several sources.

6 In looking at all the sources, we found that the monitoring  
7 covering a number of sites but not all high use areas for the OPs. Even  
8 in the largest programs, the ones that had the most intensive sampling,  
9 sampling was not frequent enough to account for daily fluctuations.  
10 And those programs, all of the programs, also have been done because  
11 of constraints of how much they cost for a limited number of years.

12 Now, I mention that the chlorpyrifos, diazinon, and malathion  
13 were the most often included OPs in monitoring programs. But not all  
14 OPs were included in monitoring at all. In NAQUA Program included  
15 nine currently registered OPs. State programs included some more  
16 that weren't in the NAQUA Program, but some of the lower use OPs  
17 were not in anything.

18 Few or no OP degradates of toxic concern were included in  
19 most of the studies. Some of the very most recent studies are starting  
20 to include those such as the pilot reservoir monitoring study that EPA  
21 is doing with the USGS. And the monitoring that was available, even

141

1 the most recent data, does not reflect the most recent regulatory  
2 actions that were taken. Like I mentioned, voluntary cancellations,  
3 although they have been made official, still have the time before they  
4 phase in.

5 So in the end, after looking at all the available monitoring that  
6 we had, we concluded that we would not be able to base our exposure  
7 assessment solely on available monitoring.

8 So if we were going to have to make up for the holes in the  
9 monitoring assessments, the monitoring programs rather, with  
10 computer modeling, this is where the guidance from the SAP we had  
11 gotten in the past was particularly helpful. And I'm just really going  
12 to run really quickly through some of the highlights of what we learned  
13 along the way, what the guidance we received along the way.

14 In 1997, first taking our model, the PRZM-EXAMS model to the  
15 SAP, we were told that it was a good tool, the best tool available, to  
16 do our screening assessments. But that in the future, we should  
17 devote resources to refining our assessment and concentrate on  
18 surface water impacts, and as we go along, to use both modeling and  
19 monitoring data in our assessment.

20 In 1998, we took a first refinement of this model to the SAP,  
21 bringing our index reservoir scenario for consideration. This

142

1 adaptation of PRZM-EXAMS includes a scenario based on an actual  
2 watershed, an actual reservoir, in the Midwest. Then having done  
3 that, we moved from working with the watershed to trying to consider  
4 what portion of a watershed would actually be cropped to get a  
5 maximum idea of what portion of the watershed could actually get  
6 treatment by pesticides.

7 The SAP actually approved of this, especially for major crops.  
8 But due to concerns about scale differences, the size of the hydrologic  
9 units, the eight-digit HUCs to drive these percent crop area factors, it  
10 was not recommended that we use the PCAs for smaller crops or that  
11 we considered percent crop treated with the pesticides without getting  
12 further monitoring.

13 Now, this is important. As Nelson will describe before,  
14 although the SAP did talk to us about this when considering aggregate  
15 assessments, this was something that we felt we had to adopt to some  
16 extent in order to do a cumulative risk assessment.

17 And then one last thing that was on the last slide, the SAP  
18 recommended that we consider regional modeling, something that we  
19 have done for this assessment.

20 In 2000, we went further in presenting proposed regression  
21 modeling approaches that the USGS was and is developing which show

143

1 promise. But, again, it's just another step in the continuing refinement  
2 of our assessment. These are still in process. And the SAP  
3 recommended that we shift our focus to monitoring programs to  
4 support model development and evaluation.

5 This is led up in December to the case study for the cumulative  
6 risk assessment. That used WARP, the regression model; but we were  
7 told at the WARP, while showing promise, was not ready for this kind  
8 of assessment because it couldn't also do the daily time step. So  
9 WARP was not used in our assessment at this time.

10 Finally, one more please. Something not directly in that line but  
11 another ongoing and very important issue that we're looking into is the  
12 effect of water treatment on pesticides. And the SAP recommended  
13 that until we have enough data for any particular assessment to really  
14 know what removal of a pesticide might occur and how much of  
15 degradates, especially toxic degradates, might be formed, that we  
16 should do our assessments based on raw and not treated water but that  
17 we had to consider the impact of transformation products.

18 This is important for the OPs because we have limited evidence  
19 that OP residues are in fact likely to not be reduced. But let me see,  
20 the concentration reduced not speaking chemical by water treatment,  
21 especially not reduced because we're talking mostly about chlorination

144

1 and oxidation processes.

2           There is, also, evidence for transformation of products that are  
3 of toxic concern. However, as consistent with the SAP, because there  
4 was not enough information for us to make quantitative adjustments to  
5 our assessment, either to figure out how much of the parent goes  
6 away, how much of toxic products are formed, and are how long they  
7 last, we were not able to quantitatively include the transformation  
8 products in, the water treatment transformation products, in our  
9 assessment.

10           So with this guidance in our head, we went forward with a  
11 watershed modeling approach for the cumulative exposure assessment.  
12 We adapted PRZM-EXAMS in an attempt to estimate pesticide levels  
13 in a small drinking water reservoir. By doing that, we derived daily  
14 distributions over multiple years with weather being the variable for  
15 12 regional assessments. By doing this, we're able to look at multiple  
16 chemicals used on crops in multiple fields within the watershed.

17           For the cumulative assessment, we adopted typical use patterns,  
18 typical rates, looking at the area that is actually treated with  
19 pesticides. This is something that we have not done in our individual  
20 assessments and we have to actually decide whether it's appropriate to  
21 do in our individual assessments.

145

1           And, finally, for each of the 12 regions, we looked at  
2 region-specific inputs. And I'll describe how we choose our scenarios  
3 in just a moment.

4           Basically, when we decided that we were going to take a look at  
5 regional exposure assessment for the cumulative assessment rather  
6 than the national assessment that we did before, the first time we  
7 considered how we were going to do it we sat around the table and  
8 decided what would be the factors that would be important in figuring  
9 out what these regions would be. And the very obvious ones that came  
10 to mind were the OP usage. It's important to have an regional  
11 assessment because some of the chemicals in the assessment aren't  
12 used nationally. Some are. But some are used in very specialty crops  
13 or just certain parts of the country. So we had to see which crops  
14 were there that OPs were being used on and how much was being used.

15           Then we decided we really need to consider what the source of  
16 drinking water is if we're going to do a drinking water assessment.  
17 And some parts of the country, say, Florida, Southern Georgia, ground  
18 water is the predominant source of drinking water; whereas in other  
19 parts of the country, surface water was the main source.

20           Then we had to consider what the vulnerability of the drinking  
21 water sources were. Some parts of the country, while having great OP

146

1 use, may not be all that vulnerable to runoff or to leaching. And we  
2 wanted to take a look, on a regional basis, what the likelihood of  
3 actual vulnerability was.

4 It just so happened that our friends in the Health Effects  
5 Decision knew of a regional framework that had already been  
6 developed by the USDA Economic Research Service. These are their  
7 farm resource regions and this had the advantage we thought right  
8 away of pretty much corresponding with what we were thinking about.

9 But on top of that, these are based on different farm types and  
10 on previous work that the USDA did for separating the country in  
11 ways that made sense, both for farms and for climate and for usage.  
12 And, of course, they had advantage of ready-made names that we could  
13 adopt.

14 Now, as you look at that, you can see that we have, we have  
15 more than 12 up there. We did, in the end, combine some of the  
16 regions based on the vulnerability. The basin and range was subsumed  
17 into the Northern Great Plains as much as anything because of the  
18 amount of OP use and where in that region the most vulnerability  
19 seemed to be.

20 Now, once we had the regions, we still had to determine how to  
21 do a drinking water assessment for an entire region. It does represent

147

1 a refinement over doing it for the entire country, but it still was a  
2 problem that had to be addressed. So in building the cumulative  
3 assessment on a regional scale, the first thing we did was to identify  
4 high OP usage areas within each of the regions.

5 You can see, if you look at the regional boundaries, that say in  
6 the Fruitful Rim Northwest you have multiple regions that have high  
7 OP use, say the Wallamet Valley, the Yakima, and then along the snake  
8 river in Idaho. So this was a good first cut.

9 But then if we go to the next slide, we built on top of that. We  
10 took a look at how vulnerable areas were in each of the regions. How  
11 vulnerable they were to surface water runoff and something that  
12 wouldn't have come through on the computer. You see the dots. On  
13 top of the vulnerability, we, also, took a look another where surface  
14 water intakes were for drinking water sources.

15 So taking all of that into account, in the end for the modeling  
16 approach, we came up with a set of areas within the regions,  
17 watersheds that were going to represent each of the 12 regions. These  
18 areas, then, have high apparent potential for cumulative exposure  
19 based on the OP use, the number and the pounds of OPs being used in  
20 those areas; they coincide with those areas high runoff potential; and  
21 where surface is an important source of drinking water.

1           It is important to recognize that, although we choose those  
2 areas to represent the highest cumulative exposure, they don't  
3 necessarily represent the areas that have the highest exposure for any  
4 single pesticide. But we still expect that the combined OP exposure to  
5 be among the highest for each region. And on top of the four regions  
6 like the Fruitful Rim Northwest, where we chose the Lamit Valley, we  
7 did consider as best we can in our characterization, we attempted to  
8 describe other important areas in those regions.

9           So for the Fruitful Rim Northwest, for instance, we went into a  
10 discussion of the Snake River Valley, the geology, the hydrology of  
11 the area, the type of use, the source of drinking water, which was  
12 ground water. So that in an attempt to try and explain, again, why we  
13 thought that the regions we choose were the best representation of  
14 risk if the drinking water was a risk driver for any particular region,  
15 which as it turned out, they were not, we were prepared to go to a  
16 finer resolution than the regions and to try and look at what those  
17 watersheds we choose actually represented within those regions and  
18 try to get a more refined assessment.

19           So what we ended up doing by choosing these watersheds was  
20 to tailor our assessment to selected areas. We used location-specific  
21 environmental data for the regions that we chose -- the soil, the sites,

149

1 the local weather and the crops that were grown there -- and we  
2 considered the major crop OP combinations within that area. And by  
3 doing that, we looked at crops that actually occurred together. We  
4 were able to look at different OPs used on multiple crops. And if OPs  
5 were actually used in those particular regions for usage data. And  
6 there the end, we did enough scenarios in an attempt to account for  
7 about 95 OP use in each of the areas that we choose.

8 And Nelson will take over from that to give more details on how  
9 we did the assessment.

10 MR. THURMAN: What I'm going to touch on here is not so  
11 much how it built upon the SAP guidance in terms of what we were  
12 doing for the individual screening assessments and how we tailored  
13 these tools for use in the cumulative assessment. Kevin's already  
14 talked about a regional framework, one of the big differences.

15 If you compare our individual assessments, we started at a  
16 national level. We tried to pick one site that represented a high-end  
17 exposure across the nation. In this case, we're starting in a regional  
18 level and we're looking high-end exposure with each region with a  
19 concept of, if we're okay on that site within the region, we're okay in  
20 the rest of the region; if not, we need to burrow down further.

21 I'm going to talk about how we did our watershed-based

150

1 modeling and talk about the way we use the data which is a little  
2 different than what we have in the individual assessments and how we  
3 took a look at usage information.

4 There some people in this SAP that have been on some of the  
5 water SAPs we've had and there are some of you folks are, at least to  
6 me, new faces. So I wanted to briefly give you at least a concept of  
7 what type of model we were using. For those of you who've heard  
8 this, it won't be too long.

9 Essentially, PRZM, which is the Pesticide Root Zone Model, is  
10 something that was developed out of EPA's ORD. It takes a look at  
11 what happens when a pesticide is applied to a field. And it basically  
12 follows the pesticide from the application to the field to the runoff  
13 right to the edge of the water body. It's a field-scale simulation using  
14 chemical movement, hydrologic factors. Accounts for ways chemicals  
15 are transported, and it is very useful in terms of using it uses a lot of  
16 chemical specific. We included both OP pesticide and those  
17 toxicological concern it was primarily the sulfone (ph) and sulfoxides.

18 We did not include degradates that were not formed in the  
19 environment, for instance, the oxons were not something we saw in the  
20 environmental studies; that is something that we do see as a result of  
21 the water treatment. But it is not formed in the environmental studies

151

1 we saw.

2 EXAMS, which is the Exposure Analysis Modeling System, is  
3 another model developed by ORD. Basically, it takes over when  
4 PRZM leaves off and looks at what happens once the pesticide reaches  
5 the water body..

6 We had a few fixed inputs. The primary fixed input was the  
7 geometry and hydrology of the reservoir itself. Essentially, as Kevin  
8 mentioned, we used the index reservoir. Essentially, what we did for  
9 each of the regions we picked up the dimensions, the hydrology, the  
10 geometry, the size, and plot them in each of the regions.

11 Now this is going to be representative more of drinking water  
12 reservoirs and drinking watersheds in the wetter parts of the country  
13 than in the west where you're going to need a larger watershed to  
14 supply that reservoir. It's also not going to be as representative where  
15 you have artificial drainage or controlled drainage conditions, which  
16 you also tend to see in the west.

17 It is a reservoir. It is not a flowing water body. Based on what  
18 evidence we have, we expect the reservoirs tend to be a little bit more  
19 vulnerable. Once again, we're looking at a site that, if we can make  
20 the conclusions we did based on this site, we're not worrying about  
21 other sites. But we do not know there were some limitations in terms

152

1 of that as we move in different regions in the country. And that's one  
2 of the reasons why we continue to go back to feedback on what the  
3 monitoring showed.

4 We had a number of variable inputs. As I mentioned early, the  
5 chemistry, chemical properties, were specific to those chemicals. The  
6 weather, the site, environmental crop, and usage information are  
7 specific to each of the assessments areas. So in that way, we are  
8 tailoring to things that actually occurred in the area where we did the  
9 assessment.

10 What you see here, in case you can't see -- what you have is  
11 concentration on the Y axis, and you have time on the X axis. And,  
12 basically, you're looking at a 10-year span here. What we get as an  
13 output of a PRZM-EXAMS are daily distributions of concentrations in  
14 water over this ten-year -- in this case, a ten-year period.

15 I want to contrast a little bit because NRDC raised a concern  
16 about one thing we do differently, which, as they pointed out, we use a  
17 peak estimate individual screens. Actually, what we use when we do a  
18 individual screen is a higher percentile what reflects a one-in-ten-year  
19 concentration that we would find over the period.

20 And I forgot to mention, most of these sites we had up to 36  
21 years of weather data. So we would run this simulation over a 36-year

153

1 period. In effect what we're doing when we do these simulations,  
2 we're holding use constant and varying the weather from year to year.  
3 So the variations you see from year to year reflect differences in the  
4 weather and runoff that we get as a result of that.

5 For an individual screening assessment, we might use this one  
6 value. And this red line there. And in effect what we're doing for that  
7 assessment is we're assuming that this is a concentration that occurs  
8 every day. What we're doing in this more-refined assessment that  
9 we're doing and looking at multiple chemicals is we're realizing that  
10 that concentration doesn't happen every day. You get your daily and  
11 seasonal and yearly variations. So we're capturing that full range of  
12 concentrations that you get.

13 We're also preserving the time component. We do know that in  
14 any given year the concentration of pesticide you might see in water  
15 on June 1 is going to be related to the concentration you had the day  
16 before and the concentration you had the day after. So there is a time  
17 relationship that we're able preserve by going to this yearly  
18 distribution; and we're able to preserve Calendex to pull those  
19 exposures in.

20 This one did not come out very well. I think we were so  
21 ambitious to make sure that you could see it that we overloaded the

154

1 memory on the computer.

2       You should see at second distribution superimposed in here.  
3 The intent, the point of that, I can tell you is that with a cumulative,  
4 we're looking not just at one chemical; we're looking at multiple  
5 chemicals that are going to have uses on different crops; their timing  
6 of application is going to be different. We have to find a way to take  
7 all of this into account.

8       Kevin mentioned briefly how as we use the use information and  
9 zoomed in on an assessment area in each of the regions, we tried to  
10 make sure that we captured all those OPs that would actually be used  
11 in the same watershed. For instance, to use as an example, the  
12 Northwest Fruitful Rim, we found that OP use on potatoes tend to be  
13 concentrated primarily in Idaho. And OP use in apples tend to be more  
14 in Washington. So we're not combining those two areas since they  
15 don't actually physically occur.

16       The other component the co-occurrence is the time of use. As I  
17 go forward in this, I will try to explain how we did try capture those  
18 windows of application so that we could separate that timing as much  
19 as we could accurately do with the data we had.

20       One of the big departures between what we have brought before  
21 this SAP in the past and what we were bringing forward in terms of

155

1 this cumulative assessment is how we use the PRZM part of the model.  
2 PRZM is a field-scale model. That basically carries a lot of baggage  
3 with it. It assumes that we can take the field scale and scale it up to a  
4 small watershed and not lose too much in the estimates.

5 We know that there are some assumptions that go with that.  
6 We're assuming a single soil in the watershed, the crop and the  
7 management practices are homogenous in that area.

8 For the cumulative assessment, we basically went back and used  
9 PRZM as a field-scale model. But what we basically did is we  
10 simulated multiple fields in the watershed. One of the things to keep  
11 in mind is that, while we did this approach and we feel it's something  
12 that does reflect what you might find is happening in the watershed,  
13 we still don't have any way of giving a spatial distinction within the  
14 watershed.

15 If you remember in the earlier slide of the pictures, the  
16 conceptual drawing of that watershed and reservoir, we basically don't  
17 have location-specific information there. We're assuming the crop  
18 that's used covers a certain percent of that area, but the percent of  
19 area is evenly distributed throughout the watershed. So we're not  
20 distinguishing between crops that may be grown in the upper end of  
21 the watershed versus those crops that may be concentrated in lower

156

1 end.

2 It also assumes that all of the runoff flows into the water body.  
3 We know those are the two limitations that we in that. We do feel that  
4 by simulating multiple fields, it better reflected what we needed to do  
5 with the cumulative.

6 We, also, had to have a way to take in the fact that we  
7 understand that not all of any watershed is going to be treated with  
8 OPs. Those areas that are treated, you're going to have different  
9 crops treated with OPs at specific times and specific rates and specific  
10 frequencies. I'll say right now, the tools to do that are probably a lot  
11 easier to do than getting the data that can do that. And one of our  
12 challenges was how to pull this data together and use it to the best we  
13 could. And in response to, I think, Daniel Botts comment, we're  
14 hoping that we used the appropriate data. And we'll try to explain to  
15 you what we did use. And we hopefully used it appropriately as we  
16 did that assessment.

17 One of the things I do want to say is the advantage of simulating  
18 multiple fields in a watershed, as we did, is each field may very well  
19 have a different soil and a different crop. And so we are getting a  
20 little bit more a reflection of a little more heterogeneous watershed  
21 than we can using it as we did before.

1           This picture happens to be in the document and it looks better in  
2 color than it does in black and white. Essentially, what I can tell you  
3 is that that map shows a percent of the crop areas taking a look at, by  
4 on a watershed basis, what the percentage of each of those watersheds  
5 are in agriculture.

6           You can't tell whether the gray tones there, but your highest  
7 concentration prejudice of agriculture occurs in the watersheds that  
8 are in the Midwest. And the lowest is, obviously, in the Basin and  
9 Range. This is where your highest concentrations are.

10           We used something we've called a cumulative adjustment factor  
11 approach to account for the relative contribution of each OP in crop  
12 use. We did this in terms that we had to take into consideration both  
13 the recommendations and the concerns of the SAP on the percent crop  
14 area factor that we brought forward to them. And I'm going to explain  
15 to you how we did this so you can take a look and see whether it  
16 makes sense. We think it makes sense, but it's one thing we want your  
17 feedback on as we go along.

18           One of things I will say is that one of the earlier  
19 recommendations of the SAP was that, when we started looking at  
20 percent crop areas, we should do this on a watershed basis. And it  
21 makes sense on a physical basis because we're looking at, we're

158

1 dealing with watersheds.

2         The thing to keep in mind the data is collected on the basis of  
3 geographical and political boundaries. In other words, most of it is  
4 collected at a county or state level, not on a watershed level. So you  
5 need to take some way to translate that.

6         We brought forward an approach in 1997 for applying a percent  
7 crop area factor starting with county level ag census data. In the '97  
8 presentation, we used the 1992 ag census. We now have the 1997  
9 agriculture census available which is one of the recommendations the  
10 Panel was, as soon as it was out, to use the most updated information.

11         We, basically, overlaid those with watersheds and used GIS to  
12 get that spatial distribution within the watersheds. Kevin mentioned  
13 what we had available for GIS were 8-digit hydrologic units, which  
14 tend to be fairly large. They average 367,000 hectares in size. And  
15 you compare that with 172-hectare watershed we were using, you can  
16 see that, at least for the smaller drinking watersheds, you get a lot of  
17 them and you can get lost in those large HUCs.

18         One of concerns of the SAP was that while you may have minor  
19 uses that don't add up to a big percentages in these large watersheds,  
20 those minor uses are often clustered and they may be clustered in a  
21 smaller watershed where they have more of an impact then they did on

159

1 a larger scale. So that was one of the challenges we had in trying to  
2 convert this data.

3 We, also, were trying to keep in mind the caution against doing  
4 too small a PCA for that reason. What we decided to do is come up  
5 with a cumulative OP-PCA. So for each of those 12 regions as you  
6 saw, we derived the percent crop areas for the total agriculture using  
7 the '97 ag census data.

8 We then took a look using the latest national agricultural  
9 statistics service data which is collected on the county level. We took  
10 a look at agriculture land that were in crops that had registered OP  
11 uses in that area. And we came up with that percentage. So we  
12 essentially adjusted your total agricultural PCA by your percentage of  
13 the aggregates from the OPs and came up with a cumulative OP-PCA.

14 This is an illustration that the numbers you see down there are  
15 based loosely on an earlier version of one of the regions we were  
16 looking at. I round them off to make it easier for me to do the math  
17 and to explain what's going on. One of the challenges we had, if you  
18 look at these total acres, they are total acres in the assessment area,  
19 which is a lot larger than what you're looking. This is one of the  
20 reasons why we went to a percentages so we could use that percentage  
21 as a way of scaling down based on the area.

1           In this particular area, we're looking at a cumulative OP-PCA of  
2           50 percent. Basically, 40 percent of that area in that region were in  
3           crops that had registered OP uses.

4           Now, if you keep in mind that not all -- we know that in any  
5           given year, not all of those crops are going to be treated with an OP.

6           It's further complicated by the fact, if you go to the next slide,  
7           that these crops may be treated with multiple OPs. Some OPs may be  
8           used on more than one crop. We used a second concept which was a  
9           percent acre or percent-acre-treated factor. This basically used the  
10          acres treated, which we collected state-level data, as a way of  
11          determining how many acres of the total -- for instance, how many  
12          acres of total corn were treated with a particular OP.

13          Now, this acre-treated doesn't take into account the fact that  
14          you may have more than one application that goes in that area. And if  
15          you were to look over at, for instance, the beans, which you see here,  
16          is a particular case we had two different OPs that were basically used  
17          on the entire crop at different times.

18          What's not reflected in here is timing and I'll get at that again in  
19          just a little bit. But we used this concept to derive a cumulative acre  
20          cumulative adjustment factor which combined both the percent-crop  
21          area and the acres treated based on the slide that -- based on the one

161

1 that had the map that you couldn't see.

2 I know you can't read all of these. What I want to just point out  
3 is that when we did this, by combining both the acre treatment and the  
4 percent-crop area, this gave us a way to distinguish between the  
5 relative contributions of each OP and crop use within that watershed.  
6 And so we use this cumulative adjustment factor as a way of making  
7 that adjustment.

8 So what we did is that we ended up with each of the crop OP  
9 uses that we identified in the assessment area, we ended up with daily  
10 distributions. And we still needed to combine these individuals  
11 distributions for different chemicals together. So what you see here in  
12 each of these distributions is that we put them on equal area. We use a  
13 crop-area factor, the cumulative adjustment factor, to put these on  
14 equal footing in terms of the area contribution they made in the  
15 watershed. We used the relative potency factor, we talked about  
16 earlier, to put them on a comparative basis so that we could combine  
17 this so that we'd end up with any regions a single distribution over up  
18 to 35, 36 years in methamidophos equivalence.

19 And so what you see there, in fact, you will see in these multiple  
20 peaks in a given year, which basically reflect different timings of  
21 applications of different pesticides.

1           Now, there are some assumptions and issues that come out of  
2           the way we did this approach. One again, we tried to address the SAP  
3           concern about the fact that data came in different scales. We're trying  
4           to take county and state level data and apply it to a watershed. And  
5           the fact that the size of the watersheds we had that we could work  
6           with to do this are a lot larger than the more vulnerable drinking  
7           watersheds. And we're trying to address the fact that some of those  
8           crops cover small areas.

9           Our feeling was that by using a cumulative OP-PCA, starting  
10          with the total agriculture and adjusting for total OP uses, we don't end  
11          up with a number of small, separate percent-crop areas that may  
12          introduce more error into it than the combined PCA in that regard.

13          Secondly, we said we still have some issues on applying an acre  
14          treatment adjustment. The percent-crop treated is complied to state  
15          level. And there's a couple exceptions in that one is California where  
16          they, California Department of Pesticide Regulations, basically has a  
17          census in that they require all users to report what they use and when.

18          The other one is whenever we were looking at the Willamet  
19          Valley, we also found some use data specific to the Willamet Valley  
20          Collective, actually folks at Oregon State, that we were able to use.

21          When we take this information to state level and we try to apply

163

1 it at a watershed within a state, there's a number of assumptions  
2 embedded into this. And one of the big ones is that we've assuming  
3 that the data that's collected at state level, the percent-acres treated,  
4 is uniform across all watersheds in the state. There's also an  
5 assumption of uniformity in time. I'll get to that in a little bit.

6 What we know is that pesticide pressures are not necessarily  
7 uniform. And so what you're going to find is that where pesticide  
8 pressures are great in a particular year, you're going to see more acres  
9 treated, possibly at higher application rates. Where they are less,  
10 you're going to see less acres treated. So there are some concerns in  
11 doing that.

12 One of the other things as we took a look at that is we, also,  
13 realized that crops aren't uniformly distributed across the entire state.  
14 So in those areas where your crops are clustered in a certain area and  
15 where your use is clustered together, there may be less of a variability  
16 than in other cases. And that may be one of the differences between  
17 some of the minor crops and some of the crops like corn which tends  
18 to be more uniformly distributed in the Midwest.

19 Our assumption in doing this is that this is probably more of an  
20 issue when you're looking at a single crop, single OP use in a single  
21 pesticide than when you're looking at an area where you're looking at

164

1 multiple crops, with multiple pest pressures that are going to vary, not  
2 necessarily all at the same time and over multiple OP uses.

3 We did take a look in one area to see -- and one effect we got  
4 some reflection of maybe some of the variability we might see in this.  
5 In the Northern Great Plains we focused on the Red River Valley  
6 which tends to be where the highest total OP use was in that region.

7 We identified high OP use areas on either side of the Red River  
8 in North Dakota and Minnesota. As we start taking a look at some of  
9 the OP use information, you could see a difference, both in terms of  
10 application rates and the percent-acres treated between those two  
11 states. Our feeling was that difference was more of a reflection of the  
12 data collected at the state level in those two states than of actual  
13 differences on either side of the river in that Red River Valley.

14 We did do comparisons using North Dakota information and  
15 then using the Minnesota information to see how much of a difference  
16 that makes. And what we did find is that at your highest percentiles --  
17 in fact, anything above 90 percent, there was roughly no more than a  
18 10-percent difference.

19 And we're talking about single parts-per-billion concentrations,  
20 so we're looking at no more than a fraction of a part per billion  
21 difference with that. A lot of that was the fact that, once again, we're

165

1 looking at a combination of uses. So there was not just one single use  
2 that was pulling together.

3 We used survey data to get at the use. We uses USDAs  
4 National Agricultural Statistic Service information on pesticide usage  
5 to give us the information on use. We did not attempt to forecast.  
6 Except for the fact that we did exclude any uses for which regulatory  
7 action has been taken to cancel.

8 We also focused on the most recent year of the use data. One of  
9 things, if you look at the data, and particularly if you look at each of  
10 the regional assessments, you will realize that some of those dates --  
11 you have different dates; different years. That's because the NASS  
12 collects the information at different times.

13 Field crops are collected every year, but fruits and vegetables  
14 are collected in alternate years. We may have had to go back more  
15 than one year to get equivalent data. The other thing to keep in mind  
16 what we did use was not your maximum application rate, but we used  
17 an average. And that was basically the average of the respondents of  
18 the survey within that assessment area.

19 We took a look -- a number of OPs have more than one method.  
20 They can be applied to either aerial or by ground. We focused on the  
21 dominant method of application in that area. While our primary source

166

1 was NASS, we did, where we could find local sources, we did  
2 supplement that information in those local sources and we have  
3 documented that in the assessments.

4 We still need a way to account for the time component of the  
5 co-occurrence and in the timing of pesticide applications are going to  
6 have a big influence, particularly the timing in relation to when a  
7 runoff event occurs.

8 So we took a look at what information we had. This is a  
9 distribution for the Central Valley, California, which we use the in the  
10 Southwest Fruitful Rim assessment. This happens to be the area that  
11 had the most OP use and the most crops with OP uses.

12 And as you can see here, you got a distribution of applications  
13 the different colors are the different pesticides, have a distribution of  
14 applications throughout the year.

15 One thing to keep in mind is the data in California is a little  
16 different than what we had elsewhere in the fact that California does  
17 require reporting of every user in terms of how much you used, when,  
18 what, where. So we could get that at a county level, and we could get  
19 that across the year. So that data reflects more of census than a  
20 survey.

21 And that's the one differences that we had there. This, in effect,

167

1 made it a little easier for us to do an assessment in California terms of  
2 timing.

3 DR. BULL: Quick question on that. Those are cumulative  
4 curves. I mean you've got one shade.

5 MR. THURMAN: Yeah. Those are cumulative curves. It may  
6 have been easier if we'd had another one where -- but this just shows  
7 you the more complex end of it.

8 In other areas, we only had surveys. So we had to find a way --  
9 we didn't have this type of distribution information. We usually had  
10 something tied to a window of application. We had to find a way to  
11 find that window in a way that would try to as accurately as we could,  
12 reflect those actual differences in applications.

13 What you'll see when you look at the document is there are  
14 different ways we accounted for this temporal variability. In  
15 California, where we had the census, it showed a distribution across  
16 the year. What we ended up doing was we selected five dates along  
17 this distribution with each date representing 20 percent of the total  
18 applied use. So, essentially, you had quintals for each of your crop OP  
19 combinations.

20 In the other regions where we didn't have that specific timing,  
21 what we usually had was information reported by a particular window.

1 It was either management windows or times of the year. We used  
2 USDA chemical usage information, their planning harvest reports,  
3 crop profiles; we talked to regional specialists or local specialists in  
4 those areas to try to define that window of the application as narrowly  
5 as possible.

6 If we had a pesticide that had a single application of a crop but  
7 we had no distribution information, for instance, if we had a pesticide  
8 that we knew was applied at planting, but there was no other  
9 information on the distribution of those applications, we would take a  
10 look, go to the local area, find out when the window of planing was.  
11 And then we would apply this pesticide at the beginning of that use  
12 window.

13 If we had a single application but we had some type of  
14 distribution window and we were able to define an active window  
15 within that, then we would select the midpoint of that active window  
16 to apply the pesticide. If we had pesticide that had multiple  
17 applications, then we tried to distribute that evenly across the use  
18 window.

19 Once again, this is given the fact that the information we had.  
20 We felt this was as tight as we could get the windows to do that. And  
21 given the data scales, it was difficult for us to get tighter values.

1 There is some conservatism when you saying we're applying all that  
2 single application on a given date on the same data in a given  
3 watershed as opposed to saying, well, we're going to distribute that  
4 application out using a uniform distribution within a use window.

5 However, we don't think that was unreasonable conservatism  
6 when you start looking at the size of the watershed we were looking  
7 at. When we're looking at adjusting those fields for the percent crop  
8 area and the percent acres treated, it made more sense that these fields  
9 were the size that all those applications would actually occur on a  
10 single day rather than at different days on there. So we felt like there  
11 was some conservatism to it, but it wasn't an unreasonable assumption  
12 to make.

13 What we found is that when we did these and in each of the  
14 regions we generally found that there were one or two chemicals that  
15 were drivers in terms of the water exposures. This is also in the  
16 Central Valley of California. One of things that we found here is these  
17 cumulative distributions that we pulled together in methamidophos  
18 equivalents, once again, were a function both of the concentration of  
19 the pesticide in water and the relative potency factor.

20 Disulfoton, which is the one that you see dominating the curve,  
21 and once again this is a cumulative curve, has a higher relative potency

170

1 factor than these other OPs that you see here. That helped skew that  
2 curve. We did find, as we went back through there, is that we were  
3 able in most of these regions to get some separation of peaks and time  
4 so that we weren't artificially adding peaks together that wouldn't  
5 actually occur together. And the fact that in each of the regions, we  
6 were pretty consistent that there were only a handful of OPs that were  
7 drivers. And these tended to be the type of OPs that we saw in the  
8 monitoring data suggested that we weren't too far off.

9 Okay. You'll be happy to know this is the last slide before the  
10 questions.

11 We kept trying to go back and compare what we did in the  
12 modeling to the monitoring data. When you look at the report, one of  
13 things where the comparison occurs is in each of the regional  
14 summaries, each of the regional write-ups we wrote up a comparison.  
15 What we're planning to do to make life easier, because of some  
16 comments we had, is to try to pull that together in one place for all the  
17 regions together to make it easier to find it all at one time.

18 One of the challenges we had when we were comparing what we  
19 did in the modeling to the monitoring is that, A, there is no single  
20 definitive study. A lot of the monitoring studies we had were on  
21 running water from streams and rivers. There were a few, a couple of

171

1 studies, that focused on reservoirs. But these did not focus across a  
2 broad geographic range or across a broad time.

3 We took a look at everything we could. We tried to compare as  
4 much as we can, particularly looking at the peaks that we estimated  
5 for each of the individual pesticides in those regions to the highest  
6 detections that were reported. We also tried to take a look what I  
7 would call an "equivalent frequency detection." Each of those, in the  
8 monitoring studies, each of those OPs has a limit of detection.

9 When you're in PRZM-EXAMS, it can carry it out well below  
10 the limits of detection. But we could, basically, take a look at what  
11 percentile fell above or below that limited detection you would see in  
12 the field to see whether or not how we were doing in terms of  
13 estimating or overestimating.

14 One of the things, because they're not necessarily easily  
15 comparable, it's difficult to draw definitive conclusions and point this  
16 tells us one thing or another. Because we looked at 12 different  
17 regions, we were -- give us a chance to take a look at what each region  
18 tells us.

19 So if we were looking at something -- it gives us another way of  
20 kind of discerning whether or not we were having a function of  
21 compensating errors or fortuitous results or whether we may actually

172

1 be on to something.

2           What we found is the other thing that we need to keep in mind is  
3 we did not have monitoring data for every OP. So we had to assume  
4 that what we had reflected in comparing for the monitoring that was  
5 there would also be have been reflected for the others that weren't  
6 monitored.

7           In each of the regions, we did find a few known detections of  
8 one or more of the OPs that occurred at levels that were higher than  
9 what we would have estimated. We were looking roughly at order of  
10 magnitude differences, in part because the results that we had showed  
11 the drinking was and order of magnitude or more lower than food  
12 exposure.

13           So we took a look at order of magnitude differences. And to be  
14 honest with you, when you're doing some of these comparisons,  
15 getting much closer, gets a little queasy, anyway.

16           We did find that some of these had reported monitoring values  
17 that were higher than what we estimated, but there were also some  
18 where our estimations were an order of magnitude more greater than  
19 what we found in the monitoring.

20           We did not find a consistent trend in one way or another. We  
21 also found that there were a number of OPs that were fairly close to

173

1 each other in each of those regions.

2 In the questions that you're going to respond to after the public  
3 comments, we were asking you about whether you say anything where  
4 we may have significantly underestimated exposures, in part, because  
5 that's the way the results of the study came out. We're just as  
6 interested in anything you see that might suggest that we're significant  
7 overestimating exposures, too, so that we can take that into account  
8 on future assessments.

9 And I think the next ones comes to the questions.

10 DR. KENDALL: I don't want to have those read at this time.  
11 First of all, any points of clarification from the Panel for the  
12 presentation?

13 DR. MCCONNELL: I'm sorry. I missed the first few minutes.  
14 Maybe you covered this, Mr. Thurman. I noticed in your geography  
15 plots up there that one of high use areas is in Florida. And I got to  
16 thinking about in a situation where you have soils, poor soils, shallow  
17 water tables, have you looked at the ground water; or did you cover  
18 that and I missed it?

19 MR. COSTELLO: We considered it. We made the decision  
20 looking at it first -- well, one step back. Again, one of the reasons  
21 why we separated regions the way that we did, was to separate those

1 regions that had ground water as the major source of drinking from  
2 those that had surface water as the major source.

3 Next, we came to the conclusion that surface, generally, would  
4 be more vulnerable as a drinking water source to contamination from  
5 the OPs. For what data was available, there was clearly a lot more  
6 contamination of surface water and, just as importantly, much more  
7 cumulative co-occurrence of OPs in surface water. Something that we  
8 don't have evidence for in ground water.

9 But compounding that is the fact that beyond the fact that the  
10 monitoring is not enough for ground water to allow us to get the daily  
11 distributions, we actually don't have a tool like PRZM and EXAMS  
12 that would allow to us do the same thing for ground water. So it is  
13 one of the uncertainties of our assessment, especially for places like  
14 Florida, that we had to do a surface water assessment and assume that  
15 the concentrations that we would come up with, the exposure we  
16 would come up with, would exceed it.

17 There are reasons for certain individual chemicals that calls that  
18 into question to some extent. In Florida in particular, one of the OPs  
19 has, in certain regions, been found at higher concentrations that we  
20 had in our surface water assessment. This is one thing that we  
21 describe in our risk characterization as one of our uncertainties.

175

1           On top of that, in all of the regions, including the ones in which  
2 surface water is the dominant source of drinking water, there is still a  
3 significant portion of the population that derives drinking from  
4 shallow, private drinking water wells.

5           Again, this is why we are hoping in the way that we did our  
6 modeling scenarios that we have come up with what is likely to give  
7 the highest cumulative exposure to OPs as opposed to potential  
8 individual higher exposures to individual OPs in shallow drinking  
9 water.

10           MR. THURMAN: One other thing I'd add to that is this is  
11 where the relative potency factor also comes into play when we're  
12 looking at cumulative impact.

13           In Florida it turns out that where we did focus on surface water  
14 -- and there are not many surface-water intakes in Florida; we know  
15 that -- there happened to be a couple of OPs -- and I'm going to blank  
16 out on which ones -- that are used on sugar cane that have relatively  
17 high application rates and had a much higher relative potency factors  
18 than the OPs that we were finding in ground water. So when you  
19 started looking at it from a cumulative impact and you take into  
20 account the relative potency factor, we did feel that the surface-water  
21 assessment is going to be protective in that regard.

1 MR. COSTELLO: And this is one of the reasons why I  
2 described -- when we figured what areas had the highest OP usage, if  
3 we had not chosen them to be representative of the entire regions, we  
4 made some attempt to characterize the likelihood of drinking-water  
5 exposure in those regions. So if you take a look at the Mississippi  
6 Portal, for instance, which, like Florida, is an area that has much more  
7 of a population deriving its water from ground water than surface  
8 water, a detailed discussion of the geology of the area of the aquifers  
9 in the area will let you see that the greatest portion of people that  
10 derive their water, at least from other than private wells, are getting  
11 water that is protected by confining layers between the aquifers.

12 It does not write off the risk especially to people on private  
13 wells. But just to say that we made our best attempt to account for  
14 the vulnerability of the drinking source other than the surface water  
15 that we used in our models.

16 DR. KENDALL: Dr. Bull.

17 DR. BULL: A couple points of clarification. The issue you  
18 raise at the end, wouldn't you want -- since this was a conservative  
19 approach that you were taking, are you a little bit surprised that you  
20 had some things that are higher than what you predicted because I  
21 would have guessed this scenario would have been more protective.

177

1 MR. THURMAN: We are going --

2 DR. BULL: I would expected most actual monitoring data to  
3 come in lower.

4 MR. THURMAN: We are going back through and taking a look  
5 at each one of those and trying to come up with a rationale, see if can  
6 identify a reason why there may have been up.

7 In some cases, we do know that they are from uses that --  
8 they're uses in the area that are being canceled. So we know that there  
9 is that type of a contribution. In some cases what we found that they  
10 are in areas were not necessarily, the monitoring was not necessarily  
11 directly located where the major use, where our cumulative impact  
12 was.

13 In one or two areas we do find that there were some watersheds  
14 where the monitoring came from that are high ag use but are not  
15 representative drinking water -- they are not drinking water sources.  
16 So those are some of the things we are going back and taking a look at  
17 to see if we can...

18 MR. COSTELLO: But if I may. Some of the monitoring that I  
19 did find, although not direct drinking water monitoring, something to  
20 keep in mind how limited direct drinking water monitoring is for the  
21 OPs. But even if they were not drinking water samples, they were in

178

1 potential drinking water sources or in small streams that fed them.

2 DR. BULL: I'm going to try to keep this to points of  
3 clarification.

4 One of things that impressed me is those areas that you got are  
5 pretty heterogeneous within those I areas. I live in one of those areas  
6 as everybody else in the room is. But I know what they are.

7 I heard you talk about weather patterns, but I didn't hear you  
8 talk about irrigation. And irrigation is a big issue on runoff because  
9 you're going to get runoff from irrigated fields. And if you're just  
10 using -- are you taking that into account?

11 MR. THURMAN: We did take irrigation into account. There  
12 were a couple of regions where, you know, PRZM does have an  
13 irrigation routine. And in some cases, we've had to do some  
14 calibration of that irrigation routine. So particularly in the Central  
15 Valley, but in a couple other areas --

16 DR. BULL: In our part of Washington State, you don't get  
17 runoff if it's not from irrigation.

18 MR. THURMAN: Yeah. To be honest with you, one of reasons  
19 why we are looking at that is taking a look at where your runoff was  
20 going to occur. And we do realize that -- that's one of things we know  
21 that, where you have controlled drainage or human influence drainage,

179

1 and in this case irrigation, is this is going to be weaker in terms of  
2 trying to capture that effect on it.

3 DR. BULL: And there's probably limited places you can  
4 actually measure it.

5 MR. THURMAN: Now the thing that helped us on that is we  
6 did do -- we were able to do some comparisons from USGS NAQUA  
7 data and different -- particularly in the Northwest Fruitful Rim, in  
8 each of those major use areas, there were some NAQUA studies that  
9 were conducted at the same time. And so we were able to do some  
10 comparisons with the monitoring data to see where the relative  
11 impacts were likely to be. So that helped guide us in selecting the  
12 site.

13 DR. BULL: There's another kind of issue that runs in a funny  
14 way, too. You mentioned the potatoes in Idaho. I've heard -- I'm not  
15 sure it's true, but I think we do more potatoes in Eastern Washington  
16 than they do in Idaho now.

17 MR. THURMAN: I apologize for that. But that's true.

18 DR. BULL: But the issue of shifting crops, I mean, there's also  
19 a good -- you can also get applewood which is very good for the  
20 fireplace in Eastern Washington because a lot of people are taking  
21 orchards and they've shifting to different locations along the river.

1 MR. THURMAN: Certainly that's --

2 DR. BULL: How do you take that into account? These are big  
3 shifts going on.

4 MR. COSTELLO: Well, you know, the usage data that we had,  
5 the attempt was to have it for as recent as possible, and the monitoring  
6 data as well, to keep it somewhat recent. You know, along those lines  
7 is why we described how things such as -- we know that the  
8 uncertainties say that in the usage that is reflecting a certain number  
9 of years that the monitoring can't reflect canceled uses or other OPs  
10 that might come in to replace cancelled uses.

11 DR. BULL: That's what bothered me about taking out the  
12 canceled ones.

13 MR. THURMAN: Once again, we weren't forecasting. But I  
14 will say that in each of the regions, as we were looking at the sites, we  
15 were laying out what are the crops and what are the uses. And the one  
16 that strikes my mind, comes to mind right now, in Eastern Uplands we  
17 were looking at an area in Kentucky which did have tobacco use. That  
18 is a crop in, at least in Kentucky, is going down in acreage and OP use  
19 is going down.

20 And the other alternative was apples which is in another part of  
21 the area which was steady or going up. And so that's one of the things

181

1 we did take a look at. It was more of in each of the regions as we're  
2 trying to decide where do we focus the assessments. We would look at  
3 that, but sometimes that's hard.

4 DR. BULL: The final question I had along the same kind of line  
5 is you said the state usage rates are state wide but you only spread  
6 that over crop areas; right? You didn't spread that over --

7 MR. THURMAN: Only over crop areas.

8 If you look at the use information that is based on surveys. So  
9 they are selecting farmers across the state that reflect -- they're  
10 reflective of different farm types and sizes and they're actually asking  
11 them what is your application rate, and how many times do you apply  
12 it on this. So that survey -- so what we're getting and let's say we get  
13 an average is actually a reflection of actual survey response. And it's  
14 aggregated at a state level.

15 DR. BULL: But the apples in Washington, in Yakima, but most  
16 of them are probably up in (inaudible) Valley and up in Columbia and  
17 up into Canada which is another. The (inaudible) Valley up in Canada.  
18 So those are all very concentrated. And then you get out in other  
19 areas and they're grains and potatoes and things up on the flat.

20 MR. THURMAN: Did it does take into that.

21 DR. BULL: It does?

1 MR. THURMAN: Yes.

2 DR. KENDALL: Any further clarification from the Panel about  
3 this issue?

4 DR. CAPEL: Yes. As part of the introduction you showed up a  
5 watershed exposure plot for drinking water. I'm not quite sure exactly  
6 what that represents. I have two question. One is: Is it the output of  
7 PRZM-EXAMS with no adjustments for treatment?

8 MR. THURMAN: Okay. It's actually more than -- the output of  
9 PRZM-EXAMS, we did not adjust the treatment. So basically we're --  
10 we did find anyway to quantitatively do that.

11 But it also takes into account where Dr. Smith Mr. Dave Miller  
12 were talking about the CSFII dietary data. Part of that data includes  
13 drinking water consumption. So you get your levels in the water,  
14 which are your residue part of that, but you also have a consumption  
15 part of that to take into account in that MOE plot that you saw,

16 DR. CAPEL: So I guess the other half of the question is: Is it  
17 based only on the parent compounds, or are the transformation  
18 products also included in that?

19 MR. THURMAN: It is based on parent compounds and  
20 transformation products as it occurs in the environmental  
21 transformation products. So basically the parents...

183

1 DR. CAPEL: So it's part of the PRZM-EXAMS model that  
2 you've got --

3 MR. THURMAN: Yeah, yeah. And there were a couple of  
4 other transformation products that were included in there. But those  
5 are the major ones that were included in that.

6 DR. BULL: This is --

7 DR. KENDALL: Dr. Zeise.

8 DR. ZEISE: I was wondering if you could speak to the drinking  
9 water consumption assumptions that were made. And then how you  
10 dealt with it. If we turn back to the food case, it looks as if a good  
11 deal of the high-end exposure coming from perhaps high consumption  
12 and high residue levels. And I'm wondering if in this example where  
13 the equivalent is sort of trying to address that high-end exposure  
14 group.

15 For example, did you address one subgroup that gets basically  
16 all it's fluid from water, bottle-fed infant? How did you deal with  
17 these more extreme cases?

18 DR. PERFETTI: As part of the food consumption data, the  
19 CSFII survey, the latest one, the 94-96 and even the '98 children level,  
20 directly asked the question how much water did the individual drink  
21 under those two nonconsecutive days. So those consumption values

184

1 are for water the same type, reflecting the same survey that the foods  
2 consumption was collected.

3 DR. ZEISE: Did it capture -- did that sort of capture bottle-fed  
4 infant? And did you look at that in particular as a special case where  
5 you might have a high exposure? Did you make sure that --

6 DR. PERFETTI: Water consumption of the bottle-fed infant or  
7 the formula consumption.

8 DR. ZEISE: Well, you would --

9 DR. PERFETTI: Well, okay. There's two components to water.  
10 There's water you get in your food, and there's the water you actually  
11 just drink to drink water. Both of those are in the CSFII but in  
12 different forms.

13 DR. ZEISE: Okay. Well, I'm just talking about this one  
14 particular subpopulation where you might have very high exposure.  
15 Do you think they were adequately captured in this analysis?

16 DR. BULL: The extreme would be formula made from water.

17 MS. MULKEY: I thought I understood Dr. Smith as saying --  
18 he's here. Do you know the answer to this question, Bill, the formula  
19 that you make up, the power the water in the powder formula.

20 DR. SMITH: Yes. As I understand it, the current survey, it  
21 breaks out the different forms of water, as Randy was saying; and they

185

1 are separately listed as water and then there's water that's used in  
2 preparing, for example, formula and all the other food components.  
3 And it is a fairly high consumption item as you would expect.

4 DR. ZEISE: Okay. Thanks. As we saw earlier this morning,  
5 we looked at different plots for different age groups. And in this case,  
6 if you think analogously, this might be an age group where you might  
7 see -- I mean, it's very upper tail high levels. And I wonder if you did  
8 any of that kind of disaggregation to look to see whether there were  
9 some subpopulations that could potentially have higher levels, both on  
10 a consumption and then from, perhaps, abnormal use applications.

11 DR. PERFETTI: Do you mean in terms of the water?

12 DR. ZEISE: One side the consumption is for the water, and the  
13 other side is the different assumptions made with respect to  
14 application of pesticide.

15 My understanding is you've used average application that you  
16 obtained from surveying. And I don't know the extent to which that  
17 might address things like outbreaks and so forth.

18 DR. PERFETTI: I'm not sure I understand all of the question.  
19 As far as based on the water consumption and the residues observed  
20 from the PRZM-EXAMS run, there was none of the subgroups had --  
21 there was hardly any -- well, the MOEs were in order of magnitude

186

1 above the food and sometimes three or four orders of magnitude. So  
2 you will even -- that subgroup zero to one, which, I assume is what  
3 you're referring to, that the water was not playing a major part in that  
4 even though, as you pointed out, both from water consumption from  
5 the formula plus any water the individual drank would be a high  
6 consumption of water.

7 MR. COSTELLO: And I think understand what you're getting  
8 at when you say "the outbreaks." You're talking about pest pressure  
9 and using higher than typical rates. And we choose for the cumulative  
10 assessment to use typical, that is to say average rates, where we might  
11 not before for individual chemicals because we thought it unlikely that  
12 the highest rate for each of the pesticides, for all the pesticides on  
13 different crops, would be used at the same time.

14 To attempt to look at -- again, because remember, these are  
15 different crops, so pest pressure wouldn't be uniform over all the ones  
16 we have in their assemblage. But to attempt to alter some to be higher  
17 would introduce another dimension of probabilistic assessment, and it  
18 is not something that we attempted.

19 DR. KENDALL: Any further points? Dr. Portier, you stand,  
20 then, between the break and closing this session.

21 DR. PORTIER: The average rates question, you answered a

187

1 question I was going to ask. You didn't consider any variability in  
2 what you got out of PRZM-EXAMS. You simply ran it and got sort of  
3 an average for each region.

4 MR. THURMAN: Yeah, actually, that was one thing. We held  
5 the application rates constant. So what you see in terms of that  
6 variability in time is due to weather differences. There was no attempt  
7 to try to -- and, actually, part of the problem is with finding the data  
8 to do.

9 DR. PORTIER: And the other question, since it's not in front of  
10 me and one of the questions you're asking us about, is whether we  
11 believe that the water component is a trivial part of the  
12 organophosphate exposure. I have to ask the obvious question. How  
13 bad were your estimates in the worse case? Since I can't see all the  
14 data you looked at in deciding the water concentration levels you  
15 observed, give me some indication of the magnitude. Is it less than an  
16 order of magnitude? Is it two orders of magnitude?

17 MR. COSTELLO: You mean compared to monitoring.

18 DR. PORTIER: Yes, compared to monitoring data.

19 MR. COSTELLO: I think the important -- I could give you a  
20 yes-no answer, but that wouldn't be serving you.

21 In the case of some of the exceedances that were significantly

188

1 higher and I think they were at somewhere at least an order of  
2 magnitude, you have to consider, again, what the monitoring  
3 represents. And this is, again, one reason why we couldn't use the  
4 monitoring by itself.

5 In looking at the available data, it's an assemblage of  
6 monitoring studies designed for different purposes. And some of the  
7 highest concentrations that we saw, the best example is an area near  
8 Salem, called Solter Creek, from the NAQUA program, where there  
9 were several of OPs that exceeded significantly when they came up in  
10 our cumulative assessment.

11 But Solter Creek, beyond the fact that it is not a direct drinking  
12 water source, also has a small watershed with 99-percent agricultural.  
13 Again, a question of scale. The percent-crop-area factors that we  
14 come up with are based on OP crops in these large 8-digit HUCs.

15 So to compare what we come up with there to actual monitoring  
16 near the time of application in very high-use area in an area that's got  
17 99-percent agricultural, we have to actually stop and think what does  
18 this mean that it exceeded our output.

19 I mean you have to consider both what does our output really  
20 mean, and that's part of one of our questions. And then what does it  
21 mean once we figure that out to compare to monitoring with...

1 MR. THURMAN: With those caveats in mind, I can tell you just  
2 from going back and going into a little more detail in each of these and  
3 figure out what it is.

4 In each of the regions, there's no more than a couple of OPs  
5 where we found monitoring that was greater. Most of it was around an  
6 order of magnitude type if it was greater. It was not much more than  
7 that. And once again, at least as I was doing initializing, you look at  
8 once we found our overestimates, first of all we found our  
9 underestimates and started taking into account the relative potencies  
10 of each of those and looking at that. We didn't see anything that  
11 suggested a consistent, you know, that we're missing that by an order  
12 by what would effect the assessment by an order of magnitude.

13 I know that's a very general. And I could probably give more  
14 details, but I'd have to go back and dig for those.

15 DR. PORTIER: That's fine. I'm not sure you haven't just  
16 answered your own question. But when we get to the discussion, I'll  
17 do that.

18 The other question is the frequency examples. I didn't get a feel  
19 for what's the magnitude of the monitored data in terms of, you know,  
20 a given region or a comparison to your model. Are we talking about  
21 30 points, 3,000, 20 on an average? Give me some feel for the size of

190

1 what you're looking at.

2 MR. COSTELLO: The very best monitoring that we might have  
3 would be a very small area from the NAQUA program, say, bi-weekly  
4 over two years. And that's not common. And on top of that, again,  
5 then you have to go deeper. Did that monitoring represent target  
6 monitoring for OPs? Was it in a high OP use area? Not usually.

7 DR. PORTIER: Thanks.

8 DR. KENDALL: Okay. I'm going to go ahead and close this  
9 clarification session. We will take a 15-minute break. When we  
10 return, we will have two public presentations as registered currently.  
11 And then we'll begin the questions at which time the Panel will have  
12 full opportunity to address additional issues and concerns.

13 Thank you.

14 [Break.]

15 -oo0oo-

1  
2  
3  
4  
5  
6  
7  
8  
9

CERTIFICATE OF STENOTYPE REPORTER

I, Jane F. Hoffman, Stenotype Reporter, do hereby certify that the foregoing proceedings were reported by me in stenotypy, transcribed under my direction and are a verbatim record of the proceedings had.

-----

JANE F. HOFFMAN

192

1     \*\*I-N-V-O-I-C-E\*\*\*\*   \*\*\*\*I-N-V-O-I-C-E\*\*\*\*

2     JANE F. HOFFMAN

3     849 S. Irving Street

4     Arlington, VA 22204

5     SS#305-52-5988

6     TODAY'S DATE: 2/20/02

7     DATE TAKEN: 2/6/02

8     CASE NAME: FIFRA SAP MEETING/PRELIMINARY CUMULATIVE RISK  
9     ASSESSMENT

10    **TOTAL: -- PAGES: 279**

11    LOCATION OF DEPO: Arlington, VA

12    DELIVERY: Regular -- conference rate

13